@NP	Transplantation	1
@NP	Schwann Cells and/or Olfactory Ensheathing Glia into the Contused Spinal Cord	20
@NP	Schwann Cells	20
@NP	Olfactory Ensheathing Glia into the Contused Spinal Cord	41
@NP	Olfactory Ensheathing Glia	41
@NP	the Contused Spinal Cord	73
@NP	Survival , Migration , Axon Association , and Functional Recovery DAMIEN D.	99
@NP	Survival	99
@NP	Migration	109
@NP	Axon Association	120
@NP	Functional Recovery DAMIEN D.	142
@NP	PEARSE ,1 * ANDRE R.	173
@NP	PEARSE	173
@NP	,1 * ANDRE R.	179
@NP	,1	179
@NP	ANDRE R.	183
@NP	SANCHEZ ,1 FRANCISCO C.	192
@NP	SANCHEZ ,1	192
@NP	FRANCISCO C.	202
@NP	PEREIRA ,2 CHRISTIAN M.	215
@NP	PEREIRA ,2	215
@NP	CHRISTIAN M.	225
@NP	ANDRADE ,1 RAISA PUZIS ,1 YELENA PRESSMAN ,1 KEVIN GOLDEN ,1 BRANDON M.	238
@NP	ANDRADE ,1 RAISA PUZIS	238
@NP	,1 YELENA PRESSMAN ,1 KEVIN GOLDEN	259
@NP	,1 YELENA PRESSMAN ,1	259
@NP	KEVIN GOLDEN	280
@NP	,1 BRANDON M.	292
@NP	KITAY ,1 BAS BLITS ,1 PATRICK M.	306
@NP	KITAY ,1 BAS BLITS	306
@NP	,1	323
@NP	PATRICK M.	326
@NP	WOOD ,1 AND MARY BARTLETT	337
@NP	WOOD ,1	337
@NP	MARY BARTLETT	348
@NP	BUNGE1 ,3	362
@NP	The Miami Project	371
@NP	Paralysis	397
@NP	University of Miami Miller School of Medicine	408
@NP	University	408
@NP	Miami Miller School of Medicine	422
@NP	Miami Miller School	422
@NP	Medicine	445
@NP	Miami	455
@NP	Florida 1Department of Neurological Surgery	462
@NP	Florida 1Department	462
@NP	Neurological Surgery	485
@NP	University of Miami Miller School of Medicine 2Department of Anatomy	507
@NP	University	507
@NP	Miami Miller School of Medicine 2Department	521
@NP	Miami Miller School	521
@NP	Medicine 2Department	544
@NP	Anatomy	568
@NP	Biomedical Sciences Institute	577
@NP	University of Sao Paulo	608
@NP	University	608
@NP	Sao Paulo	622
@NP	Brazil 3Department of Cell Biology and Anatomy	633
@NP	Brazil 3Department	633
@NP	Cell Biology and Anatomy	655
@NP	University	681
@NP	Miami Miller School	695
@NP	Medicine ABSTRACT Schwann cells	718
@NP	SCs	752
@NP	olfactory ensheathing glia	761
@NP	OEG	789
@NP	promise for spinal cord injury repair	805
@NP	promise	805
@NP	spinal cord injury repair	817
@NP	We	844
@NP	their in vivo identification following transplantation	854
@NP	their in vivo identification	854
@NP	transplantation	893
@NP	the contused adult rat spinal cord	914
@NP	1 week postinjury	952
@NP	-LRB- i -RRB- DNA	974
@NP	hybridization -LRB- ISH -RRB- with a Y-chromosome specific probe	990
@NP	hybridization -LRB- ISH -RRB-	990
@NP	hybridization	990
@NP	ISH	1005
@NP	a Y-chromosome specific probe	1015
@NP	male transplants	1057
@NP	female rats and -LRB- ii -RRB- lentiviral vector-mediated expression of EGFP	1077
@NP	female rats	1077
@NP	ii	1094
@NP	lentiviral vector-mediated expression of EGFP	1098
@NP	lentiviral vector-mediated expression	1098
@NP	EGFP	1139
@NP	Survival , migration , and axon-glia association	1145
@NP	Survival	1145
@NP	migration	1155
@NP	axon-glia association	1170
@NP	3 days	1213
@NP	9 weeks	1223
@NP	3 weeks after transplantation into the lesion	1256
@NP	3 weeks	1256
@NP	transplantation into the lesion	1270
@NP	transplantation	1270
@NP	the lesion	1291
@NP	a 60 -- 90 % loss of grafted cells	1303
@NP	a 60	1303
@NP	90 % loss of grafted cells	1308
@NP	90 % loss	1308
@NP	grafted cells	1320
@NP	OEG-only grafts	1348
@NP	the lesion	1392
@NP	injection outside the lesion	1410
@NP	injection	1410
@NP	the lesion	1428
@NP	a 60 % survival rate	1446
@NP	the injury milieu	1481
@NP	transplanted cells	1514
@NP	their proliferation	1550
@NP	later times post-grafting , p75þ	1574
@NP	later times	1574
@NP	EGFP2 cells in the lesion	1607
@NP	EGFP2 cells	1607
@NP	the lesion	1622
@NP	EGFPþ cells	1645
@NP	all paradigms	1660
@NP	evidence of significant host SC infiltration	1675
@NP	evidence	1675
@NP	significant host SC infiltration	1687
@NP	SCs and OEG	1721
@NP	the injury failed to migrate from the lesion	1747
@NP	the injury	1747
@NP	the lesion	1781
@NP	Injection of OEG outside of the injury	1793
@NP	Injection	1793
@NP	OEG outside of the injury	1806
@NP	OEG	1806
@NP	the injury	1821
@NP	their migration	1844
@NP	the SC-injected injury site	1865
@NP	host tissue	1920
@NP	the pia	1942
@NP	the central canal	1957
@NP	all paradigms	1979
@NP	host axons	1994
@NP	association	2018
@NP	transplanted glia	2052
@NP	Numerous myelinated axons	2071
@NP	regions of grafted SCs but not OEG	2115
@NP	regions	2115
@NP	SCs but not OEG	2134
@NP	SCs	2134
@NP	OEG	2146
@NP	current study details	2155
@NP	the temporal survival , migration , axon association of SCs and OEG	2177
@NP	the temporal survival	2177
@NP	migration	2200
@NP	axon association of SCs	2211
@NP	axon association	2211
@NP	SCs	2231
@NP	OEG	2239
@NP	the contused spinal cord , research previously complicated	2288
@NP	the	2288
@NP	spinal cord , research previously complicated	2301
@NP	spinal cord	2301
@NP	research previously complicated	2314
@NP	research	2314
@NP	a lack of quality	2353
@NP	a lack	2353
@NP	quality	2363
@NP	long-term markers	2372
@NP	cell tracking in vivo	2394
@NP	cell tracking	2394
@NP	vivo	2411
@NP	INTRODUCTION Trauma to the spinal cord	2418
@NP	INTRODUCTION Trauma	2418
@NP	the spinal cord	2441
@NP	progressive cell death	2466
@NP	axonal degeneration	2490
@NP	functional loss in multiple motor , sensory , and autonomic systems	2515
@NP	functional loss	2515
@NP	multiple motor , sensory , and autonomic systems	2534
@NP	multiple motor	2534
@NP	sensory	2550
@NP	autonomic systems	2563
@NP	The versatility	3893
@NP	cellular implants	3912
@NP	many obstacles encountered after SCI	3942
@NP	many obstacles	3942
@NP	SCI	3975
@NP	them	3985
@NP	ideal therapeutic candidates for repair	3990
@NP	ideal therapeutic candidates	3990
@NP	repair	4023
@NP	Schwann cells	4031
@NP	SCs	4046
@NP	the myelinating cells	4052
@NP	the peripheral nervous system	4077
@NP	axonal regeneration	4122
@NP	peripheral injury	4148
@NP	CNS axon growth either as peripheral nerve grafts or purified	4179
@NP	CNS axon growth	4179
@NP	peripheral nerve grafts	4205
@NP	fluid grafts	4242
@NP	David and Aguayo , 1981 ; Takami et al. , 2002b ; Xu et al. , 1995	4256
@NP	David and Aguayo	4256
@NP	1981 ; Takami et al. , 2002b ; Xu et al.	4274
@NP	1981	4274
@NP	Takami et al. , 2002b ; Xu et al.	4280
@NP	Takami	4280
@NP	et al. , 2002b ; Xu et al.	4287
@NP	et al. , 2002b	4287
@NP	et al.	4287
@NP	2002b	4295
@NP	Xu et al.	4302
@NP	Xu	4302
@NP	et al.	4305
@NP	1995	4313
@NP	SCs	4320
@NP	a physical support to growing axons in vivo	4337
@NP	a physical support	4337
@NP	growing axons in vivo	4359
@NP	growing axons	4359
@NP	vivo	4376
@NP	a variety	4394
@NP	growth-promoting neurotrophins	4407
@NP	Acheson	4439
@NP	et al. , 1991 ; Rende et al. , 1992	4447
@NP	et al.	4447
@NP	1991 ; Rende et al.	4455
@NP	1991	4455
@NP	Rende et al.	4461
@NP	Rende	4461
@NP	et al.	4467
@NP	1992	4475
@NP	cell adhesion molecules -LRB- reviewed by Grumet , 1997 -RRB-	4482
@NP	cell adhesion molecules	4482
@NP	Grumet , 1997	4519
@NP	Grumet	4519
@NP	1997	4527
@NP	extracellular matrix -LRB- Chiu et al. , 1991 -RRB-	4537
@NP	extracellular matrix	4537
@NP	Chiu	4559
@NP	et al. , 1991	4564
@NP	et al.	4564
@NP	1991	4572
@NP	SCs also ensheathe and myelinate these axons -LRB- Bahr et al. , 1991 -RRB- .	4579
@NP	SCs	4579
@NP	also ensheathe and myelinate these axons -LRB- Bahr et al. , 1991 -RRB-	4583
@NP	also ensheathe	4583
@NP	myelinate these axons -LRB- Bahr et al. , 1991 -RRB-	4602
@NP	myelinate these axons	4602
@NP	Bahr	4625
@NP	et al. , 1991	4630
@NP	et al.	4630
@NP	1991	4638
@NP	respect to clinical importance	4650
@NP	respect	4650
@NP	clinical importance	4661
@NP	large numbers of human SCs	4682
@NP	large numbers	4682
@NP	human SCs	4699
@NP	autologous implantation	4728
@NP	minimally invasive surgery for peripheral nerve harvesting	4758
@NP	minimally invasive surgery	4758
@NP	peripheral nerve harvesting	4789
@NP	expansion and purification in culture -LRB- Bunge and Pearse , 2003 -RRB-	4821
@NP	expansion and purification	4821
@NP	culture -LRB- Bunge and Pearse , 2003 -RRB-	4851
@NP	culture	4851
@NP	Bunge and Pearse	4860
@NP	2003	4878
@NP	Olfactory ensheathing glia -LRB- OEG -RRB-	4885
@NP	Olfactory ensheathing glia	4885
@NP	OEG	4913
@NP	fiber regeneration	4981
@NP	the injured mammalian spinal cord	5003
@NP	Li	5038
@NP	et al. , 1997 ; Ram on-Cueto et al. , 1998 ; 2000	5041
@NP	et al.	5041
@NP	1997 ; Ram on-Cueto et al.	5049
@NP	1997	5049
@NP	Ram on-Cueto et al.	5055
@NP	Ram on-Cueto	5055
@NP	et al.	5068
@NP	1998 ; 2000	5076
@NP	functional recovery -LRB- Li et al. , 2003b ; Ram on - Cueto et al. , 2000 -RRB-	5103
@NP	functional recovery	5103
@NP	Li	5124
@NP	et al. , 2003b ; Ram on - Cueto et al. , 2000	5127
@NP	et al.	5127
@NP	2003b ; Ram on - Cueto et al.	5135
@NP	2003b	5135
@NP	Ram on - Cueto et al.	5142
@NP	Ram	5142
@NP	Cueto et al.	5150
@NP	Cueto	5150
@NP	et al.	5156
@NP	2000	5164
@NP	OEG ensheathe axons of olfactory sensory neurons	5171
@NP	OEG ensheathe axons	5171
@NP	olfactory sensory neurons	5194
@NP	their growth	5229
@NP	the olfactory epithelium to the olfactory bulb	5247
@NP	the olfactory epithelium	5247
@NP	the olfactory bulb	5275
@NP	their exposure	5309
@NP	inhibitory molecules	5327
@NP	Graziadei and Graziadei , 1979 ; Ram on-Cueto and Santos-Benito , 2001	5349
@NP	Graziadei and Graziadei	5349
@NP	1979 ; Ram on-Cueto and Santos-Benito	5374
@NP	1979	5374
@NP	Ram on-Cueto and Santos-Benito	5380
@NP	Ram on-Cueto	5380
@NP	Santos-Benito	5397
@NP	2001	5412
@NP	OEG	5419
@NP	axon growth in the injured CNS	5434
@NP	axon growth	5434
@NP	the injured CNS	5449
@NP	growth factors	5479
@NP	NGF , NT4/5 , NT3 , and BDNF	5502
@NP	Lipson et al. , 2003 ; Ram on-Cueto et al. , 1998 ; Woodhall et al. , 2001	5529
@NP	Lipson	5529
@NP	et al. , 2003 ; Ram on-Cueto et al. , 1998 ; Woodhall et al. , 2001	5536
@NP	et al. , 2003	5536
@NP	et al.	5536
@NP	2003	5544
@NP	Ram on-Cueto et al. , 1998	5550
@NP	Ram on-Cueto	5550
@NP	et al. , 1998	5563
@NP	et al.	5563
@NP	1998	5571
@NP	Woodhall et al. , 2001	5577
@NP	Woodhall	5577
@NP	et al. , 2001	5586
@NP	et al.	5586
@NP	2001	5594
@NP	cell adhesion molecules	5601
@NP	L1 and laminin -LRB- Barnett et al. , 2000 ; Bartolomei et al. , 2000 -RRB-	5633
@NP	L1 and laminin	5633
@NP	Barnett	5649
@NP	et al. , 2000 ; Bartolomei et al. , 2000	5657
@NP	et al.	5657
@NP	2000 ; Bartolomei et al.	5665
@NP	2000	5665
@NP	Bartolomei et al.	5671
@NP	Bartolomei	5671
@NP	et al.	5682
@NP	2000	5690
@NP	the axon	5714
@NP	chemorepellants via ensheathment -LRB- Ram on-Cueto et al. , 2000 -RRB-	5728
@NP	chemorepellants	5728
@NP	ensheathment -LRB- Ram on-Cueto et al. , 2000 -RRB-	5748
@NP	ensheathment	5748
@NP	Ram	5762
@NP	on-Cueto et al. , 2000	5766
@NP	on-Cueto	5766
@NP	et al.	5775
@NP	2000	5783
@NP	OEG	5790
@NP	remyelinate demyelinated spinal cord axons -LRB- Imaizumi et al. , 1998 -RRB-	5811
@NP	remyelinate	5811
@NP	spinal cord axons -LRB- Imaizumi et al. , 1998 -RRB-	5836
@NP	spinal cord axons	5836
@NP	Imaizumi	5855
@NP	et al. , 1998	5864
@NP	et al.	5864
@NP	1998	5872
@NP	the transplantation of SCs and OEG into the injured spinal cord	5888
@NP	the transplantation	5888
@NP	SCs and OEG	5911
@NP	the injured spinal cord	5928
@NP	survival and integration	6001
@NP	the host spinal cord , migration , or association	6031
@NP	the host spinal cord	6031
@NP	migration	6053
@NP	association	6067
@NP	myelination of axons	6088
@NP	myelination	6088
@NP	axons	6103
@NP	the lack of specific cellular labels	6133
@NP	the lack	6133
@NP	specific cellular labels	6145
@NP	long-term tracking of the transplanted cells in vivo	6174
@NP	long-term tracking	6174
@NP	the transplanted cells in vivo	6196
@NP	the transplanted cells	6196
@NP	vivo	6222
@NP	labels	6248
@NP	leakage and transfer	6286
@NP	host cells	6310
@NP	Harvey , 1994 ; Honig and Hume , 1986 ; Horan and Slezak , 1989	6322
@NP	Harvey , 1994	6322
@NP	Harvey	6322
@NP	1994	6330
@NP	Honig and Hume , 1986	6336
@NP	Honig and Hume	6336
@NP	1986	6352
@NP	Horan and Slezak , 1989	6358
@NP	Horan and Slezak	6358
@NP	1989	6376
@NP	endogenous cells	6433
@NP	e.g. p75 ; Pearse et al. , 2004b	6451
@NP	e.g.	6451
@NP	p75 ; Pearse et al. , 2004b	6456
@NP	p75	6456
@NP	Pearse et al. , 2004b	6461
@NP	Pearse	6461
@NP	et al. , 2004b	6468
@NP	et al.	6468
@NP	2004b	6476
@NP	chemical instability	6487
@NP	loss of the label within days or weeks	6522
@NP	loss	6522
@NP	the label within days or weeks	6530
@NP	the label	6530
@NP	days or weeks	6547
@NP	post-transplantation -LRB- Li et al. , 2003a ; Mosahebi et al. , 2000 -RRB-	6561
@NP	post-transplantation	6561
@NP	Li	6583
@NP	et al. , 2003a ; Mosahebi et al. , 2000	6586
@NP	et al.	6586
@NP	2003a ; Mosahebi et al.	6594
@NP	2003a	6594
@NP	Mosahebi et al.	6601
@NP	Mosahebi	6601
@NP	et al.	6610
@NP	2000	6618
@NP	the present study	6628
@NP	we	6647
@NP	two labeling techniques	6659
@NP	these limitations	6698
@NP	DNA	6717
@NP	hybridization -LRB- ISH -RRB- with a rat Y-chromosome-specific DNA probe	6729
@NP	hybridization -LRB- ISH -RRB-	6729
@NP	hybridization	6729
@NP	ISH	6744
@NP	a rat Y-chromosome-specific DNA probe	6754
@NP	male cell grafting	6798
@NP	a female host or lentiviral vector transduction	6822
@NP	a gene	6873
@NP	a fluorescent protein	6889
@NP	the cells	6916
@NP	Chamberlin	6927
@NP	et al. , 1998	6938
@NP	et al.	6938
@NP	1998	6946
@NP	Harvey et al. , 1992	6952
@NP	Harvey	6952
@NP	et al. , 1992	6959
@NP	et al.	6959
@NP	1992	6967
@NP	Keirstead et al. , 1999	6973
@NP	Keirstead	6973
@NP	et al. , 1999	6983
@NP	et al.	6983
@NP	1999	6991
@NP	Okada et al. , 1999	6997
@NP	Okada	6997
@NP	et al. , 1999	7003
@NP	et al.	7003
@NP	1999	7011
@NP	O'Leary and Blakemore , 1997	7017
@NP	O'Leary and Blakemore	7017
@NP	1997	7040
@NP	Pearse and Bunge , 2006	7046
@NP	Pearse and Bunge	7046
@NP	2006	7064
@NP	Previous studies	7071
@NP	these labels	7102
@NP	various cell implants , including SCs and OEG	7139
@NP	various cell implants	7139
@NP	SCs and OEG	7172
@NP	SCs	7172
@NP	OEG	7180
@NP	demyelinating lesions	7188
@NP	the spinal cord	7213
@NP	Imaizumi	7230
@NP	et al. , 1998	7239
@NP	et al.	7239
@NP	1998	7247
@NP	dorsal root injuries	7254
@NP	Ramer	7276
@NP	et al. , 2004	7282
@NP	et al.	7282
@NP	2004	7290
@NP	clip compression -LRB- Boyd et al. , 2004 -RRB-	7297
@NP	clip compression	7297
@NP	Boyd	7315
@NP	et al. , 2004	7320
@NP	et al.	7320
@NP	2004	7328
@NP	chronic , contusive SCI -LRB- Barakat et al. , 2005 -RRB-	7338
@NP	chronic	7338
@NP	contusive SCI -LRB- Barakat et al. , 2005 -RRB-	7347
@NP	contusive SCI	7347
@NP	Barakat	7362
@NP	et al. , 2005	7370
@NP	et al.	7370
@NP	2005	7378
@NP	The current study	7385
@NP	improved in vivo	7424
@NP	improved	7424
@NP	vivo	7436
@NP	picture	7441
@NP	temporal	7452
@NP	glial cell survival	7469
@NP	their capacity for host cord integration	7490
@NP	their capacity	7490
@NP	host cord integration	7509
@NP	their migratory properties	7532
@NP	their ability to associate with	7564
@NP	myelinate re-growing axons within the sub-acutely contused spinal cord	7600
@NP	myelinate re-growing axons	7600
@NP	the sub-acutely contused spinal cord	7634
@NP	these properties of the two cell types in a single study	7699
@NP	these properties	7699
@NP	the two cell types in a single study	7719
@NP	the two cell types	7719
@NP	a single study	7741
@NP	MATERIALS AND METHODS	7758
@NP	Cultures SCs SCs	7780
@NP	sciatic nerves	7816
@NP	adult male -LRB- Y chromosome label -RRB-	7834
@NP	adult male	7834
@NP	Y chromosome label	7846
@NP	female -LRB- lentiviral vector GFP label -RRB-	7869
@NP	female	7869
@NP	lentiviral vector GFP label	7877
@NP	Fischer rats -LRB- Harlan Co , Indianapolis , IN -RRB- as described previously	7906
@NP	Fischer rats	7906
@NP	Harlan Co , Indianapolis	7920
@NP	Harlan Co	7920
@NP	Indianapolis	7931
@NP	Morrissey	7974
@NP	et al. , 1991	7984
@NP	et al.	7984
@NP	1991	7992
@NP	additional modifications as later detailed in Meijs et al.	8003
@NP	additional modifications	8003
@NP	Meijs	8049
@NP	et al.	8055
@NP	2004	8064
@NP	Cells	8071
@NP	confluency	8091
@NP	new dishes	8118
@NP	three times	8129
@NP	Their purity for grafting	8142
@NP	Their purity	8142
@NP	grafting	8159
@NP	a method described earlier -LRB- Takami et al. , 2002b -RRB-	8172
@NP	a method	8172
@NP	earlier -LRB- Takami et al. , 2002b -RRB-	8191
@NP	earlier	8191
@NP	Takami	8200
@NP	et al. , 2002b	8207
@NP	et al.	8207
@NP	2002b	8215
@NP	95 -- 98 %	8239
@NP	95	8239
@NP	98 %	8242
@NP	OEG Highly purified cultures of OEG	8247
@NP	OEG	8247
@NP	cultures of OEG	8267
@NP	cultures	8267
@NP	OEG	8279
@NP	the nerve fiber layer	8302
@NP	the olfactory bulb	8327
@NP	adult male -LRB- Y chromosome label -RRB-	8349
@NP	adult male	8349
@NP	Y chromosome label	8361
@NP	female -LRB- lentiviral vector GFP label -RRB-	8384
@NP	female	8384
@NP	lentiviral vector GFP label	8392
@NP	Fischer rats -LRB- Harlan Co -RRB-	8421
@NP	Fischer rats	8421
@NP	Harlan Co	8435
@NP	a procedure modified from one described previously	8452
@NP	a procedure	8452
@NP	one described previously	8478
@NP	one	8478
@NP	Ram	8504
@NP	on-Cueto et al. , 1998	8508
@NP	on-Cueto	8508
@NP	et al.	8517
@NP	1998	8525
@NP	Care	8532
@NP	the inclusion of nonnerve fiber layer bulb tissue	8559
@NP	the inclusion	8559
@NP	nonnerve fiber layer bulb tissue	8576
@NP	the pia	8614
@NP	OEG	8635
@NP	a modification to the Ram	8664
@NP	a modification	8664
@NP	the Ram	8682
@NP	on-Cueto	8690
@NP	et al. -LRB- 1998 -RRB- method ,	8699
@NP	et al.	8699
@NP	1998	8707
@NP	method	8713
@NP	5 days	8738
@NP	forskolin -LRB- 0.8 µg/mL -RRB- and pituitary extract -LRB- 2 mg/mL -RRB-	8748
@NP	forskolin	8748
@NP	0.8 µg/mL	8759
@NP	pituitary extract	8774
@NP	2 mg/mL	8793
@NP	DMEM/F12/10 % FBS before purification	8805
@NP	DMEM/F12/10 % FBS	8805
@NP	purification	8829
@NP	p75 immuno-panning	8845
@NP	Takami	8880
@NP	et al.	8887
@NP	2002b	8895
@NP	the purity	8912
@NP	SCs except that p75 rather than S100	8938
@NP	SCs	8938
@NP	that p75 rather than S100	8949
@NP	that p75	8949
@NP	S100	8970
@NP	Hoechst nuclear staining	8989
@NP	Purity	9015
@NP	94 -- 98 %	9038
@NP	94	9038
@NP	98 %	9041
@NP	Lentiviral Vectors Lentiviral vector preparation Vector preparation	9046
@NP	Lentiviral Vectors	9046
@NP	Lentiviral vector preparation Vector preparation	9065
@NP	Follenzi	9155
@NP	et al. -LRB- 2000 -RRB-	9164
@NP	et al.	9164
@NP	2000	9172
@NP	the gene encoding	9188
@NP	green fluorescent protein -LRB- EGFP -RRB-	9215
@NP	green fluorescent protein	9215
@NP	EGFP	9242
@NP	a lentiviral vector plasmid	9267
@NP	This plasmid	9296
@NP	the cytomegalovirus -LRB- CMV -RRB- promoter	9319
@NP	CMV	9340
@NP	transgene expression	9363
@NP	the Woodchuck posttranscriptional regulatory element -LRB- WPRE -RRB-	9388
@NP	the Woodchuck	9388
@NP	posttranscriptional regulatory element -LRB- WPRE -RRB-	9402
@NP	posttranscriptional regulatory element	9402
@NP	WPRE	9442
@NP	mRNA transport	9459
@NP	Transfection of plasmids and viral harvesting	9475
@NP	Transfection	9475
@NP	plasmids and viral harvesting	9491
@NP	plasmids	9491
@NP	viral harvesting	9504
@NP	293T cells	9547
@NP	Virus	9559
@NP	ultracentrifugation	9585
@NP	20,000 g	9608
@NP	phosphate buffered saline -LRB- PBS -RRB-	9635
@NP	phosphate	9635
@NP	saline -LRB- PBS -RRB-	9654
@NP	saline	9654
@NP	PBS	9662
@NP	this	9674
@NP	the viral vectors	9680
@NP	units	9727
@NP	293T cells	9743
@NP	an enzyme linked immunosorbent assay	9766
@NP	ELISA ; Perkin Elmer , Wellesley , MA	9804
@NP	ELISA	9804
@NP	Perkin Elmer , Wellesley , MA	9811
@NP	p24 core protein concentrations	9856
@NP	manufacturer 's instructions	9902
@NP	manufacturer 's	9902
@NP	viral vector stocks	9940
@NP	280 C	9975
@NP	SC or OEG infection	9987
@NP	Lentiviral vector transduction of glia to express GFP Virus concentrated in PBS	10008
@NP	Lentiviral vector transduction	10008
@NP	glia to express GFP Virus concentrated in PBS	10042
@NP	GFP Virus	10058
@NP	PBS	10084
@NP	SCs and OEG	10107
@NP	Cultures	10120
@NP	the addition of a predetermined volume of concentrated virus in DMEM	10146
@NP	the addition	10146
@NP	a predetermined volume of concentrated virus in DMEM	10162
@NP	a predetermined volume	10162
@NP	concentrated virus in DMEM	10188
@NP	concentrated virus	10188
@NP	DMEM	10210
@NP	10 % FBS and mitogens	10220
@NP	A multiplicity of infection -LRB- MOI -RRB- of 50	10242
@NP	A multiplicity	10242
@NP	infection -LRB- MOI -RRB- of 50	10260
@NP	infection -LRB- MOI -RRB-	10260
@NP	infection	10260
@NP	MOI	10271
@NP	50	10279
@NP	all cultures	10294
@NP	high transduction efficiency -LRB- 95 -- 98 % -RRB-	10317
@NP	high transduction efficiency	10317
@NP	95 -- 98 %	10347
@NP	95	10347
@NP	98 %	10350
@NP	an absence of toxicity	10360
@NP	an absence	10360
@NP	toxicity	10374
@NP	Animals Adult female Fischer rats -LRB- Harlan Co , n = 261 ; 180 -- 200 g -RRB-	10384
@NP	Animals Adult female Fischer rats	10384
@NP	Animals	10384
@NP	Adult female Fischer rats	10392
@NP	Harlan Co , n = 261 ; 180 -- 200 g	10419
@NP	Harlan Co	10419
@NP	n = 261 ; 180 -- 200 g	10430
@NP	n = 261	10430
@NP	n	10430
@NP	261	10434
@NP	180 -- 200 g	10439
@NP	180	10439
@NP	200 g	10444
@NP	NIH and The Guide for the Care and Use of Animals	10476
@NP	NIH	10476
@NP	The Guide for the Care and Use of Animals	10484
@NP	The Guide	10484
@NP	the Care and Use	10498
@NP	Animals	10518
@NP	The Institutional Animal Care and Use Committee of the University of Miami	10527
@NP	The Institutional Animal Care and Use Committee	10527
@NP	the University of Miami	10578
@NP	the University	10578
@NP	Miami	10596
@NP	all animal procedures	10611
@NP	surgery	10643
@NP	rats	10652
@NP	anesthetized -LRB- 45 mg/kg ketamine , 5 mg/kg xylazine -RRB-	10662
@NP	anesthetized	10662
@NP	45 mg/kg ketamine	10676
@NP	5 mg/kg xylazine	10695
@NP	intraperitoneal injection	10716
@NP	Moderate thoracic contusion injury	10743
@NP	Contusion injury	10778
@NP	the MASCIS weight drop device	10810
@NP	New York University -LRB- Gruner , 1992 -RRB-	10853
@NP	New York University	10853
@NP	Gruner	10874
@NP	1992	10882
@NP	A laminectomy performed at thoracic vertebra T8	10889
@NP	A laminectomy	10889
@NP	thoracic vertebra T8	10916
@NP	the dorsal surface of the spinal cord	10945
@NP	the dorsal surface	10945
@NP	the spinal cord	10967
@NP	-LRB- T9 -RRB- without disrupting the dura mater	10994
@NP	-LRB- T9 -RRB-	10994
@NP	the dura mater	11018
@NP	The exposed spinal cord	11034
@NP	a 10.0 g rod	11093
@NP	a height of 12.5 mm	11111
@NP	a height	11111
@NP	12.5 mm	11123
@NP	The contusion impact height , velocity and compression	11132
@NP	The contusion impact height	11132
@NP	velocity	11161
@NP	compression	11174
@NP	Animals -LRB- n = 16 -RRB-	11202
@NP	Animals	11202
@NP	n	11211
@NP	16	11215
@NP	height or velocity errors	11250
@NP	6 %	11285
@NP	the compression distance	11294
@NP	the range of 1.35 -- 1.75 mm	11334
@NP	the range of 1.35	11334
@NP	the range	11334
@NP	1.35	11347
@NP	1.75 mm	11352
@NP	injury	11367
@NP	the muscles	11375
@NP	layers	11403
@NP	the skin	11414
@NP	metal wound clips	11435
@NP	The rats	11454
@NP	a warmed cage with water and food easily accessible	11490
@NP	a warmed cage	11490
@NP	water and food	11509
@NP	Gentamicin	11543
@NP	5 mg/kg , intramuscular ; Abbott Laboratories , North Chicago , IL	11555
@NP	5 mg/kg	11555
@NP	intramuscular ; Abbott Laboratories , North Chicago	11564
@NP	intramuscular	11564
@NP	Abbott Laboratories , North Chicago	11579
@NP	Abbott Laboratories	11579
@NP	North Chicago	11600
@NP	IL	11615
@NP	seven days	11679
@NP	The analgesic	11691
@NP	Buprenex	11706
@NP	0.01 mg/kg of 0.3 mg/mL , subcutaneous ; Reckitt Benckiser , Richmond , VA	11716
@NP	0.01 mg/kg of 0.3 mg/mL	11716
@NP	0.01 mg/kg	11716
@NP	0.3 mg/mL	11730
@NP	subcutaneous ; Reckitt Benckiser	11741
@NP	subcutaneous	11741
@NP	Reckitt Benckiser	11755
@NP	Richmond , VA	11774
@NP	Richmond	11774
@NP	VA	11784
@NP	2 days	11828
@NP	1 week postinjury	11839
@NP	rats	11858
@NP	fluid grafts of SCs , OEG or both cell types	11872
@NP	fluid grafts	11872
@NP	SCs , OEG or both cell types	11888
@NP	SCs	11888
@NP	OEG	11893
@NP	both cell types	11900
@NP	Six uninjured animals	12505
@NP	controls	12537
@NP	Animals	12547
@NP	further	12560
@NP	each group	12587
@NP	time	12611
@NP	0 days , 3 days , 3 weeks , 9 weeks , or 12 weeks post-transplantation	12617
@NP	0 days	12617
@NP	3 days	12625
@NP	3 weeks	12633
@NP	9 weeks	12642
@NP	12 weeks post-transplantation	12654
@NP	endpoint analysis	12689
@NP	Animals	12708
@NP	the different treatment groups and outcome measures	12743
@NP	injury and implantation	12804
@NP	surgeries and interventions	12832
@NP	a randomized block design due to the large number of animals used for the study	12881
@NP	a	12881
@NP	block design	12894
@NP	the large number of animals used for the study	12914
@NP	the large number	12914
@NP	animals used for the study	12934
@NP	animals	12934
@NP	the study	12951
@NP	Transplantation Prior to implantation , EGFP transduced SCs and OEG	12962
@NP	Transplantation	12962
@NP	implantation , EGFP	12987
@NP	implantation	12987
@NP	EGFP	13001
@NP	SCs and OEG	13017
@NP	culture via trypsinization	13049
@NP	culture	13049
@NP	trypsinization	13061
@NP	SCs and OEG	13137
@NP	aliquots in DMEMF12 medium	13169
@NP	aliquots	13169
@NP	DMEMF12 medium	13181
@NP	ice	13213
@NP	surgery	13226
@NP	One week	13235
@NP	injury	13250
@NP	rats	13258
@NP	2 % halothane	13288
@NP	the injury site	13305
@NP	groups -LRB- i -RRB- 2	13337
@NP	groups	13337
@NP	i	13345
@NP	2	13348
@NP	10 ^ 6 SCs	13352
@NP	-LRB- ii -RRB- 2 x 10 ^ 6 OEG , -LRB- iii -RRB- 1 x 10 ^ 6 SCs and 1 3 106 OEG	13362
@NP	-LRB- ii -RRB- 2	13362
@NP	-LRB- ii -RRB-	13362
@NP	2	13367
@NP	10 ^ 6 OEG , -LRB- iii -RRB- 1 x 10 ^ 6 SCs and 1 3 106 OEG	13371
@NP	10 ^ 6 OEG , -LRB- iii -RRB- 1	13371
@NP	10 ^ 6 OEG , -LRB- iii -RRB-	13371
@NP	10 ^	13371
@NP	6 OEG	13374
@NP	iii	13382
@NP	1	13387
@NP	10 ^ 6 SCs	13391
@NP	10 ^	13391
@NP	6 SCs	13394
@NP	1 3 106 OEG	13404
@NP	1 3	13404
@NP	106 OEG	13408
@NP	iv	13421
@NP	1	13425
@NP	10 ^ 6 fibroblasts	13429
@NP	10 ^	13429
@NP	6 fibroblasts	13432
@NP	all in 6 µL of DMEM-F12 medium	13447
@NP	all	13447
@NP	6 µL of DMEM-F12 medium	13454
@NP	6 µL	13454
@NP	DMEM-F12 medium	13462
@NP	cells	13479
@NP	the epicenter of the contused area	13504
@NP	the epicenter	13504
@NP	the contused area	13521
@NP	v	13544
@NP	2 3 106 SCs in 6 µL of DMEM-F12 medium	13547
@NP	2 3 106 SCs	13547
@NP	6 µL of DMEM-F12 medium	13562
@NP	6 µL	13562
@NP	DMEM-F12 medium	13570
@NP	the epicenter of the contused area and 2 3 105 OEG	13605
@NP	the epicenter of the contused area	13605
@NP	the epicenter	13605
@NP	the contused area	13622
@NP	2 3 105 OEG	13644
@NP	2 3	13644
@NP	105 OEG	13648
@NP	0.5 µL of DMEM-F12	13659
@NP	0.5 µL	13659
@NP	DMEM-F12	13669
@NP	0.25 µL per injection	13693
@NP	0.25 µL	13693
@NP	injection	13705
@NP	the midline at 4 mm rostral and caudal	13731
@NP	the midline	13731
@NP	4 mm rostral and caudal	13746
@NP	the epicenter of the contused area at a depth of 1 mm	13773
@NP	the epicenter	13773
@NP	the contused area at a depth of 1 mm	13790
@NP	the contused area	13790
@NP	a depth of 1 mm	13811
@NP	a depth	13811
@NP	1 mm	13822
@NP	Injections	13828
@NP	a 10 or 1 µL	13867
@NP	Hamilton syringe	13892
@NP	a pulled , beveled glass	13914
@NP	pipette tip	13938
@NP	200 µm diameter	13951
@NP	a micromanipulator with a micro-injector	13977
@NP	a micromanipulator	13977
@NP	a micro-injector	14001
@NP	a rate of 2 µL/min -LRB- World Precision Instruments , Sarasota , FL -RRB-	14021
@NP	a rate	14021
@NP	2 µL/min -LRB- World Precision Instruments , Sarasota , FL -RRB-	14031
@NP	2 µL/min	14031
@NP	World Precision Instruments , Sarasota , FL	14041
@NP	World Precision Instruments , Sarasota	14041
@NP	FL	14080
@NP	The injection pipette	14085
@NP	place for an additional 3 min	14119
@NP	place	14119
@NP	an additional 3 min	14129
@NP	leakage	14161
@NP	withdrawal	14174
@NP	the injections	14192
@NP	the muscle layers and the skin	14208
@NP	the muscle layers	14208
@NP	the skin	14230
@NP	animals	14266
@NP	postoperative care	14283
@NP	Injury-only controls	14322
@NP	no spinal cord injections	14352
@NP	Brains from anterogradely traced animals	14858
@NP	Brains	14858
@NP	anterogradely traced animals	14870
@NP	accurate tracer injection	14937
@NP	the hind limb area of the motor cortex	14968
@NP	the hind limb area	14968
@NP	the motor cortex	14990
@NP	each animal	15010
@NP	Histology	15023
@NP	13 weeks after injury -LRB- 12 weeks post-transplantation -RRB-	15036
@NP	13 weeks	15036
@NP	injury -LRB- 12 weeks post-transplantation -RRB-	15051
@NP	injury	15051
@NP	12 weeks	15059
@NP	rats	15091
@NP	70 mg/kg ketamine	15122
@NP	10 mg/kg xylazine	15141
@NP	4 % paraformaldehyde -LRB- PFA , 0.1 M , pH 7.4 -RRB-	15193
@NP	4 % paraformaldehyde	15193
@NP	PFA	15214
@NP	0.1 M	15219
@NP	pH 7.4	15226
@NP	The brain and spinal cord	15235
@NP	The brain	15235
@NP	spinal cord	15249
@NP	overnight in 4 % PFA	15288
@NP	overnight	15288
@NP	4 % PFA	15301
@NP	4 °C	15311
@NP	phosphate-buffered 30 % sucrose for 48 hours	15340
@NP	phosphate-buffered 30 % sucrose	15340
@NP	48 hours	15375
@NP	4 C for tissue cryoprotection -LRB- gelatin embedding -RRB-	15387
@NP	4 C	15387
@NP	tissue cryoprotection -LRB- gelatin embedding -RRB-	15395
@NP	tissue cryoprotection	15395
@NP	gelatin embedding	15418
@NP	5 days in 4 % PFA -LRB- refreshed daily -RRB-	15454
@NP	5 days	15454
@NP	4 % PFA -LRB- refreshed daily -RRB-	15464
@NP	4 % PFA	15464
@NP	The T7-11 thoracic spinal cords	15490
@NP	20 - mm-long piece	15523
@NP	20	15523
@NP	mm-long piece	15527
@NP	the complete lesion and graft site	15559
@NP	paraffin	15633
@NP	n = 6 per group , no cords embedded for injury only and FB transplant	15643
@NP	n	15643
@NP	6 per group , no cords embedded for injury only and FB transplant	15647
@NP	6 per group	15647
@NP	6	15647
@NP	group	15653
@NP	no cords embedded for injury only and FB transplant	15660
@NP	no cords	15660
@NP	injury only and FB transplant	15682
@NP	injury only	15682
@NP	FB transplant	15698
@NP	phosphate-buffered 10 % gelatin solution	15719
@NP	Difco Laboratories	15760
@NP	Detroit	15780
@NP	MI	15789
@NP	n = 12 per group	15794
@NP	n = 12	15794
@NP	n	15794
@NP	12	15798
@NP	group	15805
@NP	Barakat	15813
@NP	et al. , 2005	15821
@NP	et al.	15821
@NP	2005	15829
@NP	Paraffin-embedded spinal cords	15836
@NP	10 µm on a microtome	15896
@NP	10 µm	15896
@NP	a microtome	15905
@NP	stereological counting of numbers of surviving	15930
@NP	stereological counting	15930
@NP	numbers of surviving	15956
@NP	numbers	15956
@NP	surviving	15967
@NP	transplanted male cells following DNA in situ and 3D	15978
@NP	transplanted male cells	15978
@NP	DNA in situ and 3D	16012
@NP	DNA	16012
@NP	situ and 3D	16019
@NP	reconstruction	16031
@NP	computer-assisted microscopy	16049
@NP	Every third section	16079
@NP	sectioning	16120
@NP	six series	16146
@NP	Snowcoat X-tra slides -LRB- Surgipath , Winnipeg , Manitoba -RRB-	16162
@NP	Snowcoat X-tra slides	16162
@NP	Surgipath	16185
@NP	Winnipeg	16196
@NP	Manitoba	16206
@NP	27 °C	16230
@NP	hybridization	16254
@NP	Gelatin embedded spinal cords	16269
@NP	Gelatin	16269
@NP	embedded spinal cords	16277
@NP	30 µm on a freezing microtome	16328
@NP	30 µm	16328
@NP	a freezing microtome	16337
@NP	EGFP cell migration	16375
@NP	axon growth support in combination	16399
@NP	axon growth support	16399
@NP	combination	16422
@NP	specific immunochemical stains	16439
@NP	a separate group of animals , tract tracing	16477
@NP	a separate group	16477
@NP	animals , tract tracing	16497
@NP	animals	16497
@NP	tract tracing	16506
@NP	tract	16506
@NP	Sections	16521
@NP	six series in PBS -LRB- 0.1 M , pH 7.4 -RRB-	16550
@NP	six series	16550
@NP	PBS -LRB- 0.1 M , pH 7.4 -RRB-	16564
@NP	PBS	16564
@NP	0.1 M	16569
@NP	pH 7.4	16576
@NP	4 °C	16598
@NP	further processing	16608
@NP	Western blotting Animals	16628
@NP	3 days , 3 weeks or 9 weeks post-transplantation	16681
@NP	3 days	16681
@NP	3 weeks	16689
@NP	9 weeks post-transplantation	16700
@NP	a 10-mm piece	16733
@NP	spinal cord	16750
@NP	the injury/graft site	16775
@NP	280 C in liquid nitrogen	16833
@NP	280 C	16833
@NP	liquid nitrogen	16842
@NP	n 5 4 per time point	16859
@NP	n	16859
@NP	5 4 per time point	16861
@NP	5 4	16861
@NP	time point	16869
@NP	EGFPþ SC	16881
@NP	A pregrafted aliquot of 2 million EGFPþ SCs	16904
@NP	A pregrafted aliquot	16904
@NP	2 million EGFPþ SCs	16928
@NP	a 0 day baseline control	16958
@NP	Samples	16984
@NP	Pearse et al. , 2001	17047
@NP	Pearse	17047
@NP	et al.	17054
@NP	2001	17062
@NP	Protein concentrations	17069
@NP	the Bradford protein assay -LRB- Bio-Rad , Hercules , CA -RRB-	17114
@NP	the Bradford protein assay	17114
@NP	Bio-Rad	17142
@NP	Hercules	17151
@NP	CA	17161
@NP	samples	17176
@NP	concentrations of 10 mg/mL	17189
@NP	concentrations	17189
@NP	10 mg/mL	17207
@NP	Aliquots	17217
@NP	50 µg total protein	17237
@NP	loaded for one-dimensional 10 % SDSpolyacrylamide gel electrophoresis	17262
@NP	one-dimensional 10 % SDSpolyacrylamide	17273
@NP	Proteins	17332
@NP	PVDF membranes	17366
@NP	5 % nonfat dry milk	17395
@NP	then	17418
@NP	primary rabbit anti- GFP antibody	17436
@NP	1:2,000 ; Santa Cruz Biotechnology , CA	17471
@NP	1:2,000	17471
@NP	Santa Cruz Biotechnology , CA	17480
@NP	HRP-conjugated goat	17522
@NP	anti-rabbit IgG -LRB- 1:2,000 ; Santa Cruz Biotechnology -RRB-	17542
@NP	anti-rabbit IgG	17542
@NP	1:2,000 ; Santa Cruz Biotechnology	17559
@NP	1:2,000	17559
@NP	Santa Cruz Biotechnology	17568
@NP	Membranes	17595
@NP	Chemiluminescence Reagent Plus	17630
@NP	PerkinElmer Life Sciences , Wellesley , MA	17662
@NP	PerkinElmer Life Sciences	17662
@NP	Wellesley , MA	17689
@NP	1 min	17708
@NP	Kodak X-OMAT films -LRB- Eastman Kodak , Rochester , NY -RRB-	17729
@NP	Kodak X-OMAT films	17729
@NP	Eastman Kodak	17749
@NP	Rochester	17764
@NP	NY	17775
@NP	Quantification of GFP signal	17780
@NP	Quantification	17780
@NP	GFP signal	17798
@NP	a Fluor-S Multi Imager -LRB- Bio-Rad -RRB-	17826
@NP	a Fluor-S Multi Imager	17826
@NP	Bio-Rad	17850
@NP	Band densitometry measurements	17860
@NP	Quantity One software version 4.2.0 -LRB- Bio-Rad -RRB-	17907
@NP	Quantity One software version 4.2.0	17907
@NP	Quantity One software	17907
@NP	version 4.2.0	17929
@NP	Bio-Rad	17944
@NP	consistent loading of equal protein amounts	17964
@NP	consistent loading	17964
@NP	equal protein amounts	17986
@NP	blots	18009
@NP	b-actin mouse monoclonal antibody	18053
@NP	1:1,000 , AbCam	18088
@NP	1:1,000	18088
@NP	AbCam	18097
@NP	b-actin signal	18105
@NP	Non-radioactive DNA-DNA ISH	18155
@NP	The rat Y-chromosome	18183
@NP	specific DNA probe in plasmid pUC18	18204
@NP	specific DNA probe	18204
@NP	plasmid pUC18	18226
@NP	a gift from Dr.	18244
@NP	a gift	18244
@NP	Dr.	18256
@NP	Barbara Hoebee -LRB- Essers et al. , 1995 -RRB- .	18260
@NP	Barbara Hoebee	18260
@NP	Essers	18276
@NP	et al. , 1995	18283
@NP	et al.	18283
@NP	1995	18291
@NP	The plasmid	18298
@NP	nick translation with digoxigenin	18328
@NP	nick translation	18328
@NP	digoxigenin	18350
@NP	DIG ; Roche Applied Science , Indianapolis , IN	18363
@NP	DIG	18363
@NP	Roche Applied Science , Indianapolis , IN	18368
@NP	Roche Applied Science , Indianapolis ,	18368
@NP	Roche Applied Science	18368
@NP	Indianapolis	18391
@NP	a probe size of 0.1 -- 0.5 kbp	18419
@NP	a probe size of 0.1	18419
@NP	a probe size	18419
@NP	0.1	18435
@NP	0.5 kbp	18439
@NP	The probe	18448
@NP	0.2	18478
@NP	0.5 µg/mL	18482
@NP	hybridization buffer	18495
@NP	50 % Formamide -LRB- Sigma , St.Louis , MO -RRB-	18531
@NP	50 % Formamide	18531
@NP	Sigma	18546
@NP	St.Louis	18553
@NP	MO	18563
@NP	2X SSC -LRB- pH 8.0 -RRB- , 1X Denhardt 's	18568
@NP	2X SSC -LRB- pH 8.0 -RRB-	18568
@NP	2X SSC	18568
@NP	pH 8.0	18576
@NP	1X Denhardt 's	18585
@NP	1 mg / mL Herring sperm DNA -LRB- Sigma -RRB-	18600
@NP	1 mg / mL Herring sperm DNA	18600
@NP	mL Herring sperm DNA	18606
@NP	mL Herring	18606
@NP	sperm DNA	18617
@NP	Sigma	18628
@NP	10 % Dextran sulfate -LRB- Sigma -RRB-	18639
@NP	10 % Dextran sulfate	18639
@NP	Sigma	18660
@NP	probe	18676
@NP	95 C	18699
@NP	use	18719
@NP	Sagittal	18724
@NP	10 µm paraffin-embedded spinal cord sections	18734
@NP	180 µm intervals ; ≈ 10/cord	18780
@NP	180 µm intervals	18780
@NP	≈ 10/cord	18798
@NP	xylene	18837
@NP	ethanol washes	18877
@NP	the tissue for hybridization	18904
@NP	the tissue	18904
@NP	hybridization	18919
@NP	sections	18934
@NP	10 µg/mL Proteinase K	18967
@NP	USB , Clevelend , OH	18990
@NP	USB	18990
@NP	Clevelend	18995
@NP	OH	19006
@NP	TE buffer	19013
@NP	The DNA in the tissue	19024
@NP	The DNA	19024
@NP	the tissue	19035
@NP	incubation in 0.01 M citrate buffer -LRB- pH 6.0 -RRB- at 96 °C	19067
@NP	incubation	19067
@NP	0.01 M citrate buffer -LRB- pH 6.0 -RRB- at 96 °C	19081
@NP	0.01 M citrate buffer -LRB- pH 6.0 -RRB-	19081
@NP	0.01 M citrate buffer	19081
@NP	pH 6.0	19104
@NP	96 °C	19115
@NP	slide immersion in 50 % Formamide/2X SSC at 75 C and then 70 % ethanol at 270 C.	19132
@NP	slide immersion	19132
@NP	50 % Formamide/2X SSC at 75 C and then 70 % ethanol at 270 C.	19151
@NP	50 % Formamide/2X SSC at 75 C	19151
@NP	50 % Formamide/2X SSC	19151
@NP	75 C	19175
@NP	70 % ethanol at 270 C.	19189
@NP	70 % ethanol	19189
@NP	270 C.	19204
@NP	Hybridization	19211
@NP	48 C.	19252
@NP	post-hybridization washes	19264
@NP	the immunodetection process	19291
@NP	incubation	19328
@NP	solution	19359
@NP	alkaline phosphatase-conjugated anti-DIG antibody -LRB- 1:1,000 -RRB-	19379
@NP	alkaline phosphatase-conjugated anti-DIG antibody	19379
@NP	1:1,000	19430
@NP	Roche Applied Science	19440
@NP	alkaline phosphatase detection buffer	19476
@NP	nitroblue tetrazolium chloride -LRB- NBT -RRB-	19525
@NP	nitroblue tetrazolium chloride	19525
@NP	NBT	19557
@NP	5-bromo-4-chloro-3-indolyl phosphate -LRB- BCIP -RRB-	19566
@NP	5-bromo-4-chloro-3-indolyl phosphate	19566
@NP	BCIP	19604
@NP	Roche Applied Science	19611
@NP	Methyl Green -LRB- Vector Laboratories ; Burlingame , CA -RRB-	19662
@NP	Methyl Green	19662
@NP	Vector Laboratories ; Burlingame , CA	19676
@NP	Vector Laboratories	19676
@NP	Burlingame , CA	19697
@NP	slides	19714
@NP	VectaMount medium -LRB- Vector Laboratories -RRB- for microscopic analysis	19744
@NP	VectaMount medium -LRB- Vector Laboratories -RRB-	19744
@NP	VectaMount medium	19744
@NP	Vector Laboratories	19763
@NP	microscopic analysis	19788
@NP	Male and female cord sections	19810
@NP	each ISH reaction as positive and negative controls	19857
@NP	each ISH reaction	19857
@NP	positive and negative controls	19878
@NP	Immunochemistry Every other sixth sagittal section	19924
@NP	Immunochemistry	19924
@NP	Every other sixth sagittal section	19940
@NP	fluorescent microscopy as previously described -LRB- Barakat et al. , 2005 -RRB-	20008
@NP	fluorescent microscopy	20008
@NP	Barakat	20056
@NP	et al. , 2005	20064
@NP	et al.	20064
@NP	2005	20072
@NP	the primary antibodies	20911
@NP	sections	20935
@NP	the fluorescent secondary antibodies	20964
@NP	a mix	21002
@NP	Alexa 660-conjugated donkey	21011
@NP	rabbit -LRB- 1:200 ; Molecular Probes -RRB- and Alexa	21054
@NP	rabbit -LRB- 1:200 ; Molecular Probes -RRB-	21054
@NP	rabbit	21054
@NP	1:200 ; Molecular Probes	21062
@NP	1:200	21062
@NP	Molecular Probes	21069
@NP	Alexa	21091
@NP	594-conjugated goat	21097
@NP	rabbit or rabbit	21133
@NP	rabbit	21133
@NP	rabbit	21143
@NP	anti-goat	21150
@NP	1:200 ; Molecular Probes	21161
@NP	1:200	21161
@NP	Molecular Probes	21168
@NP	Sections	21187
@NP	Snowcoat X-tra slides -LRB- Surgipath -RRB-	21214
@NP	Snowcoat X-tra slides	21214
@NP	Surgipath	21237
@NP	Vectashield mounting	21270
@NP	me	21291
@NP	dium -LRB- Vector Laboratories -RRB-	21295
@NP	dium	21295
@NP	Vector Laboratories	21301
@NP	the nuclear	21333
@NP	Hoechst	21349
@NP	4 C.	21369
@NP	fluorescent visualization of BDA-traced corticospinal tract axons	21378
@NP	fluorescent visualization	21378
@NP	BDA-traced corticospinal tract axons	21407
@NP	every other sixth section	21445
@NP	1 hour	21489
@NP	horseradish peroxidase steptavidin	21501
@NP	rhodamine -LRB- Vector Laboratories -RRB-	21550
@NP	rhodamine	21550
@NP	Vector Laboratories	21561
@NP	Sections	21583
@NP	Snowcoat X-tra slides -LRB- Surgipath -RRB-	21610
@NP	Snowcoat X-tra slides	21610
@NP	Surgipath	21633
@NP	Vectashield mounting medium -LRB- Vector Laboratories -RRB-	21666
@NP	Vectashield mounting medium	21666
@NP	Vector Laboratories	21695
@NP	the nuclear	21727
@NP	Hoechst	21743
@NP	4 °C	21763
@NP	Stereological quantification	21768
@NP	male , EGFPþ or p75þ cell number	21800
@NP	one series	21835
@NP	mounted sagittal sections	21849
@NP	male cells	21876
@NP	DNA ISH or EGFPþ and p75þ cells	21907
@NP	fluorescent signal	21954
@NP	an unbiased method	21993
@NP	computer-assisted microscopy and StereoInvestigator software	22022
@NP	MicroBrightField	22084
@NP	the 3D structure	22113
@NP	the spinal cord	22133
@NP	n	22150
@NP	= 6 per group at each time point	22152
@NP	= 6	22152
@NP	group at each time point	22160
@NP	group	22160
@NP	each time point	22169
@NP	3 days , 3 weeks , or 9 weeks post-transplantation	22186
@NP	3 days	22186
@NP	3 weeks	22194
@NP	9 weeks post-transplantation	22206
@NP	each section	22240
@NP	the boundary of the cell graft	22253
@NP	the boundary	22253
@NP	the cell graft	22269
@NP	a dense area -LRB- s -RRB-	22299
@NP	a dense area	22299
@NP	alkaline phosphatase-positive -LRB- male -RRB- cell nuclei	22318
@NP	EGFPþ or p75þ cells	22368
@NP	a 203 objective	22411
@NP	the StereoInvestigator software	22443
@NP	serial section manager	22481
@NP	the positions	22519
@NP	each section -LRB- 10 sections per spinal cord at 180 µm intervals -RRB-	22536
@NP	each section	22536
@NP	10 sections per spinal cord at 180 µm intervals	22551
@NP	10 sections	22551
@NP	spinal cord at 180 µm intervals	22567
@NP	spinal cord	22567
@NP	180 µm intervals	22582
@NP	the Z-axis of the 3D reconstruction of the spinal cord	22607
@NP	the Z-axis	22607
@NP	the 3D reconstruction of the spinal cord	22621
@NP	the 3D reconstruction	22621
@NP	the spinal cord	22646
@NP	optical fractionator , the traced contour of each section	22675
@NP	optical fractionator	22675
@NP	the traced contour of each section	22697
@NP	the traced contour	22697
@NP	each section	22719
@NP	50 3 50 µm2 counting frames	22749
@NP	these frames	22778
@NP	two	22813
@NP	four cells	22820
@NP	the grid size	22838
@NP	the software	22884
@NP	counting of 35 sampling sites	22907
@NP	counting	22907
@NP	35 sampling sites	22919
@NP	each traced contour of each section	22944
@NP	each traced contour	22944
@NP	each section	22967
@NP	each sampling site	22984
@NP	the number	23003
@NP	positive cells	23017
@NP	methyl green -LRB- in situ -RRB- or Hoechst -LRB- fluorescence -RRB-	23037
@NP	methyl green	23037
@NP	situ	23054
@NP	Hoechst	23063
@NP	fluorescence	23072
@NP	nuclei	23094
@NP	a dissector probe	23123
@NP	a 633 objective	23147
@NP	Algorithms	23164
@NP	the Zstack total counts of positive cells	23190
@NP	the Zstack total counts	23190
@NP	positive cells	23217
@NP	the 3D structure of each spinal cord	23239
@NP	the 3D structure	23239
@NP	each spinal cord	23259
@NP	StereoInvestigator 3.0 -LRB- MicroBrightField -RRB-	23304
@NP	StereoInvestigator 3.0	23304
@NP	MicroBrightField	23328
@NP	The coefficient	23347
@NP	error -LRB- CE -RRB-	23366
@NP	error	23366
@NP	CE	23373
@NP	Gundersen	23378
@NP	each estimated count	23393
@NP	less than 10 %	23418
@NP	Assessment	23433
@NP	glial cell migratory ability	23447
@NP	the migratory ability of transplanted glial cells	23486
@NP	the migratory ability	23486
@NP	transplanted glial cells	23511
@NP	the injured spinal cord , sections that contained Y-probe labeled cells	23543
@NP	the injured spinal cord	23543
@NP	sections that contained Y-probe labeled cells	23568
@NP	sections	23568
@NP	Y-probe labeled cells	23592
@NP	Y-probe	23592
@NP	cells	23608
@NP	GFAP	23637
@NP	the borders of the injury site	23652
@NP	the borders	23652
@NP	the injury site	23667
@NP	Spinal cords	23684
@NP	3D	23724
@NP	StereoInvestigator software and computer-assisted microscopy	23733
@NP	n = 5/group	23795
@NP	n	23795
@NP	= 5/group	23797
@NP	the 3D representation of the spinal cord from each animal	23816
@NP	the 3D representation	23816
@NP	the spinal cord from each animal	23841
@NP	the spinal cord	23841
@NP	each animal	23862
@NP	50	23891
@NP	x 50 x 30 µm3 3D sampling grids	23894
@NP	50	23896
@NP	30 µm3 3D sampling grids	23901
@NP	cell counts	23937
@NP	The number of cell counts obtained within each grid -LRB- 20 3 5 arrays -RRB-	23971
@NP	The number	23971
@NP	cell counts obtained within each grid -LRB- 20 3 5 arrays -RRB-	23985
@NP	cell counts	23985
@NP	each grid -LRB- 20 3 5 arrays -RRB-	24013
@NP	each grid	24013
@NP	20 3 5 arrays	24024
@NP	20 3	24024
@NP	5 arrays	24029
@NP	a percentage of the total counts for the whole spinal cord	24061
@NP	a percentage	24061
@NP	the total counts for the whole spinal cord	24077
@NP	the total counts	24077
@NP	the whole spinal cord	24098
@NP	We	24121
@NP	these percentages	24138
@NP	each of the 100 gids	24159
@NP	each	24159
@NP	the 100 gids	24167
@NP	all the animals	24186
@NP	a particular group -LRB- specific transplant type and timepoint i.e.	24209
@NP	a particular group -LRB- specific transplant type and timepoint	24209
@NP	i.e.	24268
@NP	SCs into the lesion at 3 days -RRB- .	24273
@NP	SCs	24273
@NP	the lesion at 3 days -RRB-	24282
@NP	the lesion	24282
@NP	3 days	24296
@NP	this method	24311
@NP	we	24324
@NP	the spatial density of the grafted cells	24347
@NP	the spatial density	24347
@NP	the grafted cells	24370
@NP	rostral-caudal , dorsal-ventral space relative to the injection site	24391
@NP	rostral-caudal , dorsal-ventral space	24391
@NP	the injection site	24440
@NP	visualization of how they changed over time within a specific	24495
@NP	visualization	24495
@NP	they	24516
@NP	time	24534
@NP	a specific	24546
@NP	group	24565
@NP	no deviations	24575
@NP	the method	24608
@NP	statistical comparisons	24629
@NP	Quantitative assessment of traced fibers BDA - or CTB-labeled axons	24672
@NP	Quantitative assessment	24672
@NP	fibers BDA - or CTB-labeled axons	24706
@NP	fibers BDA	24706
@NP	fibers	24706
@NP	BDA	24713
@NP	CTB-labeled axons	24721
@NP	every sixth section of the T8 -- 10 cord segments , i.e.	24756
@NP	every sixth section	24756
@NP	the T8 -- 10 cord segments , i.e.	24779
@NP	the T8	24779
@NP	10 cord segments	24786
@NP	every 180 µm interval	24809
@NP	the width of the spinal cord	24840
@NP	the width	24840
@NP	the spinal cord	24853
@NP	12 weeks	24872
@NP	axons	24911
@NP	fluorescence microscopy	24939
@NP	The number of BDA-labeled axons	24964
@NP	The number	24964
@NP	BDA-labeled axons	24978
@NP	all	25023
@NP	axons	25035
@NP	imaginary lines	25050
@NP	the rostral-caudal cord axis at 2,000 µm and 500 µm rostral	25090
@NP	the rostral-caudal cord axis	25090
@NP	2,000 µm and 500 µm rostral	25122
@NP	2,000 µm	25122
@NP	500 µm rostral	25135
@NP	the graft-host or injury-host interface	25153
@NP	the graft-host	25153
@NP	injury-host interface	25171
@NP	the GFAP-EGFP or GFAPþ-GFAP2 border	25208
@NP	the epicenter of the graft/injury site	25252
@NP	the epicenter	25252
@NP	the graft/injury site	25269
@NP	oil immersion	25297
@NP	a 633 objective	25316
@NP	The number of CTB-labeled axons	25333
@NP	The number	25333
@NP	CTB-labeled axons	25347
@NP	2,000 µm and 500 µm caudal to the graft-host or injury-host interface	25396
@NP	2,000 µm	25396
@NP	500 µm caudal to the graft-host or injury-host interface	25409
@NP	500 µm caudal	25409
@NP	the graft-host or injury-host interface	25426
@NP	the graft-host	25426
@NP	injury-host interface	25444
@NP	the epicenter of the graft/injury site	25473
@NP	the epicenter	25473
@NP	the graft/injury site	25490
@NP	The number of fibers from each section , 10 sections per spinal cord ,	25513
@NP	The number of fibers from each section	25513
@NP	The number	25513
@NP	fibers from each section	25527
@NP	fibers	25527
@NP	each section	25539
@NP	10 sections per spinal cord	25554
@NP	10 sections	25554
@NP	spinal cord	25570
@NP	each rat	25603
@NP	the number of fibers per section	25625
@NP	the number	25625
@NP	fibers per section	25639
@NP	fibers	25639
@NP	section	25650
@NP	the totals	25659
@NP	the number of sections examined	25691
@NP	the number	25691
@NP	sections examined	25705
@NP	sections	25705
@NP	Tracing efficiency	25724
@NP	animals	25768
@NP	intensity in the dorsal columns of five transverse sections	25793
@NP	intensity	25793
@NP	the dorsal columns of five transverse sections	25806
@NP	the dorsal columns	25806
@NP	five transverse sections	25828
@NP	either the C2 or L5 spinal cord	25858
@NP	the C2	25865
@NP	L5 spinal cord	25875
@NP	BDA and CTB	25894
@NP	each animal	25934
@NP	Images of the dorsal columns in each of the sections	25947
@NP	Images	25947
@NP	the dorsal columns in each of the sections	25957
@NP	the dorsal columns	25957
@NP	each of the sections	25979
@NP	each	25979
@NP	the sections	25987
@NP	intensity-measuring software	26020
@NP	van der Lest et al. , University of Njimegen ,	26050
@NP	van der	26050
@NP	et al. , University of Njimegen ,	26063
@NP	et al.	26063
@NP	University of Njimegen	26071
@NP	University	26071
@NP	Njimegen	26085
@NP	The Netherlands	26095
@NP	The software automatically measured , and gave in arbitrary units	26113
@NP	The software	26113
@NP	arbitrary units	26162
@NP	the total pixel intensity of the	26179
@NP	the total pixel intensity	26179
@NP	the	26208
@NP	staining	26216
@NP	each image	26228
@NP	These values	26240
@NP	the five sections	26277
@NP	a mean BDA or CTB intensity	26303
@NP	each animal	26335
@NP	a measure of tracing efficiency	26350
@NP	a measure	26350
@NP	efficiency	26371
@NP	Determination of 5HT and CGRP	26383
@NP	Determination	26383
@NP	5HT and CGRP	26400
@NP	fiber growth	26413
@NP	The numbers of 5HT	26426
@NP	The numbers	26426
@NP	5HT	26441
@NP	axons	26454
@NP	all	26488
@NP	axons	26500
@NP	imaginary lines	26515
@NP	the rostral-caudal axis of the spinal cord at 2,000 µm and 500 µm rostral	26555
@NP	the rostral-caudal axis	26555
@NP	the spinal cord at 2,000 µm and 500 µm rostral	26582
@NP	the spinal cord	26582
@NP	2,000 µm and 500 µm rostral	26601
@NP	2,000 µm	26601
@NP	500 µm rostral	26614
@NP	the grafthost or injury-host interface	26632
@NP	the grafthost	26632
@NP	injury-host interface	26649
@NP	the GFAPEGFP or GFAPþ-GFAP2 border	26686
@NP	the epicenter of the graft/injury site	26729
@NP	the epicenter	26729
@NP	the graft/injury site	26746
@NP	oil immersion	26774
@NP	a 633 objective	26793
@NP	The number of CGRP-labeled axons	26810
@NP	The number	26810
@NP	CGRP-labeled axons	26824
@NP	2,000 and 500 lm caudal to the graft-host or injury-host interface	26874
@NP	2,000 and 500 lm caudal	26874
@NP	the graft-host or injury-host interface	26901
@NP	the graft-host	26901
@NP	injury-host interface	26919
@NP	the epicenter of the graft/injury site	26948
@NP	the epicenter	26948
@NP	the graft/injury site	26965
@NP	The number of fibers from each section , ≈ 10 sections per spinal cord ,	26988
@NP	The number of fibers from each section	26988
@NP	The number	26988
@NP	fibers from each section	27002
@NP	fibers	27002
@NP	each section	27014
@NP	≈ 10 sections per spinal cord	27028
@NP	≈ 10 sections	27028
@NP	spinal cord	27045
@NP	each rat	27078
@NP	n = 6 per group	27088
@NP	n = 6	27088
@NP	n	27088
@NP	6	27092
@NP	group	27098
@NP	12 weeks	27107
@NP	the number of fibers per section	27151
@NP	the number	27151
@NP	fibers per section	27165
@NP	fibers	27165
@NP	section	27176
@NP	the totals	27185
@NP	the number of sections examined	27217
@NP	the number	27217
@NP	sections examined	27231
@NP	sections	27231
@NP	Assessment	27250
@NP	We	27276
@NP	myelination of axons	27288
@NP	myelination	27288
@NP	axons	27303
@NP	SC and OEG transplants in vivo using high power	27316
@NP	SC and OEG transplants	27316
@NP	high power	27353
@NP	the number	27390
@NP	axons	27404
@NP	myelin basic protein -LRB- MBP -RRB- immunostaining	27415
@NP	MBP	27437
@NP	the number	27469
@NP	EGFP	27483
@NP	cells	27496
@NP	three regions of the transplants	27510
@NP	three regions	27510
@NP	the transplants	27527
@NP	three sections	27547
@NP	one	27563
@NP	the central canal and two	27578
@NP	the central canal	27578
@NP	two	27600
@NP	180 µm on either side , 200 µm2 areas	27607
@NP	180 µm	27607
@NP	either side , 200 µm2 areas	27617
@NP	either side	27617
@NP	200 µm2 areas	27630
@NP	the center of the graft and at distances 1,500 µm both rostral and caudal	27663
@NP	the center of the graft	27663
@NP	the center	27663
@NP	the graft	27677
@NP	distances	27694
@NP	1,500 µm both rostral and caudal	27704
@NP	1,500 µm	27704
@NP	rostral and caudal	27718
@NP	the center	27740
@NP	the transplants , from pictures obtained of the grafts	27769
@NP	the transplants	27769
@NP	pictures obtained of the grafts	27791
@NP	pictures	27791
@NP	the grafts	27812
@NP	oil immersion with the 633 objective	27829
@NP	oil immersion	27829
@NP	the 633 objective	27848
@NP	Neuroleucida	27872
@NP	software -LRB- Micro - BrightField -RRB-	27898
@NP	software	27898
@NP	Micro - BrightField	27908
@NP	Micro	27908
@NP	BrightField	27915
@NP	each of these three areas	27932
@NP	each	27932
@NP	these three areas	27940
@NP	the numbers of MBPþ axons and EGFPþ cells	27959
@NP	the numbers	27959
@NP	MBPþ axons and EGFPþ cells	27974
@NP	ratios of myelinated axons to grafted cells obtained	28015
@NP	ratios	28015
@NP	myelinated axons to grafted cells obtained	28025
@NP	myelinated axons	28025
@NP	grafted cells obtained	28045
@NP	grafted cells	28045
@NP	these ratios	28072
@NP	the three sections	28106
@NP	Myelination	28126
@NP	those animals	28154
@NP	EGFPþ SCs alone or SCs and EGFPþ OEG	28181
@NP	EGFPþ SCs	28181
@NP	SCs and EGFPþ OEG	28200
@NP	the injury site due to the formation of large , substantive transplants	28223
@NP	the injury site	28223
@NP	the formation of large , substantive transplants	28246
@NP	the formation	28246
@NP	large , substantive transplants	28263
@NP	these groups	28302
@NP	Behavioral testing Gross	28316
@NP	limb performance	28346
@NP	1 to 9 weeks post-transplantation	28389
@NP	1 to 9 weeks	28389
@NP	the open field locomotor test -LRB- BBB -RRB-	28429
@NP	the open field locomotor test	28429
@NP	BBB	28460
@NP	Basso	28478
@NP	et al. -LRB- 1995 -RRB- -LRB- n = 12 per group -RRB-	28484
@NP	et al. -LRB- 1995 -RRB-	28484
@NP	et al.	28484
@NP	1995	28492
@NP	n = 12 per group	28499
@NP	n = 12	28499
@NP	n	28499
@NP	12	28503
@NP	group	28510
@NP	A BBB sub-score	28518
@NP	the recovery of some animals	28546
@NP	the recovery	28546
@NP	some animals	28562
@NP	the progression of the BBB score	28590
@NP	the progression	28590
@NP	the BBB score	28609
@NP	BBB sub-scores	28624
@NP	paw position	28665
@NP	parallel paw rotation	28679
@NP	initial contact -LRB- 1 point/limb -RRB- and liftoff -LRB- 1 point/limb -RRB-	28704
@NP	initial contact	28704
@NP	1 point/limb	28721
@NP	liftoff	28739
@NP	1 point/limb	28748
@NP	toe clearance	28763
@NP	occasional clearance -LRB- < 50 % of the time , 1 point / limb -RRB-	28778
@NP	occasional clearance	28778
@NP	< 50 % of the time , 1 point / limb	28800
@NP	< 50 %	28800
@NP	<	28800
@NP	the time , 1 point / limb	28808
@NP	the time	28808
@NP	1 point / limb	28818
@NP	limb	28827
@NP	frequent clearance -LRB- 51 -- 95 % , 2 points/limb -RRB-	28834
@NP	frequent clearance	28834
@NP	51	28854
@NP	95 % , 2 points/limb	28857
@NP	95 %	28857
@NP	2 points/limb	28862
@NP	clearance -LRB- > 95 % , 3 points/limb -RRB- ; tail position , up /	28889
@NP	clearance	28889
@NP	> 95 % , 3 points/limb	28900
@NP	>	28900
@NP	95 %	28901
@NP	3 points/limb	28906
@NP	tail position	28922
@NP	1 point	28947
@NP	2 points	28961
@NP	trunk stability -LRB- 1 point -RRB-	28976
@NP	trunk stability	28976
@NP	1 point	28993
@NP	The cumulative scores for each hind limb and tail position	29003
@NP	The cumulative scores	29003
@NP	each hind limb and tail position	29029
@NP	a single score -LRB- maximum of 13 per rat -RRB-	29083
@NP	a single score	29083
@NP	maximum of 13 per rat	29099
@NP	maximum	29099
@NP	13	29110
@NP	rat	29117
@NP	Footprint analysis	29123
@NP	endpoint	29159
@NP	a procedure	29174
@NP	de Medinaceli et al. -LRB- 1982 -RRB-	29200
@NP	de Medinaceli et al.	29200
@NP	n = 12 per group and n = 6 uninjured controls	29229
@NP	n = 12 per group and n	29229
@NP	n = 12	29229
@NP	n	29229
@NP	12	29233
@NP	group and n	29240
@NP	= 6 uninjured controls	29252
@NP	Pearse	29301
@NP	et al. , 2004a	29308
@NP	et al.	29308
@NP	2004a	29316
@NP	Deficits in descending motor control	29324
@NP	Deficits	29324
@NP	descending motor control	29336
@NP	the animals	29386
@NP	an irregularly-spaced grid walk apparatus	29401
@NP	endpoint as previously described -LRB- Pearse et al. , 2004a -RRB-	29446
@NP	endpoint	29446
@NP	Pearse	29480
@NP	et al. , 2004a	29487
@NP	et al.	29487
@NP	2004a	29495
@NP	Statistical analysis One-way ANOVA followed by the Bonferroni post-hoc test	29503
@NP	Statistical analysis One-way ANOVA	29503
@NP	the Bonferroni post-hoc test	29550
@NP	results	29602
@NP	anterograde tracing and axon counts	29613
@NP	immunohistochemical detection of specific fiber types	29655
@NP	immunohistochemical detection	29655
@NP	specific fiber types	29688
@NP	A mixed factorial	29710
@NP	measures	29738
@NP	ANOVA followed by the Tukey-Kramer test	29748
@NP	ANOVA	29748
@NP	the Tukey-Kramer test	29766
@NP	comparison of weekly functional recovery patterns	29801
@NP	comparison	29801
@NP	weekly functional recovery patterns	29815
@NP	injury	29857
@NP	Differences	29865
@NP	P < 0.05 * , < 0.01 ** and < 0.001 ***	29926
@NP	P < 0.05 * , < 0.01 **	29926
@NP	P	29926
@NP	< 0.05 * , < 0.01 **	29928
@NP	<	29928
@NP	0.05 *	29930
@NP	< 0.01 **	29937
@NP	< 0.01	29937
@NP	<	29937
@NP	0.01	29938
@NP	< 0.001 ***	29949
@NP	<	29949
@NP	0.001 ***	29950
@NP	injury-only controls	29974
@NP	All errors	29996
@NP	standard deviations	30020
@NP	RESULTS	30042
@NP	1	30056
@NP	Myelination of Axons	30059
@NP	Myelination	30059
@NP	Axons	30074
@NP	SC and OEG Transplants In Vivo	30087
@NP	SC and OEG Transplants	30087
@NP	Vivo	30113
@NP	High Power Microscopic Assessment	30124
@NP	the Number of Axons with Myelin Basic Protein -LRB- MBP -RRB- Immunostaining	30161
@NP	Number	30165
@NP	Axons	30175
@NP	Myelin Basic	30186
@NP	MBP	30208
@NP	the Number of EGFP	30242
@NP	the Number	30242
@NP	EGFP	30256
@NP	Cells	30269
@NP	Three Regions	30283
@NP	the Transplants -LRB- Rostral 200 µm2 , Center 200 µm2 , Caudal 200 µm2 -RRB-	30300
@NP	the Transplants	30300
@NP	Rostral	30317
@NP	200 µm2 , Center 200 µm2 , Caudal 200 µm2	30325
@NP	200 µm2	30325
@NP	Center 200 µm2	30334
@NP	Caudal 200 µm2	30350
@NP	Fig. 1	30367
@NP	Survival of exogenous male glia in spinal cord	30375
@NP	Survival	30375
@NP	exogenous male glia in spinal cord	30387
@NP	exogenous male glia	30387
@NP	spinal cord	30410
@NP	female rats	30430
@NP	A : The NBT-BCIP reaction product	30443
@NP	The NBT-BCIP reaction	30446
@NP	a single dark point	30490
@NP	the nucleus -LRB- methyl green nuclear counterstain -RRB-	30517
@NP	the nucleus	30517
@NP	methyl green nuclear counterstain	30530
@NP	methyl	30530
@NP	green nuclear counterstain	30537
@NP	each transplanted male SC at 9 weeks post-implantation -LRB- black arrows -RRB-	30568
@NP	each transplanted male SC	30568
@NP	9 weeks post-implantation -LRB- black arrows -RRB-	30597
@NP	9 weeks post-implantation	30597
@NP	black arrows	30624
@NP	Host female cells	30639
@NP	signal allowing differential identification of grafted versus host cells	30671
@NP	signal	30671
@NP	differential identification of grafted versus host cells	30687
@NP	differential identification	30687
@NP	host cells	30733
@NP	Scale	30745
@NP	20 µm	30757
@NP	B	30764
@NP	The graph	30767
@NP	the number of male SCs	30783
@NP	the number	30783
@NP	male SCs	30797
@NP	OEG	30809
@NP	rat expressed as a percentage of the original number of cells transplanted	30825
@NP	rat	30825
@NP	a percentage of the original number of cells transplanted	30842
@NP	a percentage	30842
@NP	the original number of cells transplanted	30858
@NP	the original number	30858
@NP	cells transplanted	30881
@NP	cells	30881
@NP	There	30901
@NP	a significant loss	30910
@NP	both cell types within all paradigms at 3 and 9 weeks post-transplantation	30932
@NP	both cell types	30932
@NP	all paradigms at 3 and 9 weeks post-transplantation	30955
@NP	all paradigms	30955
@NP	at 3 and 9 weeks	30969
@NP	SCs -LRB- SC-C -RRB-	31008
@NP	SCs	31008
@NP	SC-C	31013
@NP	better survival	31027
@NP	OEG -LRB- OEG-C -RRB-	31048
@NP	OEG	31048
@NP	OEG-C	31053
@NP	the injury epicenter	31083
@NP	OEG show	31105
@NP	survival	31123
@NP	SCs -LRB- -LSB- SC -RSB- - OEG-C -RRB-	31155
@NP	SCs	31155
@NP	-LSB- SC -RSB- - OEG-C	31160
@NP	-LSB- SC -RSB-	31160
@NP	OEG-C	31165
@NP	normal-appearing host	31180
@NP	spinal cord	31202
@NP	lower numbers -LRB- -LSB- SC -RSB- - OEG-S -RRB-	31217
@NP	lower numbers	31217
@NP	-LSB- SC -RSB- - OEG-S	31232
@NP	-LSB- SC -RSB-	31232
@NP	OEG-S	31237
@NP	*** P <	31245
@NP	*** P	31245
@NP	0.001	31252
@NP	comparisons between the 3 day	31262
@NP	comparisons	31262
@NP	the 3 day	31282
@NP	both 3 and 9 week time points as indicated by each horizontal line	31296
@NP	both 3 and 9 week time points	31296
@NP	each horizontal line	31342
@NP	Fig. 2 .	31365
@NP	Fig.	31365
@NP	2	31370
@NP	Efficiency	31373
@NP	lentiviral vector transfer	31387
@NP	EGFP to Schwann cells and olfactory ensheathing glia in vitro	31417
@NP	EGFP to Schwann cells	31417
@NP	EGFP	31417
@NP	Schwann cells	31425
@NP	olfactory ensheathing glia in vitro	31443
@NP	olfactory ensheathing glia	31443
@NP	vitro	31473
@NP	Immunostaining of A.	31480
@NP	Immunostaining	31480
@NP	A.	31498
@NP	SC or B.	31501
@NP	SC	31501
@NP	B.	31507
@NP	OEG cultures	31510
@NP	the low-affinity neurotrophin receptor -LRB- p75 -RRB-	31527
@NP	the low-affinity neurotrophin receptor	31527
@NP	p75	31567
@NP	lentiviral vector transduction and spinal cord implantation	31581
@NP	lentiviral vector transduction	31581
@NP	spinal cord implantation	31616
@NP	the majority of the cells -LRB- > 98 % -RRB-	31652
@NP	the majority	31652
@NP	the cells -LRB- > 98 % -RRB-	31668
@NP	the cells	31668
@NP	> 98 %	31679
@NP	>	31679
@NP	98 %	31680
@NP	this marker	31702
@NP	Likewise , infection of C.	31715
@NP	Likewise , infection	31715
@NP	Likewise	31715
@NP	infection	31725
@NP	C.	31738
@NP	SCs or D.	31741
@NP	SCs	31741
@NP	D.	31748
@NP	OEG with lentiviral vectors carrying the EGFP gene	31751
@NP	OEG	31751
@NP	lentiviral vectors carrying the EGFP gene	31760
@NP	lentiviral vectors	31760
@NP	the EGFP gene	31788
@NP	high transduction efficiency -LRB- 95 -- 98 % -RRB-	31813
@NP	high transduction efficiency	31813
@NP	95 -- 98 %	31843
@NP	95	31843
@NP	98 %	31846
@NP	robust transgene expression	31855
@NP	Scale bars	31884
@NP	20 µm	31897
@NP	Fig. 3 .	31905
@NP	Fig.	31905
@NP	3	31910
@NP	Comparison of EGFP and p75	31913
@NP	Comparison	31913
@NP	EGFP and p75	31927
@NP	Schwann cells and olfactory ensheathing glia in vivo	31948
@NP	Schwann cells	31948
@NP	olfactory ensheathing glia in vivo	31966
@NP	olfactory ensheathing glia	31966
@NP	vivo	31996
@NP	A -- C : EGFPþ SCs	32002
@NP	C : EGFPþ	32004
@NP	C	32004
@NP	EGFPþ	32007
@NP	the injured spinal cord	32036
@NP	9 weeks following transplantation into the injury epicenter	32063
@NP	9 weeks	32063
@NP	transplantation into the injury epicenter	32081
@NP	transplantation	32081
@NP	the injury epicenter	32102
@NP	A : Schematic of the injured spinal cord after EGFP-SC implantation .	32124
@NP	A : Schematic of the injured spinal cord	32124
@NP	Schematic of the injured spinal cord	32127
@NP	Schematic	32127
@NP	the injured spinal cord	32140
@NP	EGFP-SC implantation	32170
@NP	a central region	32202
@NP	EGFPþ/p75þ implanted SCs and EGFP2/p75þ endogenous SCs	32222
@NP	EGFPþ/p75þ	32222
@NP	SCs and EGFP2/p75þ endogenous SCs	32243
@NP	SCs	32243
@NP	EGFP2/p75þ endogenous SCs	32251
@NP	green dotted line	32278
@NP	green	32278
@NP	line	32291
@NP	areas	32315
@NP	EGFP2/p75þ endogenous SCs within the lesion area -LRB- red dotted line -RRB-	32324
@NP	EGFP2/p75þ endogenous SCs	32324
@NP	the lesion area	32357
@NP	red dotted line	32374
@NP	red	32374
@NP	line	32385
@NP	B	32392
@NP	Immunoreactivity for p75 -LRB- red -RRB-	32395
@NP	Immunoreactivity	32395
@NP	p75 -LRB- red -RRB-	32416
@NP	p75	32416
@NP	red	32421
@NP	regions	32449
@NP	transplanted EGFPþ SCs and in areas devoid of EGFPþ SCs	32468
@NP	transplanted EGFPþ SCs and in areas devoid	32468
@NP	transplanted EGFPþ SCs and in areas	32468
@NP	EGFPþ SCs	32481
@NP	EGFPþ SCs	32514
@NP	C	32525
@NP	The number of p75þ cells	32528
@NP	The number	32528
@NP	p75þ cells	32542
@NP	that of EGFPþ SCs	32588
@NP	that	32588
@NP	EGFPþ SCs	32596
@NP	the center of the graft	32613
@NP	the center	32613
@NP	the graft	32627
@NP	D	32638
@NP	F	32640
@NP	9 weeks	32643
@NP	transplantation of unlabeled SCs and EGFPþ OEG into the injury epicenter	32657
@NP	transplantation of unlabeled SCs	32657
@NP	transplantation	32657
@NP	unlabeled SCs	32676
@NP	EGFPþ OEG into the injury epicenter	32694
@NP	EGFPþ OEG	32694
@NP	the injury epicenter	32709
@NP	D	32731
@NP	Schematic	32734
@NP	the injured spinal cord	32747
@NP	combination grafting	32777
@NP	a smaller EGFPþ	32804
@NP	that	32828
@NP	EGFP2/p75þ unlabeled exogenous and in-migrating endogenous SCs	32869
@NP	EGFP2/p75þ unlabeled exogenous	32869
@NP	EGFP2/p75þ	32869
@NP	in-migrating endogenous SCs	32904
@NP	E	32933
@NP	Regions	32936
@NP	p75þ/EGFP2 and p75þ/EGFPþ cells	32955
@NP	the injured spinal cord	33003
@NP	F	33028
@NP	areas of EGFPþ OEG	33038
@NP	areas	33038
@NP	EGFPþ OEG	33047
@NP	p75 immunoreactivity	33058
@NP	both EGFPþ and EGFP2 cells	33102
@NP	G -- I	33130
@NP	G	33130
@NP	I	33132
@NP	unlabeled SCs	33143
@NP	the lesion and EGFPþ OEG	33162
@NP	normal-appearing host tissue	33192
@NP	9 weeks	33224
@NP	almost all of the p75 reactivity	33275
@NP	almost all	33275
@NP	the p75 reactivity	33289
@NP	present within the grafted region	33308
@NP	present	33308
@NP	the grafted region	33323
@NP	GFAP -LRB- blue -RRB-	33343
@NP	GFAP	33343
@NP	blue	33349
@NP	host astrocytes	33376
@NP	All in vivo images	33393
@NP	All	33393
@NP	vivo images	33400
@NP	10 µm-thick confocal projection images	33416
@NP	White boxes	33456
@NP	regions that are shown as accompanying higher magnification images	33475
@NP	regions	33475
@NP	higher magnification images	33514
@NP	White scale bars	33543
@NP	20 µm , yellow scale bars = 200 µm	33562
@NP	20 µm	33562
@NP	yellow scale bars = 200 µm	33569
@NP	yellow scale bars	33569
@NP	= 200 µm	33587
@NP	200	33589
@NP	Fig. 4 .	33598
@NP	Fig.	33598
@NP	4	33603
@NP	Comparison	33606
@NP	EGFPþ and p75þ cell counts	33620
@NP	the injured spinal cord over time	33654
@NP	the injured spinal cord	33654
@NP	time	33683
@NP	different transplant paradigms	33691
@NP	EGFPþ cells	33723
@NP	counts of cells immunoreactive for p75	33751
@NP	counts	33751
@NP	cells immunoreactive for p75	33761
@NP	cells	33761
@NP	p75	33786
@NP	3 days	33793
@NP	groups	33819
@NP	A : EGFPþ SCs into the injury epicenter or C : EGFPþ OEG	33843
@NP	EGFPþ SCs into the injury epicenter or C	33846
@NP	EGFPþ SCs	33846
@NP	the injury epicenter or C	33861
@NP	SCs -LSB- 1:1 -RSB-	33902
@NP	SCs	33902
@NP	1:1 -RSB-	33907
@NP	the injury epicenter	33917
@NP	the number of EGFPþ cells	33939
@NP	the number	33939
@NP	EGFPþ cells	33953
@NP	3 to 9 weeks post-transplantation	33991
@NP	3 to 9 weeks	33991
@NP	the number of p75þ cells	34031
@NP	the number	34031
@NP	p75þ cells	34045
@NP	B	34076
@NP	EGFPþ	34082
@NP	OEG only	34088
@NP	both EGFPþ and p75þ cell	34105
@NP	3 to 9 weeks	34152
@NP	a large central cavity	34168
@NP	the injury/transplant site	34204
@NP	The number of p75þ cells	34232
@NP	The number	34232
@NP	p75þ cells	34246
@NP	counts of EGFPþ cells	34297
@NP	counts	34297
@NP	EGFPþ cells	34307
@NP	these time points	34322
@NP	D	34341
@NP	Transplantation	34344
@NP	non-labeled SCs	34363
@NP	the injury epicenter with a low number of EGFPþ OEG grafted on either side	34384
@NP	the injury epicenter	34384
@NP	a low number of EGFPþ OEG grafted on either side	34410
@NP	a low number	34410
@NP	EGFPþ OEG grafted on either side	34426
@NP	EGFPþ OEG	34426
@NP	either side	34447
@NP	a significant disparity	34471
@NP	all time points between the numbers of cells with the two different labels	34498
@NP	all time points	34498
@NP	the numbers of cells with the two different labels	34522
@NP	the numbers	34522
@NP	cells with the two different labels	34537
@NP	cells	34537
@NP	the two different labels	34548
@NP	E	34587
@NP	Graph	34590
@NP	temporal changes	34606
@NP	the number	34626
@NP	EGFPþ cells	34640
@NP	p75 immunoreactivity	34680
@NP	stereological cell counts	34706
@NP	grafted EGFP-OEG	34741
@NP	largely p75	34765
@NP	all time points at a percentage	34799
@NP	all time points	34799
@NP	a percentage	34818
@NP	that observed in vitro	34842
@NP	that	34842
@NP	implanted EGFP-SCs	34866
@NP	reduced p75 labeling over time	34895
@NP	reduced p75 labeling	34895
@NP	time	34921
@NP	some of the cells	34941
@NP	some	34941
@NP	the cells	34949
@NP	a myelinating phenotype	34980
@NP	Lines -- solid , EGFPþ ; dashed , p75þ .	35005
@NP	Lines -- solid , EGFPþ	35005
@NP	Lines	35005
@NP	solid , EGFPþ	35011
@NP	solid	35011
@NP	EGFPþ	35018
@NP	p75þ	35033
@NP	P <	35040
@NP	P	35040
@NP	<	35042
@NP	0.05	35044
@NP	P <	35052
@NP	P	35052
@NP	<	35054
@NP	0.01 and *** P	35056
@NP	0.01	35056
@NP	*** P	35065
@NP	0.001	35072
@NP	comparisons at each time point	35082
@NP	comparisons	35082
@NP	each time point	35097
@NP	the number	35121
@NP	cells with the two different labels	35135
@NP	cells	35135
@NP	the two different labels	35146
@NP	Fig. 5 .	35173
@NP	Fig.	35173
@NP	5	35178
@NP	Survival of EGFP	35181
@NP	Survival	35181
@NP	EGFP	35193
@NP	Schwann cells	35206
@NP	transplantation	35226
@NP	A : Immunoblot detection of EGFP levels in an aliquot of	35243
@NP	A : Immunoblot detection of EGFP levels	35243
@NP	Immunoblot detection of EGFP	35246
@NP	Immunoblot detection	35246
@NP	EGFP	35270
@NP	an aliquot of	35285
@NP	an aliquot	35285
@NP	SCs	35307
@NP	transplantation -LRB- 0 days -RRB-	35332
@NP	transplantation	35332
@NP	0 days	35349
@NP	a 10 mm piece of spinal cord	35363
@NP	a 10 mm piece	35363
@NP	spinal cord	35380
@NP	the injury epicenter/graft site	35405
@NP	3	35440
@NP	21 or 63 days following transplantation	35443
@NP	21 or 63 days	35443
@NP	transplantation	35467
@NP	Detection of b-actin following blot stripping	35484
@NP	Detection	35484
@NP	b-actin following blot stripping	35497
@NP	b-actin following blot	35497
@NP	equal protein loading	35549
@NP	B : Densitometry measurements for EGFP band intensity .	35572
@NP	B	35572
@NP	Densitometry measurements for EGFP band intensity	35575
@NP	Densitometry measurements	35575
@NP	EGFP band intensity	35605
@NP	A significant reduction in EGFP signal	35626
@NP	A significant reduction	35626
@NP	EGFP signal	35653
@NP	21 and 63	35677
@NP	3 days	35696
@NP	pregrafted controls	35738
@NP	EGFP levels	35759
@NP	21 and 63 days	35822
@NP	Legend	35838
@NP	EGFPþ SCs immediately prior to grafting into the injury site	35846
@NP	EGFPþ SCs	35846
@NP	the injury site	35891
@NP	EGFPþ SCs at 3 days post-transplantation	35908
@NP	EGFPþ SCs	35908
@NP	3 days	35921
@NP	EGFPþ SCs at 21 days post-transplantation	35950
@NP	EGFPþ SCs	35950
@NP	21 days	35963
@NP	EGFPþ SCs at 63 days post-transplantation	35993
@NP	EGFPþ SCs	35993
@NP	63 days	36006
@NP	*** P < 0.001 for comparisons between time points post-transplantation	36036
@NP	*** P	36036
@NP	< 0.001 for comparisons between time points post-transplantation	36041
@NP	0.001	36043
@NP	comparisons between time points	36053
@NP	comparisons	36053
@NP	time points	36073
@NP	0 days	36110
@NP	Fig. 6 .	36119
@NP	Fig.	36119
@NP	6	36124
@NP	Three-dimensional position of	36127
@NP	Three-dimensional position	36127
@NP	glial cells	36165
@NP	the injured spinal cord over time	36184
@NP	the injured spinal cord	36184
@NP	time	36213
@NP	different transplant paradigms	36221
@NP	A -- C : Localization of male SCs transplanted into the injury site at A	36253
@NP	A -- C : Localization	36253
@NP	C	36255
@NP	male SCs	36274
@NP	the injury site at A	36301
@NP	the injury site	36301
@NP	3 days , B	36323
@NP	3 days	36323
@NP	B	36331
@NP	3 weeks and C	36334
@NP	3 weeks	36334
@NP	C	36346
@NP	9 weeks after grafting	36349
@NP	9 weeks	36349
@NP	grafting	36363
@NP	SCs	36381
@NP	the initial site of deposition -LRB- red arrow -RRB-	36410
@NP	the initial site	36410
@NP	deposition -LRB- red arrow -RRB-	36430
@NP	deposition	36430
@NP	red arrow	36442
@NP	D	36454
@NP	F	36456
@NP	male OEG	36472
@NP	greater spread	36491
@NP	the injured spinal cord after transplantation	36513
@NP	the injured spinal cord	36513
@NP	transplantation	36543
@NP	the epicenter than SCs over time	36564
@NP	the epicenter	36564
@NP	SCs over time	36583
@NP	SCs	36583
@NP	time	36592
@NP	D	36601
@NP	3 days , E	36604
@NP	3 days	36604
@NP	E	36612
@NP	3 weeks or F	36615
@NP	3 weeks	36615
@NP	F	36626
@NP	9 weeks after grafting	36629
@NP	9 weeks	36629
@NP	grafting	36643
@NP	G	36653
@NP	I	36655
@NP	Transplantation	36658
@NP	SCs and EGFPþ OEG	36677
@NP	1:1 -RSB- into the injury epicenter	36696
@NP	1:1 -RSB-	36696
@NP	the injury epicenter	36706
@NP	a spinal cord distribution of OEG	36734
@NP	a spinal cord distribution	36734
@NP	OEG	36764
@NP	G	36771
@NP	3 days to H	36774
@NP	3 days	36774
@NP	H	36784
@NP	3 weeks to I	36787
@NP	3 weeks	36787
@NP	I	36798
@NP	9 weeks that was similar to their grafting alone	36801
@NP	9 weeks	36801
@NP	their grafting	36829
@NP	J	36851
@NP	L	36853
@NP	The injection	36856
@NP	EGFPþ OEG	36873
@NP	normal	36888
@NP	host cord	36905
@NP	rostral and caudal to SCs that were grafted into the injury epicenter	36921
@NP	rostral and caudal	36921
@NP	SCs that were grafted into the injury epicenter	36943
@NP	SCs	36943
@NP	the injury epicenter	36970
@NP	a temporal change in EGFPþ OEG distribution	37004
@NP	a temporal change	37004
@NP	EGFPþ OEG distribution	37025
@NP	J	37053
@NP	3 days to K	37056
@NP	3 days	37056
@NP	K	37066
@NP	3 weeks to L	37069
@NP	3 weeks	37069
@NP	L	37080
@NP	9 weeks as EGFPþ OEG migrated towards the injury site	37083
@NP	9 weeks	37083
@NP	EGFPþ OEG	37094
@NP	the injury site	37121
@NP	Abbreviations for 3D space locations	37138
@NP	Abbreviations	37138
@NP	3D space locations	37156
@NP	R , rostral ; C , caudal ; D , dorsal ; and V , ventral	37176
@NP	R , rostral	37176
@NP	R	37176
@NP	rostral	37179
@NP	C , caudal	37188
@NP	C	37188
@NP	caudal	37191
@NP	D , dorsal	37199
@NP	D	37199
@NP	dorsal	37202
@NP	V , ventral	37214
@NP	V	37214
@NP	ventral	37217
@NP	Intervals on 3D pimple graphs	37226
@NP	Intervals	37226
@NP	3D pimple graphs	37239
@NP	distances of 500 µm	37266
@NP	distances	37266
@NP	500 µm	37279
@NP	Red arrows	37287
@NP	the approximate location of the original deposition of the fluid graft	37307
@NP	the approximate location	37307
@NP	the original deposition of the fluid graft	37335
@NP	the original deposition	37335
@NP	the fluid graft	37362
@NP	injection	37381
@NP	The color of each square on the graph	37392
@NP	The color	37392
@NP	each square	37405
@NP	the graph	37420
@NP	the number of cells within each 500 µm3 3D space	37438
@NP	the number	37438
@NP	cells within each 500 µm3 3D space	37452
@NP	cells	37452
@NP	each 500 µm3 3D space	37465
@NP	a percentage of total remaining cells	37500
@NP	a percentage	37500
@NP	total remaining cells	37516
@NP	the injured spinal cord	37553
@NP	n	37595
@NP	= 5 : 1 %	37597
@NP	= 5	37597
@NP	1 %	37602
@NP	9 %	37634
@NP	cell type	37649
@NP	cell	37677
@NP	Fig. 7 .	37684
@NP	Fig.	37684
@NP	7	37689
@NP	Migration of EGFP	37692
@NP	Migration	37692
@NP	EGFP	37705
@NP	olfactory ensheathing glia and Schwann cells	37718
@NP	9 weeks	37776
@NP	no EGFPþ OEG	37784
@NP	host cord	37824
@NP	gray or white matter towards the injury after injection on either side	37834
@NP	gray or white matter	37834
@NP	the injury after injection on either side	37863
@NP	the injury	37863
@NP	injection on either side	37880
@NP	injection	37880
@NP	either side	37893
@NP	numerous EGFPþ OEG	37906
@NP	graft-injury sites	37944
@NP	either A : sub-pial from the injection entry site or B :	37976
@NP	either A	37976
@NP	sub-pial from the injection entry site or B	37986
@NP	sub-pial	37986
@NP	the injection entry site or B	38000
@NP	the injection entry site	38000
@NP	B	38028
@NP	the central canal	38035
@NP	C	38054
@NP	EGFPþ SCs	38065
@NP	the original site of deposition	38098
@NP	the original site	38098
@NP	deposition	38119
@NP	the injury epicenter	38137
@NP	GFAP	38159
@NP	blue or yellow	38165
@NP	immunostaining	38181
@NP	host astrocytes	38207
@NP	A : and B : are 20 µm-thick confocal projection images .	38224
@NP	A : and B : are 20 µm-thick confocal projection images	38224
@NP	A : and B :	38224
@NP	20 µm-thick confocal projection images	38238
@NP	White scale	38278
@NP	0 20 µm , yellow scale bar 0 1 µm	38294
@NP	0 20 µm	38294
@NP	yellow scale bar 0 1 µm	38303
@NP	yellow scale bar	38303
@NP	0 1 µm	38320
@NP	Fig. 8 .	38329
@NP	Fig.	38329
@NP	8	38334
@NP	Axonal growth support by transplanted glia .	38337
@NP	Axonal growth support	38337
@NP	transplanted glia	38362
@NP	Schematics	38381
@NP	Fig. 3A	38397
@NP	C to show location of areas in panels D	38405
@NP	location of areas in panels D	38415
@NP	location	38415
@NP	areas in panels D	38427
@NP	areas	38427
@NP	panels D	38436
@NP	K : EGFP-SC implantation into the injury epicenter -LRB- A -RRB-	38445
@NP	K	38445
@NP	EGFP-SC implantation into the injury epicenter -LRB- A -RRB-	38448
@NP	EGFP-SC implantation	38448
@NP	the injury epicenter -LRB- A -RRB-	38474
@NP	the injury epicenter	38474
@NP	A	38496
@NP	unlabeled SC grafting into the lesion with EGFP-OEG	38502
@NP	unlabeled SC	38502
@NP	the lesion with EGFP-OEG	38529
@NP	the lesion	38529
@NP	EGFP-OEG	38545
@NP	-LRB- B -RRB- or within -LRB- C -RRB- the lesion	38585
@NP	-LRB- B -RRB-	38585
@NP	within -LRB- C -RRB- the lesion	38592
@NP	within	38592
@NP	C	38600
@NP	the lesion	38603
@NP	EGFPþ SCs -LRB- D , E -RRB-	38615
@NP	EGFPþ SCs	38615
@NP	D , E	38626
@NP	D	38626
@NP	E	38628
@NP	the epicenter and EGFPþ OEG -LRB- F , G -RRB- grafts were supportive	38646
@NP	the epicenter and EGFPþ OEG -LRB- F , G -RRB-	38646
@NP	the epicenter and EGFPþ OEG	38646
@NP	F , G	38675
@NP	F	38675
@NP	G	38677
@NP	grafts	38680
@NP	substrates for the growth of numerous neurofilament	38703
@NP	substrates	38703
@NP	the growth of numerous neurofilament	38718
@NP	the growth	38718
@NP	numerous neurofilament	38732
@NP	positive axons -LRB- red -RRB-	38756
@NP	positive axons	38756
@NP	red	38772
@NP	both nearby dorsal roots and central neurons	38794
@NP	both nearby dorsal roots	38794
@NP	central neurons	38823
@NP	the spinal cord	38846
@NP	These axons	38863
@NP	parallel	38883
@NP	the orientation	38895
@NP	the grafted cells , whether cells were oriented	38914
@NP	the grafted cells	38914
@NP	cells	38941
@NP	D , E	38962
@NP	D	38962
@NP	E	38964
@NP	parallel	38967
@NP	F , G	38980
@NP	F	38980
@NP	G	38982
@NP	perpendicular to the rostral-caudal axis of the host spinal cord	38985
@NP	the rostral-caudal axis of the host	39002
@NP	the rostral-caudal axis	39002
@NP	the host	39029
@NP	supraspinal axons	39063
@NP	serotonergic axons	39090
@NP	red	39110
@NP	able to enter grafts of EGFPþ SCs	39116
@NP	grafts of EGFPþ	39130
@NP	grafts	39130
@NP	EGFPþ	39140
@NP	OEG : H : EGFPþ OEG grafted rostral to the injury epicenter	39153
@NP	OEG	39153
@NP	H : EGFPþ OEG grafted rostral to the injury epicenter	39158
@NP	H	39158
@NP	EGFPþ OEG grafted rostral to the injury epicenter	39161
@NP	EGFPþ OEG	39161
@NP	rostral	39179
@NP	the injury epicenter	39190
@NP	I : EGFPþ SCs grafted into the injury epicenter	39212
@NP	I	39212
@NP	EGFPþ SCs grafted into the injury epicenter	39215
@NP	EGFPþ SCs	39215
@NP	the injury epicenter	39238
@NP	J : EGFPþ OEG grafted with unlabeled SCs into the injury epicenter	39260
@NP	J	39260
@NP	EGFPþ OEG grafted with unlabeled SCs into the injury epicenter	39263
@NP	EGFPþ OEG	39263
@NP	unlabeled SCs	39286
@NP	the injury epicenter	39305
@NP	K	39327
@NP	Ascending axonal populations , such as those positive for CGRP -LRB- red -RRB- ,	39330
@NP	Ascending axonal populations	39330
@NP	those positive for CGRP -LRB- red -RRB-	39368
@NP	those positive for CGRP	39368
@NP	red	39393
@NP	EGFPþ SC or EGFPþ OEG	39410
@NP	EGFPþ SC	39410
@NP	EGFPþ OEG	39422
@NP	growth	39469
@NP	The number of CGRPþ axons present immediately caudal to the grafts	39477
@NP	The number of CGRPþ axons present	39477
@NP	The number of CGRPþ axons	39477
@NP	The number	39477
@NP	CGRPþ axons	39491
@NP	the grafts	39533
@NP	injury-only controls	39584
@NP	GFAP -LRB- blue -RRB-	39606
@NP	GFAP	39606
@NP	blue	39612
@NP	host astrocytes	39639
@NP	All images	39656
@NP	20 µm-thick confocal projection images	39671
@NP	White boxes	39711
@NP	regions that are shown as accompanying higher magnification images	39730
@NP	regions	39730
@NP	higher magnification images	39769
@NP	White scale bars	39798
@NP	50 µm , yellow scale bars = 200 µm	39817
@NP	50 µm	39817
@NP	yellow scale bars = 200 µm	39824
@NP	yellow scale bars	39824
@NP	= 200 µm	39842
@NP	200	39844
@NP	Fig. 9 .	39853
@NP	Fig.	39853
@NP	9	39858
@NP	Quantification of ascending and descending axon growth into grafts .	39861
@NP	Quantification	39861
@NP	axon growth	39904
@NP	grafts	39921
@NP	A : Quantification of CTB-labeled ascending axons from the sciatic nerve	39929
@NP	: Quantification of CTB-labeled ascending axons from the sciatic nerve	39930
@NP	Quantification	39932
@NP	axons	39972
@NP	the sciatic nerve	39983
@NP	provision of a SC or OEG or a SC-OEG graft into the injured spinal cord	40012
@NP	provision	40012
@NP	a SC or OEG or a SC-OEG graft into the injured spinal cord	40025
@NP	a SC or OEG	40025
@NP	a SC-OEG graft into the injured spinal cord	40040
@NP	a SC-OEG graft	40040
@NP	the injured spinal cord	40060
@NP	the growth of these traced fibers caudal to , or into , the injury-graft site	40100
@NP	the growth	40100
@NP	these traced fibers caudal to , or into , the injury-graft site	40114
@NP	these	40114
@NP	fibers	40127
@NP	the injury-graft site	40154
@NP	injury only	40188
@NP	significance	40205
@NP	OEG only	40243
@NP	B : SC-OEG grafts	40253
@NP	B	40253
@NP	SC-OEG grafts	40256
@NP	the number of CGRPþ axons present at 2,000 µm and 500 µm caudal	40289
@NP	the number of CGRPþ axons	40289
@NP	the number	40289
@NP	CGRPþ axons	40303
@NP	2,000 µm and 500 µm	40326
@NP	2,000 µm	40326
@NP	500 µm	40339
@NP	the graft/injury site	40370
@NP	Characterization	40393
@NP	5HTþ serotonergic fibers from the brainstem -LRB- C -RRB-	40413
@NP	5HTþ serotonergic fibers	40413
@NP	the brainstem -LRB- C -RRB-	40443
@NP	the brainstem	40443
@NP	C	40458
@NP	BDA-traced corticospinal tract axons from the sensorimotor cortex	40464
@NP	BDA-traced corticospinal tract axons	40464
@NP	the sensorimotor cortex	40506
@NP	D	40531
@NP	none of the grafts	40552
@NP	none	40552
@NP	the grafts	40560
@NP	the amount of axon growth above that observed within , or rostral	40581
@NP	the amount of axon growth above that observed within	40581
@NP	the amount	40581
@NP	axon growth above that observed within	40595
@NP	axon growth	40595
@NP	that observed within	40613
@NP	that	40613
@NP	rostral	40638
@NP	trabeculae of injury-only controls	40650
@NP	trabeculae	40650
@NP	injury-only controls	40664
@NP	12 weeks	40686
@NP	Legend : SCI only , SC graft	40716
@NP	Legend	40716
@NP	SCI only , SC graft	40724
@NP	SCI only	40724
@NP	SC graft	40734
@NP	the injury epicenter , OEG graft	40748
@NP	the injury epicenter	40748
@NP	OEG graft	40770
@NP	the injury epicenter	40785
@NP	SC and OEG combination graft	40807
@NP	SC	40807
@NP	OEG combination graft	40814
@NP	1:1 -RSB-	40837
@NP	the injury epicenter , SC graft	40847
@NP	the injury epicenter	40847
@NP	SC graft	40869
@NP	the injury epicenter with OEG on either side	40883
@NP	the injury epicenter	40883
@NP	OEG on either side	40909
@NP	OEG	40909
@NP	either side	40916
@NP	P <	40930
@NP	P	40930
@NP	<	40932
@NP	0.05	40934
@NP	P < 0.01 , and *** P <	40942
@NP	P	40942
@NP	< 0.01 , and *** P <	40944
@NP	< 0.01	40944
@NP	<	40944
@NP	0.01	40946
@NP	*** P <	40956
@NP	*** P	40956
@NP	<	40961
@NP	0.001	40963
@NP	injury-only controls	40988
@NP	grafted groups	41020
@NP	the horizontal lines	41051
@NP	Fig. 10 .	41074
@NP	Fig.	41074
@NP	10	41079
@NP	Myelination by transplanted glia .	41083
@NP	Myelination	41083
@NP	transplanted glia	41098
@NP	Diagram	41120
@NP	the grafted spinal cord	41131
@NP	the three regions	41163
@NP	the transplant	41184
@NP	rostral	41200
@NP	central	41209
@NP	caudal	41218
@NP	200 µm2 regions -LRB- black boxes -RRB-	41235
@NP	200 µm2 regions	41235
@NP	black boxes	41252
@NP	the determination of ratios of myelinated axons	41283
@NP	the determination	41283
@NP	ratios of myelinated axons	41304
@NP	ratios	41304
@NP	myelinated axons	41314
@NP	EGFPþ cells	41334
@NP	B	41347
@NP	The rostral region	41350
@NP	a SC graft	41372
@NP	the injury epicenter	41401
@NP	similar numbers of myelinated axons -LRB- red -RRB- and EGFPþ cells	41433
@NP	similar numbers	41433
@NP	myelinated axons -LRB- red -RRB- and EGFPþ cells	41452
@NP	myelinated axons -LRB- red -RRB-	41452
@NP	myelinated axons	41452
@NP	red	41470
@NP	EGFPþ cells	41479
@NP	this region	41511
@NP	A myelinated axon	41524
@NP	the white arrow	41559
@NP	C	41576
@NP	contrast	41582
@NP	no myelinated axons , only myelin debris ,	41592
@NP	no myelinated axons	41592
@NP	only myelin debris	41613
@NP	a comparable area of an OEG graft	41647
@NP	a comparable area	41647
@NP	an OEG graft	41668
@NP	unlabeled SCs	41700
@NP	the injury epicenter	41722
@NP	GFAP immunostaining , blue .	41744
@NP	GFAP immunostaining	41744
@NP	blue	41765
@NP	Scale	41771
@NP	5 20 µm	41781
@NP	Fig. 11 .	41791
@NP	Fig.	41791
@NP	11	41796
@NP	Open-field locomotor ability after glial cell transplantation .	41800
@NP	Open-field locomotor ability	41800
@NP	glial cell transplantation	41835
@NP	Only those animals	41866
@NP	combination SC and OEG grafts into the injury epicenter	41895
@NP	combination SC and OEG grafts	41895
@NP	the injury epicenter	41930
@NP	a modest , but significant , improvement in open-field locomotion	41964
@NP	a modest , but significant , improvement	41964
@NP	open-field locomotion	42006
@NP	injury-only or fibroblast controls	42040
@NP	BBB sub-score analysis	42076
@NP	animals receiving combination SC and OEG grafts into the injury epicenter	42116
@NP	animals	42116
@NP	combination SC and OEG grafts	42134
@NP	the injury epicenter	42169
@NP	significantly higher scores	42194
@NP	Legend : SCI only , fibroblast graft	42223
@NP	Legend	42223
@NP	SCI only , fibroblast graft	42231
@NP	SCI only	42231
@NP	fibroblast graft	42241
@NP	the injury epicenter , SC graft	42263
@NP	the injury epicenter	42263
@NP	SC graft	42285
@NP	the injury epicenter	42299
@NP	OEG graft into the injury epicenter , SC and OEG combination graft	42321
@NP	OEG graft	42321
@NP	the injury epicenter , SC and OEG combination graft	42336
@NP	the injury epicenter	42336
@NP	SC	42358
@NP	OEG combination graft	42365
@NP	1:1 -RSB-	42388
@NP	the injury epicenter , SC graft	42398
@NP	the injury epicenter	42398
@NP	SC graft	42420
@NP	the injury epicenter with OEG on either side	42434
@NP	the injury epicenter	42434
@NP	OEG on either side	42460
@NP	OEG	42460
@NP	either side	42467
@NP	P < 0.05 as compared to injury-only controls , n = 12/group	42481
@NP	P <	42481
@NP	P	42481
@NP	0.05	42485
@NP	injury-only controls , n = 12/group	42505
@NP	injury-only controls	42505
@NP	n = 12/group	42527
@NP	Fig. 12 .	42542
@NP	Fig.	42542
@NP	12	42547
@NP	Footprint analysis of conditioned locomotion and grid	42551
@NP	Footprint analysis	42551
@NP	conditioned locomotion and grid	42573
@NP	performance	42610
@NP	glial cell transplantation	42628
@NP	A : The angle of foot exorotation of the hind paws .	42656
@NP	A : The angle of foot exorotation of the hind paws	42656
@NP	A : The angle of foot exorotation	42656
@NP	The angle of foot	42659
@NP	The angle	42659
@NP	foot	42672
@NP	the hind paws	42692
@NP	B : The distance of the base of support between the hind paws .	42707
@NP	B	42707
@NP	The distance of the base of support between the hind paws	42710
@NP	The distance	42710
@NP	the base of support between the hind paws	42726
@NP	the base	42726
@NP	support between the hind paws	42738
@NP	support	42738
@NP	the hind paws	42754
@NP	C : The stride length .	42769
@NP	C	42769
@NP	The stride length	42772
@NP	D : The number of footfall errors on a grid walk test .	42791
@NP	D	42791
@NP	The number of footfall errors on a grid walk test	42794
@NP	The number	42794
@NP	footfall errors on a grid walk test	42808
@NP	footfall errors	42808
@NP	a grid walk test	42827
@NP	Significant improvements in foot rotation	42845
@NP	Significant improvements	42845
@NP	foot rotation	42873
@NP	animals receiving either SC only grafts	42904
@NP	animals	42904
@NP	SC only grafts	42929
@NP	SC only	42929
@NP	combination SC and OEG grafts	42947
@NP	the injury epicenter	42982
@NP	Legend	43004
@NP	uninjured control	43012
@NP	SCI only	43031
@NP	fibroblast graft into the injury epicenter	43041
@NP	fibroblast graft	43041
@NP	the injury epicenter	43063
@NP	SC graft into the injury epicenter	43085
@NP	SC graft	43085
@NP	the injury epicenter	43099
@NP	OEG graft into the injury epicenter	43121
@NP	OEG graft	43121
@NP	the injury epicenter	43136
@NP	SC and OEG combination graft	43158
@NP	-LSB- 1:1	43187
@NP	the injury epicenter	43198
@NP	SC graft into the injury epicenter with OEG	43220
@NP	SC graft	43220
@NP	the injury epicenter with OEG	43234
@NP	the injury epicenter	43234
@NP	OEG	43260
@NP	either side ; * P < 0.05	43267
@NP	either side	43267
@NP	P <	43281
@NP	P	43281
@NP	<	43283
@NP	0.05	43285
@NP	injury-only controls , n = 12/group	43307
@NP	injury-only controls	43307
@NP	n = 12/group	43329
@NP	Determination	43344
@NP	Cell Survival	43361
@NP	the Male Chromosome Marker After Transplantation Into	43381
@NP	the Male Chromosome	43381
@NP	Marker After Transplantation Into	43401
@NP	the Injury Site	43443
@NP	SCs	43470
@NP	OEG within the injured spinal cord following implantation	43481
@NP	OEG	43481
@NP	the injured spinal cord following implantation	43492
@NP	the injured spinal cord	43492
@NP	implantation	43526
@NP	the male chromosome	43583
@NP	a definitive marker	43606
@NP	Survival	43627
@NP	male SCs or OEG	43639
@NP	the injury epicenter of female rats	43685
@NP	the injury epicenter	43685
@NP	female rats	43709
@NP	1 week	43724
@NP	3 days	43756
@NP	82.6 ± 12.4 % and 69.4	43783
@NP	± 6.0 %	43805
@NP	the original number	43815
@NP	cells prepared for transplantation -LRB- 2 million -RRB- , respectively	43838
@NP	cells	43838
@NP	transplantation -LRB- 2 million -RRB-	43857
@NP	transplantation	43857
@NP	2 million	43874
@NP	Fig. 1A , B	43900
@NP	Fig. 1A	43900
@NP	B	43908
@NP	this time	43915
@NP	the survival of the two cell types	43926
@NP	the survival	43926
@NP	the two cell types	43942
@NP	one another	43998
@NP	3 days	44025
@NP	survival	44033
@NP	OEG	44045
@NP	1:1	44057
@NP	SCs	44066
@NP	the injury site	44075
@NP	4-mm rostral and caudal	44102
@NP	the injury/SC graft site	44129
@NP	71.1 ± 11.9 % and 68.9 ± 10.1 %	44170
@NP	71.1 ± 11.9 %	44170
@NP	71.1 ±	44170
@NP	11.9 %	44177
@NP	68.9 ± 10.1 %	44187
@NP	68.9	44187
@NP	± 10.1 %	44192
@NP	Fig. 1B	44216
@NP	Survival of OEG	44226
@NP	Survival	44226
@NP	OEG	44238
@NP	disparate locations	44281
@NP	different numbers of cells	44309
@NP	different numbers	44309
@NP	cells	44330
@NP	The small amount	44353
@NP	leakage	44373
@NP	spinal cord injection or the loss of cells	44398
@NP	spinal cord injection	44398
@NP	the loss of cells	44423
@NP	the loss	44423
@NP	cells	44435
@NP	procedures	44459
@NP	original counting to syringe loading	44475
@NP	original counting	44475
@NP	syringe loading	44496
@NP	some degree of this observed reduction in cell number in all cell groups	44535
@NP	some degree	44535
@NP	this observed reduction in cell number in all cell groups	44550
@NP	this	44550
@NP	reduction in cell number	44564
@NP	reduction	44564
@NP	cell number	44577
@NP	all cell groups	44592
@NP	SCs	45039
@NP	significantly greater survival -LRB- 7-fold , P < 0.001 -RRB-	45053
@NP	significantly greater survival	45053
@NP	7-fold , P < 0.001	45085
@NP	7-fold , P <	45085
@NP	7-fold	45085
@NP	P <	45093
@NP	P	45093
@NP	<	45095
@NP	0.001	45097
@NP	OEG	45109
@NP	the injury site	45136
@NP	Transplantation	45153
@NP	OEG	45172
@NP	the relatively healthy tissue near the injury site at lower density	45181
@NP	the relatively healthy tissue	45181
@NP	the injury site at lower density	45216
@NP	the injury site	45216
@NP	lower density	45235
@NP	SCs into the injury site	45257
@NP	SCs	45257
@NP	the injury site	45266
@NP	their survival	45306
@NP	transplantation	45333
@NP	OEG	45352
@NP	the injury site : 16-fold -LRB- P < 0.001 -RRB- and 3-fold -LRB- P < 0.01 -RRB-	45367
@NP	the injury site : 16-fold -LRB- P < 0.001 -RRB- and 3-fold	45367
@NP	the injury site	45367
@NP	P < 0.001	45393
@NP	P	45393
@NP	< 0.001	45395
@NP	<	45395
@NP	0.001	45397
@NP	P < 0.01	45416
@NP	P	45416
@NP	< 0.01	45418
@NP	<	45418
@NP	0.01	45420
@NP	Assessment of cell survival at 9 weeks following transplantation	45441
@NP	Assessment	45441
@NP	cell survival at 9 weeks following transplantation	45455
@NP	cell survival	45455
@NP	9 weeks following transplantation	45472
@NP	9 weeks	45472
@NP	transplantation	45490
@NP	there	45518
@NP	no significant further loss	45528
@NP	grafted cells	45559
@NP	all of the transplantation paradigms compared to 3 weeks -LRB- Fig. 1B -RRB-	45576
@NP	all	45576
@NP	the transplantation paradigms compared to 3 weeks -LRB- Fig. 1B -RRB-	45583
@NP	the transplantation paradigms	45583
@NP	3 weeks -LRB- Fig. 1B -RRB-	45625
@NP	3 weeks	45625
@NP	Fig. 1B	45634
@NP	Determination	45644
@NP	Cell Survival	45661
@NP	EGFP	45681
@NP	Transplantation	45701
@NP	Into or Near the Injury Site Numbers of SCs	45717
@NP	Into or Near the Injury Site Numbers	45717
@NP	Into	45717
@NP	the Injury Site	45730
@NP	SCs	45757
@NP	OEG within the injured spinal cord following implantation	45768
@NP	OEG	45768
@NP	the injured spinal cord following implantation	45779
@NP	the injured spinal cord	45779
@NP	implantation	45813
@NP	a second independent marker , transfer of EGFP	45869
@NP	a second independent marker	45869
@NP	transfer of EGFP	45898
@NP	transfer	45898
@NP	EGFP	45910
@NP	lentiviral vector infection	45918
@NP	Cultures	45947
@NP	purified SCs and OEG	45959
@NP	immunoreactivity	45998
@NP	the low-affinity neurotrophin receptor p75	46019
@NP	high levels on both cell types	46081
@NP	high levels	46081
@NP	both cell types	46096
@NP	Fig. 2A , B	46113
@NP	Fig. 2A	46113
@NP	B	46121
@NP	a single exposure	46134
@NP	EGFP-encoding lentiviral vectors	46155
@NP	Lentiviral vector infection of either SCs or OEG at a MOI of 50	46189
@NP	Lentiviral vector infection	46189
@NP	either SCs or OEG	46220
@NP	SCs	46227
@NP	OEG	46234
@NP	a MOI of 50	46241
@NP	a MOI	46241
@NP	50	46250
@NP	robust expression of the EGFP transgene in 98 -- 99 % of the cells	46265
@NP	robust expression	46265
@NP	the EGFP transgene in 98 -- 99 % of the cells	46286
@NP	the EGFP transgene in 98	46286
@NP	the EGFP transgene	46286
@NP	98	46308
@NP	99 % of the cells	46311
@NP	99 %	46311
@NP	the cells	46318
@NP	48 hours	46335
@NP	EGFP	46345
@NP	fluorescent microscopy	46368
@NP	a strong signal within the cell nucleus	46394
@NP	a strong signal	46394
@NP	the cell nucleus	46417
@NP	efficient labeling of the cytoplasm and processes -LRB- Fig. 2C , D -RRB-	46439
@NP	efficient labeling	46439
@NP	the cytoplasm and processes -LRB- Fig. 2C , D -RRB-	46461
@NP	the cytoplasm and processes	46461
@NP	Fig. 2C , D	46490
@NP	Fig. 2C	46490
@NP	D	46498
@NP	MOIs lower than 50	46505
@NP	MOIs	46505
@NP	50	46521
@NP	reduced transduction efficiency	46525
@NP	Andrade et al. , 2007	46571
@NP	Andrade	46571
@NP	et al.	46579
@NP	2007	46587
@NP	Cells receiving the EGFP transgene	46594
@NP	Cells	46594
@NP	the EGFP transgene	46610
@NP	nontransduced cell controls	46649
@NP	proliferation rate or morphology for up to 9 passages -LRB- data not shown -RRB-	46687
@NP	proliferation rate or morphology	46687
@NP	up to 9 passages	46724
@NP	data not shown	46742
@NP	data	46742
@NP	Cells for transplantation	46759
@NP	Cells	46759
@NP	transplantation	46769
@NP	passage 4 -LRB- OEG -RRB- or 5 -LRB- SCs -RRB-	46798
@NP	passage 4	46798
@NP	OEG	46809
@NP	5	46817
@NP	SCs	46820
@NP	The implantation of EGFP-SCs into the lesion site -LRB- Fig. 3A -- C -RRB-	46826
@NP	The implantation	46826
@NP	EGFP-SCs into the lesion site -LRB- Fig. 3A -- C -RRB-	46846
@NP	EGFP-SCs	46846
@NP	the lesion site -LRB- Fig. 3A -- C -RRB-	46860
@NP	the lesion site	46860
@NP	Fig. 3A -- C	46877
@NP	Fig. 3A	46877
@NP	C	46885
@NP	EGFP-OEG	46889
@NP	unlabeled SCs	46903
@NP	the lesion site -LRB- Fig. 3D -- F -RRB-	46922
@NP	the lesion site	46922
@NP	Fig. 3D -- F	46939
@NP	Fig. 3D	46939
@NP	F	46947
@NP	unlabeled SCs into the lesion site with EGFP-OEG on either side	46954
@NP	unlabeled SCs	46954
@NP	the lesion site with EGFP-OEG on either side	46973
@NP	the lesion site	46973
@NP	EGFP-OEG on either side	46994
@NP	EGFP-OEG	46994
@NP	either side	47006
@NP	Fig. 3G -- I	47019
@NP	Fig. 3G	47019
@NP	I	47027
@NP	all	47030
@NP	substantive grafts that were able to significantly retard cavitation	47043
@NP	substantive grafts	47043
@NP	cavitation	47101
@NP	Only the implantation of EGFP-OEG alone within the lesion site	47113
@NP	Only the implantation	47113
@NP	EGFP-OEG alone within the lesion site	47138
@NP	EGFP-OEG alone	47138
@NP	the lesion site	47160
@NP	significant cavity formation that was similar to injury-only controls	47188
@NP	significant cavity formation	47188
@NP	injury-only controls	47237
@NP	The dramatic loss of male cells from 3 days to 3 weeks	47259
@NP	The dramatic loss	47259
@NP	male cells from 3 days to 3 weeks	47280
@NP	male cells	47280
@NP	3 days to 3 weeks	47296
@NP	the same	47334
@NP	groups	47351
@NP	EGFP	47363
@NP	the marker	47401
@NP	itself	47412
@NP	cell loss	47435
@NP	the cells but rather the conditions to which the cells were exposed	47466
@NP	the cells	47466
@NP	the conditions to which the cells were exposed	47487
@NP	the conditions	47487
@NP	the cells	47511
@NP	their disappearance -LRB- Fig. 4A -- D , solid lines -RRB-	47546
@NP	their disappearance	47546
@NP	Fig. 4A	47567
@NP	D , solid lines	47575
@NP	D	47575
@NP	solid lines	47578
@NP	Statistical comparison	47592
@NP	the numbers of identified cells within each transplant cohort at each time point	47618
@NP	the numbers	47618
@NP	identified cells within each transplant cohort at each time point	47633
@NP	identified cells	47633
@NP	each transplant cohort at each time point	47657
@NP	each transplant cohort	47657
@NP	each time point	47683
@NP	there	47711
@NP	no significant differences	47722
@NP	the numbers	47752
@NP	cells stereologically quantified using either EGFP or the male chromosome marker	47767
@NP	cells	47767
@NP	either EGFP or the male chromosome marker	47806
@NP	EGFP	47813
@NP	the male chromosome marker	47821
@NP	transplanted male cells	47854
@NP	EGFP SCs	47879
@NP	significantly better survival	47898
@NP	EGFP OEG	47933
@NP	the injury epicenter -LRB- Fig. 4A , B -RRB-	47962
@NP	the injury epicenter	47962
@NP	Fig. 4A , B	47984
@NP	Fig. 4A	47984
@NP	B	47992
@NP	a greater percentage of EGFP OEG	47999
@NP	a greater percentage	47999
@NP	EGFP OEG	48023
@NP	they	48050
@NP	the injury epicenter -LRB- Fig. 4B , D -RRB-	48080
@NP	the injury epicenter	48080
@NP	Fig. 4B , D	48102
@NP	Fig. 4B	48102
@NP	D	48110
@NP	cell survival	48133
@NP	transplantation	48164
@NP	we	48181
@NP	western blot analysis of GFP signal using only the EGFPþ SC group	48193
@NP	western blot analysis	48193
@NP	GFP signal using only the EGFPþ SC group	48218
@NP	GFP signal	48218
@NP	the EGFPþ SC group	48240
@NP	the aliquots prior to transplantation at 0 days or from a 10	48272
@NP	the aliquots	48272
@NP	transplantation	48294
@NP	0 days	48313
@NP	a 10	48328
@NP	mm block	48334
@NP	spinal cord	48346
@NP	the injury/graft site	48371
@NP	3 , 21 , or 56 days	48396
@NP	3	48396
@NP	21	48399
@NP	56 days	48406
@NP	injection of EGFPþ SCs	48420
@NP	injection	48420
@NP	EGFPþ SCs	48433
@NP	the injury site -LRB- n = 4 per time point -RRB- -LRB- Fig. 5A , B -RRB-	48448
@NP	the injury site -LRB- n = 4 per time point -RRB-	48448
@NP	the injury site	48448
@NP	n = 4 per time point	48465
@NP	n = 4	48465
@NP	n	48465
@NP	4	48469
@NP	time point	48475
@NP	Fig. 5A , B	48488
@NP	Fig. 5A	48488
@NP	B	48496
@NP	densitometry measurements of the resulting bands	48506
@NP	densitometry measurements	48506
@NP	the resulting bands	48535
@NP	we	48556
@NP	no significant reduction	48568
@NP	GFP signal from 0	48596
@NP	GFP signal	48596
@NP	0	48612
@NP	3 days post-transplantation -LRB- Fig. 5B -RRB-	48617
@NP	3 days post-transplantation	48617
@NP	Fig. 5B	48646
@NP	21 and 56 days after grafting	48659
@NP	21 and 56 days	48659
@NP	grafting	48680
@NP	significant reductions in EGFP signal	48699
@NP	significant reductions	48699
@NP	EGFP signal	48725
@NP	: 21 days , 54.7 % decrease , P < 0.001	48746
@NP	21 days , 54.7 % decrease	48748
@NP	21 days	48748
@NP	54.7 % decrease	48757
@NP	P < 0.001	48773
@NP	P <	48773
@NP	P	48773
@NP	0.001	48777
@NP	56 days , 67.1 % decrease	48784
@NP	56 days	48784
@NP	67.1 % decrease	48793
@NP	P < 0.001 -LRB- Fig. 5B -RRB-	48809
@NP	P	48809
@NP	< 0.001 -LRB- Fig. 5B -RRB-	48811
@NP	<	48811
@NP	0.001 -LRB- Fig. 5B -RRB-	48813
@NP	0.001	48813
@NP	Fig. 5B	48820
@NP	The pattern of decreased GFP signal by western blot analysis	48830
@NP	The pattern	48830
@NP	decreased GFP signal by western blot analysis	48845
@NP	decreased GFP signal	48845
@NP	western blot analysis	48869
@NP	the loss of Y-probe positive and EGFP SCs	48910
@NP	the loss	48910
@NP	Y-probe positive and EGFP SCs	48922
@NP	Y-probe positive	48922
@NP	EGFP SCs	48943
@NP	stereological quantification	48974
@NP	Examination of EGFP-labeled cells at 3 days posttransplantation	49004
@NP	Examination	49004
@NP	EGFP-labeled cells at 3 days posttransplantation	49019
@NP	EGFP-labeled cells	49019
@NP	3 days posttransplantation	49041
@NP	both SCs and OEG	49080
@NP	SCs	49085
@NP	OEG	49093
@NP	the site of deposition -LRB- Fig. 6A , D , G -RRB-	49116
@NP	the site	49116
@NP	deposition -LRB- Fig. 6A , D , G -RRB-	49128
@NP	deposition	49128
@NP	Fig. 6A	49140
@NP	D	49148
@NP	G	49150
@NP	many cells	49191
@NP	a rounded shape and few processes	49213
@NP	a rounded shape	49213
@NP	few processes	49233
@NP	EGFPþ cells	49248
@NP	patches of immune cells	49287
@NP	patches	49287
@NP	immune cells	49298
@NP	GFAPþ astrocytes	49329
@NP	the host spinal cord	49351
@NP	Identification of surviving cells at 3 -- 9 weeks using EGFP	49373
@NP	Identification	49373
@NP	surviving cells at 3 -- 9 weeks using EGFP	49391
@NP	surviving cells at 3	49391
@NP	surviving cells	49391
@NP	3	49410
@NP	9 weeks using EGFP	49412
@NP	9 weeks	49412
@NP	EGFP	49426
@NP	the cells	49443
@NP	one	49481
@NP	relatively continuous mass	49485
@NP	the site of the injection in both SC or SC plus OEG groups	49515
@NP	the site	49515
@NP	the injection in both SC or SC plus OEG groups	49527
@NP	the injection	49527
@NP	both SC or SC plus OEG groups	49544
@NP	SC	49549
@NP	SC plus OEG groups	49555
@NP	Figs. 6B , E , H , and 7C	49575
@NP	Figs. 6B	49575
@NP	E , H , and 7C	49584
@NP	smaller patches of EGFPþ cells	49609
@NP	smaller patches	49609
@NP	EGFPþ cells	49628
@NP	the main body of the graft	49666
@NP	the main body	49666
@NP	the graft	49683
@NP	small cavities	49696
@NP	areas of immune cells and debris	49732
@NP	areas	49732
@NP	immune cells and debris	49741
@NP	these cells	49773
@NP	the confines of the lesion	49803
@NP	the confines	49803
@NP	the lesion	49819
@NP	the animals	49834
@NP	OEG	49856
@NP	the injury site	49871
@NP	the dramatic , greater than 95 % loss of grafted cells	49888
@NP	the dramatic , greater than 95 % loss	49888
@NP	grafted cells	49927
@NP	pronounced central cavitation , not dissimilar	49953
@NP	pronounced central cavitation	49953
@NP	injury-only controls	50002
@NP	surviving cells	50029
@NP	the rim of injured tissue	50062
@NP	the rim	50062
@NP	injured tissue	50073
@NP	the cavity	50100
@NP	Comparison	50112
@NP	Cell Numbers	50126
@NP	Ex Vivo Introduction of EGFP	50153
@NP	Ex Vivo Introduction	50153
@NP	EGFP	50177
@NP	Viral Vector Versus Immunochemical Detection	50185
@NP	p75 + SCs or OEG The low affinity neurotrophin receptor p75	50233
@NP	p75 + SCs	50233
@NP	OEG The low affinity neurotrophin receptor p75	50245
@NP	OEG	50245
@NP	The low affinity neurotrophin receptor p75	50249
@NP	SCs and OEG	50347
@NP	vivo	50375
@NP	transplantation	50390
@NP	due to the high level of p75 expression	50407
@NP	the high level of p75	50414
@NP	the high level	50414
@NP	p75	50432
@NP	the nonmyelinating phenotypes	50450
@NP	these cells -LRB- Plant et al. , 2002 ; Fig. 2A , B -RRB-	50483
@NP	these cells	50483
@NP	Plant et al. , 2002 ; Fig. 2A , B	50496
@NP	Plant	50496
@NP	et al. , 2002 ; Fig. 2A , B	50502
@NP	et al. , 2002	50502
@NP	et al.	50502
@NP	2002	50510
@NP	Fig. 2A , B	50516
@NP	Fig. 2A	50516
@NP	B	50524
@NP	nontransplanted animals , p75þ endogenous cells	50540
@NP	the injury site	50608
@NP	the dorsal	50644
@NP	columns as early as 3 days	50655
@NP	columns	50655
@NP	early as 3 days	50666
@NP	early	50666
@NP	3 days	50675
@NP	contusion	50688
@NP	The presence of p75	50699
@NP	The presence	50699
@NP	p75	50715
@NP	axons within these areas	50740
@NP	axons	50740
@NP	these areas	50753
@NP	3 and 9 weeks	50769
@NP	numbers of p75þ cells within the injured spinal cord	50784
@NP	numbers	50784
@NP	p75þ cells within the injured spinal cord	50795
@NP	p75þ cells	50795
@NP	the injured spinal cord	50813
@NP	these cells	50859
@NP	the injury site	50900
@NP	a total of 80,000 cells per animal	50929
@NP	a total	50929
@NP	80,000 cells per animal	50940
@NP	80,000 cells	50940
@NP	animal	50957
@NP	any timepoint examined -LRB- results not shown -RRB-	50967
@NP	any timepoint	50967
@NP	grafting of SCs	51021
@NP	grafting	51021
@NP	SCs	51033
@NP	a high level of dense p75 immunoreactivity , predominantly cellular in nature ,	51038
@NP	a high level of dense p75 immunoreactivity	51038
@NP	a high level	51038
@NP	dense p75 immunoreactivity	51054
@NP	cellular in nature	51096
@NP	cellular	51096
@NP	nature	51108
@NP	the injury site -LRB- Fig. 3A -- C -RRB-	51147
@NP	the injury site	51147
@NP	Fig. 3A -- C	51164
@NP	Fig. 3A	51164
@NP	C	51172
@NP	A smaller amount of p75 immunoreactivity	51176
@NP	A smaller amount	51176
@NP	p75 immunoreactivity	51196
@NP	rostral and caudal streams	51237
@NP	nearby dorsal root entry sites	51296
@NP	similar to those observed in injured only animals	51328
@NP	those observed in injured only	51339
@NP	those	51339
@NP	We	51379
@NP	the groups	51391
@NP	either EGFPþ SCs or EGFPþ OEG	51412
@NP	EGFPþ SCs	51419
@NP	EGFPþ OEG	51432
@NP	the injury site	51447
@NP	3 days	51472
@NP	the number of EGFPþ cells	51501
@NP	the number	51501
@NP	EGFPþ cells	51515
@NP	the number of p75þ cells -LRB- Fig. 4A -- B -RRB-	51564
@NP	the number	51564
@NP	p75þ cells -LRB- Fig. 4A -- B -RRB-	51578
@NP	p75þ cells	51578
@NP	Fig. 4A -- B	51590
@NP	Fig. 4A	51590
@NP	B	51598
@NP	later time intervals following transplantation	51607
@NP	later time intervals	51607
@NP	transplantation	51638
@NP	there	51664
@NP	a significant loss of EGFPþ cells	51674
@NP	a significant loss	51674
@NP	EGFPþ cells	51696
@NP	contrast	51712
@NP	the number of p75þ cells within the injured spinal cord	51722
@NP	the number	51722
@NP	p75þ cells within the injured spinal cord	51736
@NP	p75þ cells	51736
@NP	the injured spinal cord	51754
@NP	a decrease that was significantly less than observed with EGFP cell counts	51788
@NP	a decrease	51788
@NP	EGFP cell counts	51846
@NP	both 3 and 9 weeks	51867
@NP	post-transplantation , p75þ cell counts	51886
@NP	counts	51956
@NP	EGFP cells	51966
@NP	SC	51980
@NP	3 weeks	51984
@NP	301 % higher , P < 0.05 ; 9 weeks : 307 % , P < 0.05 , Figs. 3A -- C , 4A	51993
@NP	301 % higher , P < 0.05	51993
@NP	301 %	51993
@NP	P	52006
@NP	0.05	52010
@NP	9 weeks	52016
@NP	9	52016
@NP	weeks	52018
@NP	307 % , P < 0.05 , Figs. 3A	52025
@NP	307 %	52025
@NP	P < 0.05	52031
@NP	P <	52031
@NP	P	52031
@NP	0.05	52035
@NP	Figs. 3A	52041
@NP	C , 4A	52050
@NP	C	52050
@NP	4A	52053
@NP	OEG -LRB- 3 weeks : 892 %	52061
@NP	OEG	52061
@NP	3 weeks : 892 %	52066
@NP	3 weeks	52066
@NP	892 %	52075
@NP	P < 0.05	52081
@NP	P <	52081
@NP	P	52081
@NP	0.05	52085
@NP	9 weeks	52091
@NP	755 %	52100
@NP	P < 0.05 , Fig. 4B -RRB- only transplant groups	52106
@NP	P	52106
@NP	0.05 , Fig. 4B	52110
@NP	0.05	52110
@NP	Fig. 4B	52116
@NP	transplant groups	52130
@NP	animals	52152
@NP	mixed grafts of nonlabeled SCs and EGFPþ OEG	52170
@NP	mixed grafts	52170
@NP	nonlabeled SCs and EGFPþ OEG	52186
@NP	nonlabeled SCs	52186
@NP	EGFPþ OEG	52205
@NP	counts of p75þ cells within the injured spinal cord	52216
@NP	counts	52216
@NP	p75þ cells within the injured spinal cord	52226
@NP	p75þ cells	52226
@NP	the injured spinal cord	52244
@NP	EGFP cells	52290
@NP	3 days	52304
@NP	the presence of large numbers of unlabeled	52332
@NP	the presence	52332
@NP	large numbers of unlabeled	52348
@NP	large numbers	52348
@NP	transplanted SCs -LRB- Fig. 4C -- D -RRB-	52376
@NP	transplanted SCs	52376
@NP	Fig. 4C -- D	52394
@NP	Fig. 4C	52394
@NP	D	52402
@NP	The number of p75þ cells	52406
@NP	The number	52406
@NP	p75þ cells	52420
@NP	3 to 9 weeks	52450
@NP	the number of EGFPþ OEG	52469
@NP	the number	52469
@NP	EGFPþ OEG	52483
@NP	Figs.	52509
@NP	3D -- I and 4C -- D	52515
@NP	3D	52515
@NP	I and 4C	52518
@NP	I	52518
@NP	4C	52524
@NP	D	52527
@NP	EGFP2/p75þ cells	52531
@NP	a number of different environments	52562
@NP	a number	52562
@NP	different environments	52574
@NP	the injury site	52618
@NP	Densely packed EGFP2/p75þ cells	52635
@NP	EGFPþ grafted cells within the injury site	52696
@NP	EGFPþ	52696
@NP	cells	52710
@NP	the injury site	52723
@NP	a scattered distribution with immune cells within EGFP2 areas of the injury site	52743
@NP	a scattered distribution	52743
@NP	immune cells within EGFP2 areas of the injury site	52773
@NP	immune cells	52773
@NP	EGFP2 areas of the injury site	52793
@NP	EGFP2 areas	52793
@NP	the injury site	52808
@NP	EGFP2 streams	52831
@NP	cells	52848
@NP	the injury site and nearby dorsal root entry sites	52867
@NP	the injury site	52867
@NP	nearby dorsal root entry sites	52887
@NP	Fig. 3D -- I	52919
@NP	Fig. 3D	52919
@NP	I	52927
@NP	Examination of p75 immunoreactivity within EGFP	52931
@NP	Examination	52931
@NP	p75 immunoreactivity within EGFP	52946
@NP	p75 immunoreactivity	52946
@NP	EGFP	52974
@NP	groups	52987
@NP	EGFP-OEG	53014
@NP	time	53058
@NP	90 %	53080
@NP	all time points	53087
@NP	the percentage of p75 immunoreactive EGFP-SCs	53105
@NP	the percentage	53105
@NP	p75 immunoreactive EGFP-SCs	53123
@NP	both 3 days to 3 weeks	53180
@NP	97.8 ±	53204
@NP	1.0 %	53211
@NP	75.6 ± 2.1 % EGFPp75 co-labeling , respectively , a 22.7 % decrease , P < 0.001	53219
@NP	2.1 % EGFPp75 co-labeling , respectively	53226
@NP	2.1 %	53226
@NP	EGFPp75 co-labeling	53231
@NP	a 22.7 % decrease	53266
@NP	a 22.7 %	53266
@NP	decrease	53274
@NP	P < 0.001	53284
@NP	P <	53284
@NP	P	53284
@NP	0.001	53288
@NP	3 to 9 weeks	53304
@NP	75.6 ±	53318
@NP	2.1 %	53325
@NP	8.0 % EGFP-p75 co-labeling , respectively	53340
@NP	8.0 %	53340
@NP	EGFP-p75 co-labeling	53345
@NP	a further 23.1 % decrease	53381
@NP	a further 23.1 %	53381
@NP	decrease	53397
@NP	P < 0.05	53407
@NP	P <	53407
@NP	P	53407
@NP	0.05	53411
@NP	implantation	53423
@NP	A loss of p75 immunoreactivity on SCs	53437
@NP	A loss	53437
@NP	p75 immunoreactivity on SCs	53447
@NP	p75 immunoreactivity	53447
@NP	SCs	53471
@NP	their conversion	53494
@NP	a myelinating phenotype -LRB- Morgan et al. , 1994 -RRB-	53514
@NP	a myelinating phenotype	53514
@NP	Morgan	53539
@NP	et al. , 1994	53546
@NP	et al.	53546
@NP	1994	53554
@NP	the transplanted SCs	53589
@NP	the myelination	53627
@NP	axons that had grown into the grafts -LRB- see Myelination section below -RRB-	53646
@NP	axons	53646
@NP	the grafts -LRB- see Myelination section below -RRB-	53672
@NP	the grafts	53672
@NP	Myelination section	53688
@NP	Assessment	53716
@NP	Cell Migration from the Site of Transplantation	53730
@NP	Cell Migration	53730
@NP	the Site of Transplantation	53750
@NP	the Site	53750
@NP	Transplantation	53762
@NP	The combination	53778
@NP	EGFP	53797
@NP	cells	53810
@NP	Y-probe DNA in situ of transplanted male cells with immunoreactivity for GFAP	53819
@NP	Y-probe DNA	53819
@NP	situ	53834
@NP	transplanted male cells with immunoreactivity for GFAP	53842
@NP	transplanted male cells	53842
@NP	immunoreactivity for GFAP	53871
@NP	immunoreactivity	53871
@NP	GFAP	53892
@NP	assessment	53907
@NP	the degree	53921
@NP	transplanted cells	53941
@NP	their original site of deposition	53986
@NP	their original site	53986
@NP	deposition	54009
@NP	regions of normalappearing host white and gray	54025
@NP	regions	54025
@NP	normalappearing host white and gray	54036
@NP	normalappearing host	54036
@NP	We	54080
@NP	the migratory ability of the transplanted cells	54092
@NP	the migratory ability	54092
@NP	the transplanted cells	54117
@NP	3 days , 3 weeks , or 9 weeks post-transplantation	54143
@NP	3 days	54143
@NP	3 weeks	54151
@NP	9 weeks post-transplantation	54163
@NP	the relative distribution	54205
@NP	labeled cells within the rostral	54234
@NP	labeled cells	54234
@NP	the rostral	54255
@NP	caudal	54268
@NP	dorsal-ventral 3D space	54276
@NP	the injured spinal cord for each grafting paradigm -LRB- Fig. 6 -RRB-	54303
@NP	the injured spinal cord	54303
@NP	each grafting paradigm -LRB- Fig. 6 -RRB-	54331
@NP	each grafting paradigm	54331
@NP	Fig. 6	54355
@NP	no migration of labeled cells	54373
@NP	no migration	54373
@NP	labeled cells	54389
@NP	regions of dense GFAP immunoreactivity	54421
@NP	regions	54421
@NP	dense GFAP immunoreactivity	54432
@NP	normal-appearing white and gray matter in all groups	54464
@NP	normal-appearing white and gray matter	54464
@NP	all groups	54506
@NP	grafts of labeled SCs or OEG into the injury site	54527
@NP	grafts	54527
@NP	labeled SCs or OEG into the injury site	54537
@NP	labeled SCs or OEG	54537
@NP	the injury site	54561
@NP	the two different cell types	54578
@NP	different distributions	54619
@NP	the area of original deposition	54650
@NP	the area	54650
@NP	original deposition	54662
@NP	SCs	54689
@NP	the immediate site	54736
@NP	injection over time -LRB- Figs. 6A -- C and 7C -RRB- , OEG ,	54758
@NP	injection over time	54758
@NP	injection	54758
@NP	time	54773
@NP	Figs. 6A -- C and 7C	54779
@NP	Figs. 6A	54779
@NP	C and 7C	54788
@NP	OEG	54799
@NP	SCs	54827
@NP	the lesion -LRB- Fig. 6D -- I -RRB-	54865
@NP	the lesion	54865
@NP	Fig. 6D -- I	54877
@NP	Fig. 6D	54877
@NP	I	54885
@NP	contrast	54892
@NP	injection of EGFPþ OEG 4 mm on either side of the injury site	54902
@NP	injection	54902
@NP	EGFPþ OEG 4 mm on either side of the injury site	54915
@NP	EGFPþ OEG	54915
@NP	4 mm on either side of the injury site	54925
@NP	4 mm	54925
@NP	either side of the injury site	54933
@NP	either side	54933
@NP	the injury site	54948
@NP	the presence	54978
@NP	small numbers of labeled OEG within the injury site -LRB- Fig. 6J -- L -RRB-	54994
@NP	small numbers	54994
@NP	labeled OEG within the injury site -LRB- Fig. 6J -- L -RRB-	55011
@NP	labeled OEG	55011
@NP	the injury site -LRB- Fig. 6J -- L -RRB-	55030
@NP	the injury site	55030
@NP	Fig. 6J -- L	55047
@NP	Fig. 6J	55047
@NP	L	55055
@NP	No EGFPþ OEG	55059
@NP	normal-appearing white or gray matter	55109
@NP	the injection sites and the injury site	55155
@NP	the injection sites	55155
@NP	the injury site	55179
@NP	EGFPþ OEG	55196
@NP	access	55223
@NP	the injury site	55233
@NP	the pia from the injection entry site -LRB- Fig. 7A -RRB-	55275
@NP	the pia	55275
@NP	the injection entry site -LRB- Fig. 7A -RRB-	55288
@NP	the injection entry site	55288
@NP	Fig. 7A	55314
@NP	the central canal -LRB- Fig. 7B -RRB-	55330
@NP	the central canal	55330
@NP	Fig. 7B	55349
@NP	the OEG injections	55388
@NP	the dorsal columns	55412
@NP	The implantation	55432
@NP	both EGFPOEG and unlabeled SCs	55452
@NP	EGFPOEG	55457
@NP	unlabeled SCs	55469
@NP	a combination graft into the injury epicenter	55486
@NP	a combination graft	55486
@NP	the injury epicenter	55511
@NP	in an	55541
@NP	that	55555
@NP	a heterogeneous mix of EGFPþ OEG and p75þ/EGFP2	55572
@NP	a heterogeneous mix	55572
@NP	EGFPþ OEG and p75þ/EGFP2	55595
@NP	endogenous or unlabeled exogenous SCs	55620
@NP	regions where EGFP cells were located -LRB- Fig. 3E -RRB-	55661
@NP	regions	55661
@NP	EGFP cells	55675
@NP	Fig. 3E	55700
@NP	Axonal Interactions and Growth Support	55710
@NP	Axonal Interactions	55710
@NP	Growth Support	55734
@NP	Glia	55765
@NP	Neurofilament-immunoreactive -LRB- NF-IR -RRB- axons	55770
@NP	NF-IR	55800
@NP	high densities	55827
@NP	all substantive EGFPþ cell grafts -LRB- Fig. 8A -- G -RRB-	55849
@NP	all substantive EGFPþ cell grafts	55849
@NP	Fig. 8A -- G	55884
@NP	Fig. 8A	55884
@NP	G	55892
@NP	NF-IR axons	55896
@NP	a parallel orientation	55935
@NP	EGFPþ cellular processes	55961
@NP	a few	55994
@NP	very random growth patterns	56015
@NP	perpendicular or U-shaped directional growth	56053
@NP	Grafts containing EGFPþ SCs	56099
@NP	Grafts	56099
@NP	EGFPþ SCs	56117
@NP	a greater density	56147
@NP	NF-IR axons	56168
@NP	Fig. 8D -- E	56197
@NP	Fig. 8D	56197
@NP	E	56205
@NP	EGFPþ OEG implants -LRB- Fig. 8F -- G -RRB-	56213
@NP	EGFPþ OEG implants	56213
@NP	Fig. 8F -- G	56233
@NP	Fig. 8F	56233
@NP	G	56241
@NP	these axons	56245
@NP	a significant portion of the extracellular space	56266
@NP	a significant portion	56266
@NP	the extracellular space	56291
@NP	NF-IR axons	56316
@NP	EGFPþ cell grafts	56348
@NP	all directions	56371
@NP	the identification	56394
@NP	their origin	56416
@NP	fiber type specific markers	56448
@NP	Phenotypic Identification	56489
@NP	Axon Populations	56518
@NP	Present	56535
@NP	the Grafts Identification of specific	56550
@NP	the Grafts Identification	56550
@NP	specific	56579
@NP	fiber systems	56612
@NP	anterograde tract tracing or immunochemistry	56640
@NP	anterograde tract tracing	56640
@NP	anterograde tract	56640
@NP	immunochemistry	56669
@NP	the majority of axons recognized	56700
@NP	the majority	56700
@NP	axons recognized	56716
@NP	axons	56716
@NP	an appreciable distance	56757
@NP	any of the graft types employed , i.e.	56786
@NP	any	56786
@NP	the graft types employed , i.e.	56793
@NP	the graft types	56793
@NP	i.e.	56819
@NP	the center of the grafts -LRB- Figs. 8H -- K and 9A -- D -RRB-	56827
@NP	the center	56827
@NP	the grafts -LRB- Figs. 8H -- K and 9A -- D -RRB-	56841
@NP	the grafts	56841
@NP	Figs. 8H	56853
@NP	K and 9A -- D	56862
@NP	K and 9A	56862
@NP	D	56871
@NP	sensory axons	56901
@NP	the hind limbs	56920
@NP	we	56935
@NP	CTB	56972
@NP	2,000 and 500 µm caudal to the graft	56980
@NP	2,000 and 500 µm caudal	56980
@NP	the graft	57007
@NP	the number of CTBþ fibers	57018
@NP	the number	57018
@NP	CTBþ fibers	57032
@NP	all groups	57062
@NP	SCI control : an average of 33 ± 7 fibers per section	57074
@NP	SCI control	57074
@NP	an average of 33 ± 7 fibers per section	57087
@NP	an average	57087
@NP	33 ± 7 fibers per section	57101
@NP	33 ± 7 fibers	57101
@NP	section	57119
@NP	f/s	57128
@NP	2,000 µm and 13 ± 3 f/s	57136
@NP	2,000 µm	57136
@NP	13 ± 3 f/s	57149
@NP	500 µm	57163
@NP	Growth of CTB	57172
@NP	Growth	57172
@NP	CTB	57182
@NP	fibers	57203
@NP	all graft types	57226
@NP	a small number	57247
@NP	axons present within the center of the grafts -LRB- Fig. 9A -RRB-	57265
@NP	axons present within the center of the grafts	57265
@NP	axons	57265
@NP	the center of the grafts	57286
@NP	the center	57286
@NP	the grafts	57300
@NP	Fig. 9A	57312
@NP	This growth	57322
@NP	the number of CTBþ axons	57381
@NP	the number	57381
@NP	CTBþ axons	57395
@NP	the tissue trabeculae of injured-only controls	57413
@NP	the tissue trabeculae	57413
@NP	injured-only controls	57438
@NP	The growth of CGRPþ -LRB- untraced -RRB- fibers	57461
@NP	The growth of CGRPþ -LRB- untraced -RRB-	57461
@NP	The growth	57461
@NP	CGRPþ	57475
@NP	caudal	57530
@NP	the grafts	57540
@NP	Growth of CGRPþ axons into the graft/injury site	58095
@NP	Growth	58095
@NP	CGRPþ axons into the graft/injury site	58105
@NP	CGRPþ axons	58105
@NP	the graft/injury site	58122
@NP	any of the grafted groups compared to injury-only controls	58189
@NP	any	58189
@NP	the grafted groups compared to injury-only controls	58196
@NP	the grafted groups	58196
@NP	injury-only controls	58227
@NP	descending fiber systems	58261
@NP	we	58286
@NP	anterograde	58298
@NP	BDA from the sensorimotor cortex	58323
@NP	BDA	58323
@NP	the sensorimotor cortex	58332
@NP	corticospinal tract axons	58365
@NP	immunochemical detection	58395
@NP	5-hydroxytryptophan	58423
@NP	a marker	58444
@NP	serotonergic axons	58457
@NP	constituents of the raphespinal system	58495
@NP	constituents	58495
@NP	the raphespinal system	58511
@NP	injury-only controls	58538
@NP	we	58559
@NP	± 50 and 58 ± 18 serotonergic f/s	58572
@NP	2,000 and 500 µm rostral	58609
@NP	2,000	58609
@NP	500 µm rostral	58619
@NP	the injury site	58637
@NP	7 ±	58672
@NP	6 serotonergic f/s within the center of trabeculae at the injury site	58676
@NP	6 serotonergic f/s	58676
@NP	the center of trabeculae at the injury site	58702
@NP	the center	58702
@NP	trabeculae at the injury site	58716
@NP	trabeculae	58716
@NP	the injury site	58730
@NP	Grafting of SCs or OEG or both	58747
@NP	Grafting	58747
@NP	SCs or OEG or both	58759
@NP	SCs or OEG	58759
@NP	both	58773
@NP	the number of serotonergic axons	58795
@NP	the number	58795
@NP	serotonergic axons	58809
@NP	rostral to or within the graft/injury site -LRB- Figs. 8H -- J and 9C -RRB-	58835
@NP	rostral	58835
@NP	the graft/injury site	58856
@NP	Figs. 8H -- J and 9C	58879
@NP	Figs. 8H	58879
@NP	J and 9C	58888
@NP	the number of BDA	58910
@NP	the number	58910
@NP	BDA	58924
@NP	fibers	58935
@NP	31 ±	58946
@NP	12 and 18 ±	58951
@NP	12	58951
@NP	18 ±	58958
@NP	7 f/s	58963
@NP	at 2,000 and 500 µm rostral to the injury site , respectively , and 3 ± 3 f/s	58969
@NP	at 2,000 and 500 µm rostral to the injury site , respectively ,	58969
@NP	at 2,000 and 500 µm rostral	58969
@NP	the injury site , respectively ,	59000
@NP	the injury site	59000
@NP	3 ± 3 f/s	59035
@NP	3 ±	59035
@NP	3 f/s	59039
@NP	the center of tissue trabeculae	59052
@NP	the center	59052
@NP	tissue trabeculae	59066
@NP	the injury site of injury-only controls	59087
@NP	the injury site	59087
@NP	injury-only controls	59106
@NP	the number of BDA	59135
@NP	the number	59135
@NP	BDA	59149
@NP	axons	59160
@NP	rostral to or within the graft	59205
@NP	rostral	59205
@NP	the graft	59226
@NP	injury site	59237
@NP	all transplantation paradigms -LRB- Fig. 9D -RRB-	59259
@NP	all transplantation paradigms	59259
@NP	Fig. 9D	59290
@NP	neither SC nor OEG grafts	59316
@NP	SC	59324
@NP	OEG grafts	59331
@NP	the contusion injury model	59352
@NP	substrates for significant cortico	59405
@NP	substrates	59405
@NP	significant cortico	59420
@NP	raphe-spinal axon growth	59444
@NP	Similar axon growth responses from ascending and descending systems	59470
@NP	Similar axon growth responses	59470
@NP	systems	59530
@NP	fibroblast implants	59557
@NP	data not shown	59592
@NP	data	59592
@NP	the growth of supraspinal axons	59618
@NP	the growth	59618
@NP	supraspinal axons	59632
@NP	EGFP glial cell grafts	59689
@NP	significant numbers	59715
@NP	appreciable distances	59742
@NP	many of these axons	59765
@NP	many	59765
@NP	these axons	59773
@NP	regions	59801
@NP	adjacent to the rostral edge of the EGFP implants	59821
@NP	the rostral edge of the EGFP	59833
@NP	the rostral edge	59833
@NP	the EGFP	59853
@NP	Fig. 8J	59872
@NP	an area which contained a mixture of largely p75þ endogenous SCs	59882
@NP	an area	59882
@NP	a mixture of largely p75þ endogenous SCs	59906
@NP	a mixture	59906
@NP	largely p75þ endogenous SCs	59919
@NP	immune cells , such as macrophages	59951
@NP	immune cells	59951
@NP	macrophages	59973
@NP	A similar phenomenon	59986
@NP	the caudal edge of the EGFP implants with respect	60023
@NP	the caudal edge	60023
@NP	the EGFP implants with respect	60042
@NP	the EGFP implants	60042
@NP	respect	60065
@NP	CTB-labeled ascending or CGRPþ axons -LRB- Fig. 8K -RRB-	60076
@NP	CTB-labeled ascending or CGRPþ axons	60076
@NP	Fig. 8K	60114
@NP	the EGFP SC group	60138
@NP	it	60157
@NP	the implant milieu and the surrounding host	60192
@NP	milieu and the surrounding host	60204
@NP	milieu	60204
@NP	the surrounding host	60215
@NP	lesion environment	60236
@NP	SCs	60279
@NP	factors produced by intermingling cell types , such as macrophages	60291
@NP	factors	60291
@NP	intermingling cell types	60311
@NP	macrophages	60345
@NP	the differential responses of these SC populations to the factors or ECM	60361
@NP	the differential responses	60361
@NP	these SC populations to the factors or ECM	60391
@NP	these SC populations	60391
@NP	the factors or ECM	60415
@NP	the factors	60415
@NP	ECM	60430
@NP	they	60434
@NP	a more permissive environment for axon growth	60466
@NP	a more permissive environment	60466
@NP	axon growth	60500
@NP	Myelination	60513
@NP	Axons by Transplanted Glia Myelination by transplanted SCs and OEG	60528
@NP	Axons	60528
@NP	Transplanted Glia Myelination by transplanted SCs and OEG	60537
@NP	Transplanted Glia Myelination	60537
@NP	transplanted SCs and OEG	60570
@NP	transplanted SCs	60570
@NP	OEG	60591
@NP	high power microscopic assessment	60622
@NP	the ratio	60659
@NP	MBP immunostaining and EGFP	60672
@NP	cells in the rostral , central , and caudal regions of EGFPþ SC	60708
@NP	cells	60708
@NP	the rostral , central , and caudal regions of EGFPþ SC	60717
@NP	the rostral	60717
@NP	central	60730
@NP	caudal regions of EGFPþ SC	60743
@NP	caudal regions	60743
@NP	EGFPþ SC	60761
@NP	SC and EGFPþ OEG transplants -LRB- Fig. 10A -RRB-	60778
@NP	SC and EGFPþ OEG transplants	60778
@NP	Fig. 10A	60808
@NP	axons	60830
@NP	both SC and OEG grafts	60853
@NP	SC	60858
@NP	OEG grafts	60865
@NP	SC grafts	60880
@NP	numerous myelinated axons	60891
@NP	both rostral and caudal regions	60938
@NP	the grafts with ratios of MBPþ axons to EGFPþ cells of 1:1.4 and 1:1.2	60973
@NP	the grafts	60973
@NP	ratios of MBPþ axons to EGFPþ cells of 1:1.4 and 1:1.2	60989
@NP	ratios	60989
@NP	MBPþ axons to EGFPþ cells of 1:1.4 and 1:1.2	60999
@NP	MBPþ axons	60999
@NP	EGFPþ cells of 1:1.4 and 1:1.2	61013
@NP	EGFPþ cells	61013
@NP	1:1.4 and 1:1.2	61028
@NP	the center of the grafts	61062
@NP	the center	61062
@NP	the grafts	61076
@NP	significantly fewer myelinated axons	61097
@NP	a ratio of MBPþ axons to EGFPþ cells of 1:5.8 -LRB- Table 1 , Fig. 10B -RRB-	61154
@NP	a ratio	61154
@NP	MBPþ axons to EGFPþ cells of 1:5.8 -LRB- Table 1 , Fig. 10B -RRB-	61165
@NP	MBPþ axons	61165
@NP	EGFPþ cells of 1:5.8 -LRB- Table 1 , Fig. 10B -RRB-	61179
@NP	EGFPþ cells	61179
@NP	1:5.8 -LRB- Table 1 , Fig. 10B -RRB-	61194
@NP	1:5.8	61194
@NP	Table 1	61201
@NP	Fig. 10B	61210
@NP	SC and EGFPþ OEG grafts	61224
@NP	there	61249
@NP	a reasonable distinction	61270
@NP	the two	61303
@NP	transplanted cell types	61311
@NP	the injury/graft site	61342
@NP	The mass of EGFPþ OEG	61365
@NP	The mass	61365
@NP	EGFPþ OEG	61377
@NP	closely comparable p75þ-EGFPþ cell profiles	61397
@NP	these areas	61458
@NP	many EGFP2	61497
@NP	exogenous or endogenous SCs	61508
@NP	Care	61537
@NP	regions used to analyze myelination	61567
@NP	regions	61567
@NP	myelination	61591
@NP	EGFP2-p75þ areas of the injury	61621
@NP	EGFP2-p75þ areas	61621
@NP	the injury	61641
@NP	graft site	61653
@NP	SCs	61670
@NP	abundance	61686
@NP	Assessment of myelination within EGFPþ OEG grafts	61697
@NP	Assessment	61697
@NP	myelination within EGFPþ OEG grafts	61711
@NP	myelination	61711
@NP	EGFPþ OEG grafts	61730
@NP	very few MBPþ profiles	61756
@NP	all three regions	61786
@NP	ratios for MBPþ axons	61809
@NP	ratios	61809
@NP	MBPþ axons	61820
@NP	EGFPþ cells	61834
@NP	1:46.2 , 1:58.8 , and 1:41.9	61849
@NP	rostral , central and caudal regions of the transplants , respectively	61879
@NP	rostral	61879
@NP	central and caudal regions of the transplants	61888
@NP	central and caudal regions	61888
@NP	the transplants	61918
@NP	Table	61949
@NP	I , Fig. 10C	61955
@NP	I	61955
@NP	Fig. 10C	61958
@NP	The very low numbers of MBPþ axons in the EGFPþ OEG graft regions	61969
@NP	The very low numbers	61969
@NP	MBPþ axons in the EGFPþ OEG graft regions	61993
@NP	MBPþ axons	61993
@NP	the EGFPþ OEG graft regions	62007
@NP	the possibility	62066
@NP	these axons	62087
@NP	the small numbers	62122
@NP	exogenous or endogenous SCs	62143
@NP	EGFPþ OEG	62199
@NP	Recovery of Hind Limb Function	62210
@NP	Recovery	62210
@NP	Hind Limb Function	62222
@NP	Glia Transplantation	62247
@NP	the	62273
@NP	Spinal Cord Animals	62285
@NP	both the injury only and most transplant groups	62310
@NP	the injury only	62315
@NP	most transplant groups	62335
@NP	a characteristic improvement	62368
@NP	open-field locomotion that reached a plateau by ≈ 6 weeks -LRB- Fig. 11A -RRB-	62400
@NP	open-field locomotion	62400
@NP	a plateau	62435
@NP	≈	62448
@NP	6 weeks	62449
@NP	Fig. 11A	62458
@NP	endpoint -LRB- 9 weeks -RRB-	62472
@NP	endpoint	62472
@NP	9 weeks	62482
@NP	injury-only controls	62492
@NP	a BBB score of 10.7 ± 0.7	62526
@NP	a BBB score	62526
@NP	10.7 ± 0.7	62541
@NP	the animals	62569
@NP	occasional	62591
@NP	frequent weight-supported	62605
@NP	no fore limb-hind limb coordination	62645
@NP	The other control group , which received fibroblast grafts ,	62682
@NP	The other control group	62682
@NP	fibroblast grafts	62722
@NP	any significant improvement over the injury	62754
@NP	any significant improvement	62754
@NP	the injury	62787
@NP	group	62803
@NP	an endpoint BBB score of 9.8 ± 1.4	62820
@NP	an endpoint BBB score	62820
@NP	9.8 ± 1.4	62845
@NP	the SC and OEG transplant groups	62861
@NP	only those animals receiving both SCs and OEG into the injury site	62895
@NP	both SCs and OEG	62924
@NP	SCs	62929
@NP	OEG	62937
@NP	the injury site	62946
@NP	a significant improvement	62975
@NP	BBB score	63004
@NP	fibroblast transplant and injury-only controls	63026
@NP	fibroblast transplant	63026
@NP	injury-only controls	63052
@NP	The SC and OEG combination group	63074
@NP	statistically significant increases in locomotor ability	63117
@NP	statistically significant increases	63117
@NP	locomotor ability	63156
@NP	5 to 9 weeks post-transplantation with the animals	63179
@NP	5 to 9 weeks	63179
@NP	the animals	63218
@NP	an average BBB score of 12.3 ± 0.7	63239
@NP	an average BBB score	63239
@NP	12.3 ± 0.7	63263
@NP	endpoint	63277
@NP	fibroblast transplants , P < 0.001 ; versus injury controls , P < 0.05	63294
@NP	fibroblast transplants , P < 0.001 ; versus injury controls	63294
@NP	fibroblast transplants	63294
@NP	P < 0.001	63318
@NP	P <	63318
@NP	P	63318
@NP	0.001	63322
@NP	injury controls	63336
@NP	P < 0.05	63353
@NP	P <	63353
@NP	P	63353
@NP	0.05	63357
@NP	These animals	63364
@NP	frequent to consistent plantar	63388
@NP	occasional fore limb-hind limb coordination	63433
@NP	the open field	63480
@NP	A subscore analysis	63496
@NP	the BBB score	63538
@NP	the presence of features above a score of 14	63563
@NP	the presence	63563
@NP	features above a score of 14	63579
@NP	features	63579
@NP	a score of 14	63594
@NP	a score	63594
@NP	14	63605
@NP	the BBB scale -LRB- Fig. 11B -RRB-	63611
@NP	the BBB scale	63611
@NP	Fig. 11B	63626
@NP	a BBB subscore of 6.1 ± 3.1	63669
@NP	a BBB subscore	63669
@NP	6.1 ± 3.1	63687
@NP	endpoint	63700
@NP	The transplantation of fibroblasts	63710
@NP	The transplantation	63710
@NP	fibroblasts	63733
@NP	BBB subscores	63768
@NP	4 to 9 weeks post-transplantation with animals	63787
@NP	4 to 9 weeks	63787
@NP	animals	63826
@NP	2.6 ± 3.2	63843
@NP	endpoint -LRB- P < 0.05 -RRB-	63856
@NP	endpoint	63856
@NP	P < 0.05	63866
@NP	P	63866
@NP	< 0.05	63868
@NP	<	63868
@NP	0.05	63870
@NP	Animals	63877
@NP	the combination of SCs and OEG	63898
@NP	the combination	63898
@NP	SCs and OEG	63917
@NP	the injury site	63934
@NP	significantly higher BBB subscores	63957
@NP	8 and 9 weeks compared with injury	63995
@NP	8 and 9 weeks	63995
@NP	injury	64023
@NP	The average endpoint BBB subscore	64045
@NP	9.2 ± 1.2 -LRB- P < 0.05 -RRB-	64083
@NP	9.2 ± 1.2	64083
@NP	P < 0.05	64094
@NP	P	64094
@NP	< 0.05	64096
@NP	<	64096
@NP	0.05	64098
@NP	No significant improvements in the BBB subscore	64105
@NP	No significant improvements	64105
@NP	the BBB subscore	64136
@NP	the other three transplant groups	64172
@NP	9 weeks	64210
@NP	footprint analysis of the hind paws	64240
@NP	footprint analysis	64240
@NP	the hind paws	64262
@NP	the animals performed conditioned locomotion -LRB- Fig. 12A -- C -RRB-	64292
@NP	the animals	64292
@NP	conditioned locomotion -LRB- Fig. 12A -- C -RRB-	64314
@NP	conditioned locomotion	64314
@NP	Fig. 12A -- C	64338
@NP	Fig. 12A	64338
@NP	C	64347
@NP	Analysis of uninjured animals	64351
@NP	Analysis	64351
@NP	uninjured animals	64363
@NP	a mean angle of rotation of the hind limbs of 13.0 ± 1.0 °	64390
@NP	a mean angle	64390
@NP	rotation of the hind limbs of 13.0 ± 1.0 °	64406
@NP	rotation	64406
@NP	the hind limbs of 13.0 ± 1.0 °	64418
@NP	the hind limbs	64418
@NP	13.0 ± 1.0 °	64436
@NP	13.0 ±	64436
@NP	1.0 °	64443
@NP	injury	64455
@NP	this parameter	64462
@NP	a mean of 32.2 ± 2.0 °	64490
@NP	a mean	64490
@NP	32.2 ± 2.0 °	64500
@NP	32.2 ±	64500
@NP	2.0 °	64507
@NP	Fibroblast transplantation	64513
@NP	the rotation of the hind limbs , 32.1 ± 3.1 °	64568
@NP	the rotation	64568
@NP	the hind limbs , 32.1 ± 3.1 °	64584
@NP	the hind limbs	64584
@NP	32.1 ± 3.1 °	64600
@NP	32.1 ±	64600
@NP	3.1 °	64607
@NP	Transplantation of either SCs alone or both SCs and OEG into the injury site	64613
@NP	Transplantation of either SCs alone or both SCs	64613
@NP	Transplantation	64613
@NP	either SCs alone or both SCs	64632
@NP	SCs alone	64639
@NP	SCs	64639
@NP	both SCs	64652
@NP	OEG into the injury site	64665
@NP	OEG	64665
@NP	the injury site	64674
@NP	foot rotation	64702
@NP	the degree of deficit	64726
@NP	the degree	64726
@NP	deficit	64740
@NP	26.0 ±	64751
@NP	1.8 ° -LRB- P < 0.05 -RRB- and 25.3 ± 4.6 ° -LRB- P < 0.05 -RRB-	64758
@NP	1.8 ° -LRB- P < 0.05 -RRB- and 25.3 ± 4.6 °	64758
@NP	1.8 ° -LRB- P < 0.05 -RRB-	64758
@NP	P < 0.05	64764
@NP	P	64764
@NP	< 0.05	64766
@NP	<	64766
@NP	0.05	64768
@NP	25.3 ± 4.6 °	64778
@NP	25.3 ±	64778
@NP	4.6 °	64785
@NP	P < 0.05	64791
@NP	P	64791
@NP	< 0.05	64793
@NP	<	64793
@NP	0.05	64795
@NP	No differences	64816
@NP	the other transplant groups -LRB- Fig. 12A -RRB-	64848
@NP	the other transplant groups	64848
@NP	Fig. 12A	64877
@NP	The other parameters measured , stride length and base of support ,	64888
@NP	The other parameters measured	64888
@NP	The other parameters	64888
@NP	stride length	64919
@NP	base of support	64937
@NP	base	64937
@NP	support	64945
@NP	significant deficits	64961
@NP	injury	64988
@NP	any of the transplants -LRB- Fig. 12B , C -RRB-	65019
@NP	any	65019
@NP	the transplants -LRB- Fig. 12B , C -RRB-	65026
@NP	the transplants	65026
@NP	Fig. 12B , C	65043
@NP	Fig. 12B	65043
@NP	C	65052
@NP	the final test , for coordinated motor performance	65059
@NP	the final test	65059
@NP	coordinated motor performance	65079
@NP	animals	65110
@NP	a grid	65159
@NP	bars	65187
@NP	the number of footfall errors -LRB- missed bars -RRB- made by each hind limb	65196
@NP	the number of footfall errors -LRB- missed bars -RRB-	65196
@NP	the number of footfall errors	65196
@NP	the number	65196
@NP	footfall errors	65210
@NP	bars	65234
@NP	each hind limb	65248
@NP	a pronounced impairment	65286
@NP	injury compared with uninjured controls	65333
@NP	injury	65333
@NP	uninjured controls	65354
@NP	none of the transplant groups	65374
@NP	none	65374
@NP	the transplant groups	65382
@NP	a significant improvement in performance over the injury	65413
@NP	a significant improvement	65413
@NP	performance over the injury	65442
@NP	performance	65442
@NP	the injury	65459
@NP	Fig. 12D	65485
@NP	DISCUSSION The use of a cellular transplant to bridge the injured spinal cord	65497
@NP	DISCUSSION	65497
@NP	The use of a cellular transplant	65508
@NP	The use	65508
@NP	a cellular transplant	65519
@NP	the injured spinal cord	65551
@NP	a cornerstone	65584
@NP	many successful repair strategies	65601
@NP	e.g.	65636
@NP	Li	65642
@NP	et al. , 2003b	65645
@NP	et al.	65645
@NP	2003b	65653
@NP	McDonald et al. , 1999	65660
@NP	McDonald	65660
@NP	et al. , 1999	65669
@NP	et al.	65669
@NP	1999	65677
@NP	Pearse et al. , 2004b	65683
@NP	Pearse	65683
@NP	et al. , 2004b	65690
@NP	et al.	65690
@NP	2004b	65698
@NP	Ram on-Cueto et al.	65705
@NP	Ram on-Cueto	65705
@NP	et al.	65718
@NP	2000	65726
@NP	We	66156
@NP	cells	66170
@NP	vivo over time post-transplantation	66179
@NP	vivo	66179
@NP	time post-transplantation	66189
@NP	the use	66223
@NP	genetic markers	66234
@NP	the Y chromosome or lentiviral vector transfer	66251
@NP	EGFP	66301
@NP	markers	66307
@NP	leakage or cellular transfer	66347
@NP	leakage	66347
@NP	cellular transfer	66358
@NP	the host to permit long-term tracking	66400
@NP	long-term tracking	66419
@NP	Barakat	66439
@NP	et al. , 2005	66447
@NP	et al.	66447
@NP	2005	66455
@NP	Consiglio et al. , 2004	66461
@NP	Consiglio	66461
@NP	et al. , 2004	66471
@NP	et al.	66471
@NP	2004	66479
@NP	Ericson et al. , 2002	66485
@NP	Ericson	66485
@NP	et al. , 2002	66493
@NP	et al.	66493
@NP	2002	66501
@NP	Harvey et al. , 1992	66507
@NP	Harvey	66507
@NP	et al. , 1992	66514
@NP	et al.	66514
@NP	1992	66522
@NP	Tamaki et al. , 2002	66528
@NP	Tamaki	66528
@NP	et al. , 2002	66535
@NP	et al.	66535
@NP	2002	66543
@NP	Our study	66550
@NP	the relatively low survival of both types of glial cells after transplantation	66571
@NP	the relatively low survival	66571
@NP	both types of glial cells after transplantation	66602
@NP	both types	66602
@NP	glial cells after transplantation	66616
@NP	glial cells	66616
@NP	transplantation	66634
@NP	the epicenter of the injured spinal cord	66655
@NP	the epicenter	66655
@NP	the injured spinal cord	66672
@NP	survival of OEG	66704
@NP	survival	66704
@NP	OEG	66716
@NP	they	66741
@NP	combination	66762
@NP	lower densities	66778
@NP	host spinal cord distant	66803
@NP	host spinal cord	66803
@NP	the injury epicenter	66833
@NP	all grafting paradigms	66858
@NP	significant infiltration of endogenous SCs	66882
@NP	significant infiltration	66882
@NP	endogenous SCs	66910
@NP	accompanying transplantation	66938
@NP	endogenous cell numbers	66973
@NP	numbers of labeled cells within the injured spinal cord over time	67032
@NP	numbers	67032
@NP	labeled cells within the injured spinal cord over time	67043
@NP	labeled cells	67043
@NP	the injured spinal cord over time	67064
@NP	the injured spinal cord	67064
@NP	time	67093
@NP	contrast	67102
@NP	other studies -LRB- Ram on-Cueto et al. , 1998 , 2000 -RRB- , grafted	67114
@NP	other studies -LRB- Ram on-Cueto et al. , 1998 , 2000 -RRB-	67114
@NP	other studies	67114
@NP	Ram on-Cueto et al. , 1998 , 2000	67129
@NP	Ram on-Cueto et al. , 1998	67129
@NP	Ram	67129
@NP	et al. , 1998	67142
@NP	et al.	67142
@NP	1998	67150
@NP	2000	67156
@NP	glial cells	67171
@NP	their original site of deposition	67207
@NP	their original site	67207
@NP	deposition	67230
@NP	they	67253
@NP	access	67278
@NP	the central canal	67288
@NP	the pia from the injection entry site	67328
@NP	the pia	67328
@NP	the injection entry site	67341
@NP	both SCs and OEG	67376
@NP	highly supportive substrates	67398
@NP	NFþ axons	67431
@NP	the growth of long tract	67494
@NP	the growth	67494
@NP	long tract	67508
@NP	axons and only SC grafts	67543
@NP	axons	67543
@NP	SC grafts	67558
@NP	large numbers of myelinated axons	67578
@NP	large numbers	67578
@NP	myelinated axons	67595
@NP	The combination of SC and OEG implantation into the injury site	67613
@NP	The combination	67613
@NP	SC and OEG implantation into the injury site	67632
@NP	SC and OEG implantation	67632
@NP	the injury site	67661
@NP	modest , though significant , improvements	67699
@NP	open-field locomotion and hind paw positioning	67743
@NP	open-field locomotion	67743
@NP	hind paw positioning	67769
@NP	local axon growth	67807
@NP	DRG	67838
@NP	sensory or spinal cord proprioceptive neurons	67842
@NP	sensory or spinal cord	67842
@NP	proprioceptive neurons	67865
@NP	partial recovery of function	67903
@NP	partial recovery	67903
@NP	function	67923
@NP	previous studies	67936
@NP	a number of nuclear -LRB- Hoechst -RRB- and cytoplasmic dyes -LRB- PKH26 -RRB-	67953
@NP	a number	67953
@NP	nuclear -LRB- Hoechst -RRB- and cytoplasmic dyes -LRB- PKH26 -RRB-	67965
@NP	nuclear	67965
@NP	Hoechst	67974
@NP	cytoplasmic dyes	67987
@NP	PKH26	68005
@NP	SCs and OEG	68059
@NP	Evercooren et al. , 1991 ; Ram on-Cueto et al. , 1998 , 2000	68072
@NP	Evercooren et al.	68072
@NP	Evercooren	68072
@NP	et al.	68083
@NP	1991 ; Ram on-Cueto et al.	68091
@NP	1991	68091
@NP	Ram on-Cueto et al.	68097
@NP	Ram on-Cueto	68097
@NP	et al.	68110
@NP	1998 , 2000	68118
@NP	1998	68118
@NP	2000	68124
@NP	These labels	68131
@NP	the cells in culture prior to their transplantation	68163
@NP	the cells	68163
@NP	culture	68176
@NP	their transplantation	68193
@NP	the dyes label cells well in vitro ,	68225
@NP	the dyes label cells	68225
@NP	vitro	68254
@NP	a few passages	68277
@NP	leak	68310
@NP	the short-term -LRB- Mosahebi et al. , 2000 -RRB- , once transplanted	68318
@NP	the short-term -LRB- Mosahebi et al. , 2000 -RRB-	68318
@NP	the short-term	68318
@NP	Mosahebi	68334
@NP	et al. , 2000	68343
@NP	et al.	68343
@NP	2000	68351
@NP	transplanted	68363
@NP	the death of the labeled cells	68377
@NP	the death	68377
@NP	the labeled cells	68390
@NP	the	68418
@NP	it	68434
@NP	endogenous cells	68456
@NP	label host structures	68476
@NP	Ansselin et al. , 1997 ; Hermanns et al. , 1997 ; Horan and Slezak , 1989	68499
@NP	Ansselin	68499
@NP	et al. , 1997 ; Hermanns et al. , 1997 ; Horan and Slezak , 1989	68508
@NP	et al. , 1997	68508
@NP	et al.	68508
@NP	1997	68516
@NP	Hermanns et al. , 1997	68522
@NP	Hermanns	68522
@NP	et al. , 1997	68531
@NP	et al.	68531
@NP	1997	68539
@NP	Horan and Slezak , 1989	68545
@NP	Horan and Slezak	68545
@NP	1989	68563
@NP	specific identification of the grafted cells very difficult	68577
@NP	specific identification	68577
@NP	the grafted cells very difficult	68604
@NP	the grafted cells	68604
@NP	Other studies	68638
@NP	immunochemistry	68666
@NP	an antibody	68688
@NP	a protein	68703
@NP	the grafted glia	68741
@NP	the low-affinity neurotrophin receptor p75	68767
@NP	Takami	68811
@NP	et al. , 2002 ; Pearse et al. , 2004b	68818
@NP	et al.	68818
@NP	2002 ; Pearse et al.	68826
@NP	2002	68826
@NP	Pearse et al.	68832
@NP	Pearse	68832
@NP	et al.	68839
@NP	2004b	68847
@NP	The infiltration	68855
@NP	peripheral nerve elements	68875
@NP	the CNS	68906
@NP	SCs and afferent fibers -LRB- Beattie et al. , 1997 ; Brook et al. , 1998 -RRB-	68923
@NP	SCs and afferent fibers	68923
@NP	Beattie	68948
@NP	et al. , 1997 ; Brook et al. , 1998	68956
@NP	et al.	68956
@NP	1997 ; Brook et al.	68964
@NP	1997	68964
@NP	Brook et al.	68970
@NP	Brook	68970
@NP	et al.	68976
@NP	1998	68984
@NP	SCI	68997
@NP	this labeling	69012
@NP	both exogenous and endogenous glia and thus estimation of grafted cell survival	69037
@NP	both exogenous and endogenous glia	69037
@NP	estimation of grafted cell survival	69081
@NP	estimation	69081
@NP	grafted cell survival	69095
@NP	Pearse et al.	69133
@NP	2002 , 2004c	69148
@NP	2002	69148
@NP	2004c	69154
@NP	there	69176
@NP	concomitant expression	69185
@NP	p75 by microglia and astrocytes -LRB- Harvey , 1994 -RRB-	69211
@NP	p75	69211
@NP	microglia and astrocytes -LRB- Harvey , 1994 -RRB-	69218
@NP	microglia and astrocytes	69218
@NP	Harvey	69244
@NP	1994	69252
@NP	there	69262
@NP	a loss	69271
@NP	expression	69281
@NP	p75 on SCs following myelination -LRB- Jessen and Mirsky , 1991 -RRB-	69295
@NP	p75	69295
@NP	SCs following myelination -LRB- Jessen and Mirsky , 1991 -RRB-	69302
@NP	SCs	69302
@NP	myelination -LRB- Jessen and Mirsky , 1991 -RRB-	69316
@NP	myelination	69316
@NP	Jessen and Mirsky , 1991	69329
@NP	Jessen	69329
@NP	Mirsky , 1991	69340
@NP	Mirsky	69340
@NP	1991	69348
@NP	early generation viral vectors	69363
@NP	early generation	69363
@NP	viral vectors	69380
@NP	retro - and adeno-viral vectors ,	69395
@NP	retro	69395
@NP	adeno-viral vectors	69406
@NP	nonmammalian genes such as lacZ or GFP	69457
@NP	nonmammalian genes	69457
@NP	lacZ or GFP	69484
@NP	glial cells ex vivo prior to implantation -LRB- Langford and Owens , 1990 -RRB-	69499
@NP	glial cells ex vivo prior to implantation	69499
@NP	glial cells	69499
@NP	ex vivo	69511
@NP	implantation	69528
@NP	Langford and Owens	69542
@NP	1990	69562
@NP	These delivery systems	69569
@NP	apparent short-term expression	69621
@NP	rapid down-regulation of the gene	69659
@NP	rapid down-regulation	69659
@NP	the gene	69684
@NP	interest	69696
@NP	Blits et al. , 1999 ; Ruitenberg et al. , 2002 ; Hendriks et al. , 2004	69706
@NP	Blits	69706
@NP	et al. , 1999 ; Ruitenberg et al. , 2002 ; Hendriks et al. , 2004	69712
@NP	et al. , 1999	69712
@NP	et al.	69712
@NP	1999	69720
@NP	Ruitenberg et al. , 2002	69726
@NP	Ruitenberg	69726
@NP	et al. , 2002	69737
@NP	et al.	69737
@NP	2002	69745
@NP	Hendriks et al. , 2004	69751
@NP	Hendriks	69751
@NP	et al. , 2004	69760
@NP	et al.	69760
@NP	2004	69768
@NP	the long-term tracking	69786
@NP	the cell 's fate	69812
@NP	the cell 's	69812
@NP	the present study	70446
@NP	we	70465
@NP	labels	70482
@NP	their particular strengths	70502
@NP	the overall characterization of the glia transplants in the contused spinal cord	70533
@NP	the overall characterization	70533
@NP	the glia transplants in the contused spinal cord	70565
@NP	the glia transplants	70565
@NP	the contused spinal cord	70589
@NP	the	70589
@NP	spinal cord	70602
@NP	Stereological assessment of male SCs and/or OEG	70615
@NP	Stereological assessment	70615
@NP	male SCs and/or OEG	70643
@NP	male SCs	70643
@NP	OEG	70659
@NP	the survival of these cells	70681
@NP	the survival	70681
@NP	these cells	70697
@NP	the hostile milieu of the injury epicenter	70742
@NP	the hostile milieu	70742
@NP	the injury epicenter	70764
@NP	the presence of	70794
@NP	the presence	70794
@NP	gross examination	70817
@NP	a large graft	70856
@NP	most animals	70874
@NP	the formation of a central cavity	70902
@NP	the formation	70902
@NP	a central cavity	70919
@NP	The absence	70937
@NP	statistical significance	70952
@NP	cell survival	70980
@NP	all transplant groups between 3 and 9 weeks post-transplantation	70997
@NP	all transplant groups	70997
@NP	between 3 and 9 weeks	71019
@NP	dramatic cell loss	71077
@NP	3 days and 3 weeks post-transplantation	71113
@NP	3 days	71113
@NP	3 weeks post-transplantation	71124
@NP	The temporal profile of cell loss quantified by the number of male cells	71154
@NP	The temporal profile	71154
@NP	cell loss quantified by the number of male cells	71178
@NP	cell loss	71178
@NP	the number of male cells	71202
@NP	the number	71202
@NP	male cells	71216
@NP	a sequential reduction	71243
@NP	GFP signal	71269
@NP	immunoblot analysis	71297
@NP	stereological quantification	71323
@NP	numbers of GFP cells -LRB- Andrade et al. , 2007 -RRB-	71355
@NP	numbers	71355
@NP	GFP cells -LRB- Andrade et al. , 2007 -RRB-	71366
@NP	GFP cells	71366
@NP	Andrade	71377
@NP	et al. , 2007	71385
@NP	et al.	71385
@NP	2007	71393
@NP	The loss	71400
@NP	cells appeared to result primarily from cell death	71420
@NP	cells	71420
@NP	cell death	71460
@NP	the down-regulation	71484
@NP	lentiviral vector	71507
@NP	EGFP -LRB- Johansen et al. , 2002 -RRB-	71537
@NP	EGFP	71537
@NP	Johansen	71543
@NP	et al. , 2002	71552
@NP	et al.	71552
@NP	2002	71560
@NP	no statistically significant difference	71570
@NP	the cell counts obtained with both markers within	71631
@NP	the cell counts	71631
@NP	both markers	71661
@NP	cohorts across time	71689
@NP	cohorts	71689
@NP	time	71704
@NP	it	71732
@NP	the introduction	71759
@NP	a foreign protein	71779
@NP	EGFP	71798
@NP	the surface of producing cells	71839
@NP	the surface	71839
@NP	producing cells	71854
@NP	prime	71885
@NP	them for rejection	71891
@NP	them	71891
@NP	rejection	71900
@NP	the immune system	71913
@NP	a role	71948
@NP	the observed loss of cells	71958
@NP	the observed loss	71958
@NP	cells	71979
@NP	the lack of significant difference in cell counts between markers	71992
@NP	the lack	71992
@NP	significant difference in cell counts between markers	72004
@NP	significant difference	72004
@NP	cell counts between markers	72030
@NP	cell counts	72030
@NP	markers	72050
@NP	EGFP expression	72077
@NP	the major factor responsible for triggering cell death	72101
@NP	the major factor	72101
@NP	cell death	72145
@NP	The implantation of male cells into a female host	72157
@NP	The implantation	72157
@NP	male cells into a female host	72177
@NP	male cells	72177
@NP	a female host	72193
@NP	a targeted immune response	72226
@NP	the complement cascade through which this mechanism occurs	72261
@NP	the complement cascade	72261
@NP	this mechanism	72298
@NP	implantation -LRB- hours -RRB-	72357
@NP	implantation	72357
@NP	hours	72371
@NP	most of the cell death	72431
@NP	most	72431
@NP	the cell death	72439
@NP	we	72459
@NP	time points	72474
@NP	3 days	72493
@NP	implantation -LRB- Hodgetts and Grounds , 2001	72506
@NP	implantation -LRB- Hodgetts and Grounds	72506
@NP	implantation	72506
@NP	Hodgetts and Grounds	72520
@NP	Hodgetts	72520
@NP	Grounds	72533
@NP	2001	72542
@NP	this mechanism of sex-mismatched rejection	72562
@NP	this mechanism	72562
@NP	sex-mismatched rejection	72580
@NP	an important event	72615
@NP	humans	72637
@NP	a much smaller role in rodents -LRB- Hodgetts and Grounds , 2001 -RRB-	72661
@NP	a much smaller role	72661
@NP	rodents -LRB- Hodgetts and Grounds , 2001 -RRB-	72684
@NP	rodents	72684
@NP	Hodgetts and Grounds , 2001	72693
@NP	Hodgetts	72693
@NP	Grounds	72706
@NP	2001	72715
@NP	another study of SC survival	72725
@NP	another study	72725
@NP	SC survival	72742
@NP	SCs expressing human placental alkaline phosphatase	72755
@NP	SCs	72755
@NP	human placental alkaline phosphatase	72770
@NP	cyclosporin treatment	72829
@NP	we	72859
@NP	disappearance of the labeled cells	72875
@NP	disappearance	72875
@NP	the labeled cells	72892
@NP	cell death , not loss of the label -LRB- Hill et al. , 2006 -RRB-	72921
@NP	cell death	72921
@NP	not loss of the label -LRB- Hill et al. , 2006 -RRB-	72933
@NP	not loss	72933
@NP	the label -LRB- Hill et al. , 2006 -RRB-	72945
@NP	the label	72945
@NP	Hill	72956
@NP	et al. , 2006	72961
@NP	et al.	72961
@NP	2006	72969
@NP	Survival of transplanted OEG	73758
@NP	Survival	73758
@NP	transplanted OEG	73770
@NP	the cells	73804
@NP	lower densities	73837
@NP	normalappearing tissue rostral and caudal	73859
@NP	normalappearing tissue rostral	73859
@NP	caudal	73894
@NP	the injury site	73904
@NP	Grafting of the cells in lower densities	73921
@NP	Grafting	73921
@NP	the cells in lower densities	73933
@NP	the cells	73933
@NP	lower densities	73946
@NP	survival	73977
@NP	individual cells	74000
@NP	greater access	74017
@NP	the limited resources	74035
@NP	the injury milieu	74072
@NP	survival	74103
@NP	oxygen -LRB- Ducker and Perot , 1971 ; Griffiths , 1976 -RRB-	74121
@NP	oxygen	74121
@NP	Ducker and Perot	74129
@NP	Ducker	74129
@NP	Perot	74140
@NP	1971 ; Griffiths , 1976	74147
@NP	1971	74147
@NP	Griffiths , 1976	74153
@NP	Griffiths	74153
@NP	1976	74164
@NP	Survival of SCs or OEG	74171
@NP	Survival	74171
@NP	SCs or OEG	74183
@NP	other studies	74223
@NP	lower numbers	74242
@NP	the grafting	74274
@NP	a milder injury -LRB- Keyvan-Fouladi et al. , 2003 ; Li et al. , 2002 -RRB-	74315
@NP	a milder injury	74315
@NP	Keyvan-Fouladi	74332
@NP	et al. , 2003 ; Li et al. , 2002	74347
@NP	et al.	74347
@NP	2003 ; Li et al.	74355
@NP	2003	74355
@NP	Li et al.	74361
@NP	Li	74361
@NP	et al.	74364
@NP	2002	74372
@NP	the transplantation	74393
@NP	glia outside the hostile environment of the injury site	74416
@NP	glia	74416
@NP	the hostile environment of the injury site	74429
@NP	the hostile environment	74429
@NP	the injury site	74456
@NP	relatively normal-appearing tissue	74476
@NP	cell death	74525
@NP	their exposure	74548
@NP	excitotoxic , oxidative and proinflammatory molecules	74566
@NP	Bao and Liu , 2002 ; Hall and Braughler , 1986 ; Pearse et al. , 2003	74620
@NP	Bao and Liu	74620
@NP	Bao	74620
@NP	Liu	74628
@NP	2002 ; Hall and Braughler	74633
@NP	2002	74633
@NP	Hall and Braughler	74639
@NP	1986 ; Pearse et al. , 2003	74659
@NP	1986	74659
@NP	Pearse et al. , 2003	74665
@NP	Pearse	74665
@NP	et al. , 2003	74672
@NP	et al.	74672
@NP	2003	74680
@NP	Previous studies employing OEG for SCI repair	74687
@NP	Previous studies	74687
@NP	OEG for SCI repair	74714
@NP	OEG	74714
@NP	SCI repair	74722
@NP	efficacy when the cells were deposited both rostral and caudal	74751
@NP	efficacy when the cells were deposited	74751
@NP	efficacy	74751
@NP	the cells	74765
@NP	Fouad et al. , 2005 ; Ram on-Cueto et al. , 1998 , 2000	74815
@NP	Fouad et al.	74815
@NP	Fouad	74815
@NP	et al.	74821
@NP	2005 ; Ram on-Cueto et al.	74829
@NP	2005	74829
@NP	Ram on-Cueto et al.	74835
@NP	Ram on-Cueto	74835
@NP	et al.	74848
@NP	1998 , 2000	74856
@NP	1998	74856
@NP	2000	74862
@NP	within -LRB- Barakat et al. , 2005 -RRB- , the injury site	74881
@NP	within	74881
@NP	Barakat	74889
@NP	et al. , 2005	74897
@NP	et al.	74897
@NP	2005	74905
@NP	the injury site	74912
@NP	addition	74932
@NP	methods for preparing the cells in culture prior to their implantation	74942
@NP	methods	74942
@NP	the cells in culture	74964
@NP	the cells	74964
@NP	culture	74977
@NP	their implantation	74994
@NP	the hostile environment of the injured spinal cord	75070
@NP	the hostile environment	75070
@NP	the injured spinal cord	75097
@NP	the study by Li et al. -LRB- 2003b -RRB-	75125
@NP	the study	75125
@NP	Li et al. -LRB- 2003b -RRB-	75138
@NP	Li et al.	75138
@NP	Li	75138
@NP	et al.	75141
@NP	2003b	75149
@NP	OEG	75157
@NP	the matrix they had produced during culture	75183
@NP	the matrix	75183
@NP	they	75194
@NP	culture	75219
@NP	The OEG-matrix	75228
@NP	the culture dishes	75259
@NP	pieces	75295
@NP	the hemisected spinal cord	75307
@NP	a fluid	75354
@NP	the current study	75376
@NP	The use of this procedure	75395
@NP	The use	75395
@NP	this procedure	75406
@NP	good survival of the GFP	75433
@NP	good survival	75433
@NP	the GFP	75450
@NP	OEG	75469
@NP	improvements	75484
@NP	functional outcome	75500
@NP	The spinal cord implantation of glia within their own or a purified matrix	75520
@NP	The spinal cord implantation	75520
@NP	glia within their own or a purified matrix	75552
@NP	glia within their own	75552
@NP	glia	75552
@NP	their own	75564
@NP	a purified matrix	75577
@NP	their death	75607
@NP	a result	75622
@NP	anoikis	75634
@NP	apoptosis that is induced by removal of cells from their matrix	75643
@NP	apoptosis	75643
@NP	removal of cells	75672
@NP	removal	75672
@NP	cells	75683
@NP	their matrix	75694
@NP	neighboring cells -LRB- Frisch and Screaton , 2001 -RRB-	75710
@NP	neighboring cells	75710
@NP	Frisch and Screaton	75729
@NP	2001	75750
@NP	we	76867
@NP	the current study	76878
@NP	OEG	76901
@NP	SCs	76940
@NP	a cell type	76945
@NP	significant numbers	76980
@NP	OEG cultures derived from embryonic tissue or the lamina propria	77003
@NP	OEG cultures	77003
@NP	embryonic tissue or the lamina propria	77029
@NP	embryonic tissue	77029
@NP	the lamina propria	77049
@NP	early passage	77079
@NP	Rizek and Kawaja	77094
@NP	2006	77112
@NP	preimplantation conditions	77132
@NP	glia survival	77165
@NP	also the postimplantation , hypoxic conditions of the poorly vascularized ,	77199
@NP	also the postimplantation	77199
@NP	hypoxic conditions of the poorly vascularized	77226
@NP	hypoxic conditions	77226
@NP	the poorly vascularized	77248
@NP	the	77248
@NP	spinal cord can -LRB- Balentine , 1978 -RRB-	77281
@NP	spinal cord can	77281
@NP	spinal cord	77281
@NP	Balentine	77298
@NP	1978	77309
@NP	prime implanted cells to survive better within hypoxic tissues	77319
@NP	prime	77319
@NP	cells	77335
@NP	better	77352
@NP	hypoxic tissues	77366
@NP	recent studies	77383
@NP	culture methods	77412
@NP	cells	77440
@NP	a sublethal hypoxic or hyperthermic environment	77459
@NP	Schramm	77508
@NP	et al. , 2002 ; Yao et al. , 2005	77516
@NP	et al.	77516
@NP	2002 ; Yao et al.	77524
@NP	2002	77524
@NP	Yao et al.	77530
@NP	Yao	77530
@NP	et al.	77534
@NP	2005	77542
@NP	genes	77571
@NP	heme oxygenase	77586
@NP	them	77614
@NP	hypoxic stress -LRB- Tang et al. , 2005 -RRB-	77639
@NP	hypoxic stress	77639
@NP	Tang	77655
@NP	et al. , 2005	77660
@NP	et al.	77660
@NP	2005	77668
@NP	This conditioning	77675
@NP	survival	77726
@NP	transplanted cells within injured organs -LRB- Tang et al. , 2005 -RRB-	77738
@NP	transplanted cells	77738
@NP	injured organs -LRB- Tang et al. , 2005 -RRB-	77764
@NP	injured organs	77764
@NP	Tang	77780
@NP	et al. , 2005	77785
@NP	et al.	77785
@NP	2005	77793
@NP	the limited survival	77808
@NP	glia	77832
@NP	the	77840
@NP	spinal cord	77853
@NP	the use of an allograft	77871
@NP	the use	77871
@NP	an allograft	77882
@NP	the highly genetically inbred Fischer strain of rat	77902
@NP	the highly genetically inbred Fischer strain	77902
@NP	rat	77950
@NP	contrast	77960
@NP	the good survival	77972
@NP	cell allografts	77993
@NP	the same strains of mice -LRB- Colson et al. , 1995 -RRB-	78025
@NP	the same strains	78025
@NP	mice -LRB- Colson et al. , 1995 -RRB-	78045
@NP	mice	78045
@NP	Colson	78051
@NP	et al. , 1995	78058
@NP	et al.	78058
@NP	1995	78066
@NP	the importance	78087
@NP	Beattie et al. , 2002 ; Beattie , 2004	78140
@NP	Beattie	78140
@NP	et al. , 2002 ; Beattie , 2004	78148
@NP	et al. , 2002	78148
@NP	et al.	78148
@NP	2002	78156
@NP	Beattie , 2004	78162
@NP	Beattie	78162
@NP	2004	78171
@NP	Theele	78211
@NP	et al. , 1996	78218
@NP	et al.	78218
@NP	1996	78226
@NP	graft efficacy	78243
@NP	future studies	78261
@NP	male or GFPþ cells	78301
@NP	increasing numbers of host SCs	78331
@NP	increasing numbers	78331
@NP	host SCs	78353
@NP	the damaged dorsal root entry zones to gain access to the injured CNS	78400
@NP	the damaged dorsal root	78400
@NP	entry zones	78424
@NP	access	78444
@NP	the injured CNS	78454
@NP	This phenomenon	78471
@NP	the relatively static gross structure of the graft	78501
@NP	the relatively static gross structure	78501
@NP	the graft	78542
@NP	the different time points	78559
@NP	Previous reports	78586
@NP	both experimental models -LRB- Beattie et al. , 1997 ; Brook et al. , 1998 -RRB-	78606
@NP	both experimental models	78606
@NP	Beattie	78632
@NP	et al. , 1997 ; Brook et al. , 1998	78640
@NP	et al.	78640
@NP	1997 ; Brook et al.	78648
@NP	1997	78648
@NP	Brook et al.	78654
@NP	Brook	78654
@NP	et al.	78660
@NP	1998	78668
@NP	human cases of SCI	78678
@NP	human cases	78678
@NP	SCI	78693
@NP	Guest	78698
@NP	et al. , 2005	78704
@NP	et al.	78704
@NP	2005	78712
@NP	significant spinal cord infiltration	78734
@NP	peripheral nervous system restricted SCs	78774
@NP	Bunge and Wood	78816
@NP	2006	78832
@NP	the present study	78842
@NP	numbers of these endogenous cells	78861
@NP	numbers	78861
@NP	these endogenous cells	78872
@NP	GFPþ glia -LRB- 2 - to 10-fold -RRB-	78934
@NP	GFPþ glia	78934
@NP	2	78945
@NP	9 weeks	78966
@NP	a false picture	79003
@NP	the exogenous cell grafts	79024
@NP	numbers over time	79079
@NP	numbers	79079
@NP	time	79092
@NP	p75 immunostaining	79138
@NP	These results	79164
@NP	the inadequacies	79200
@NP	immunohistochemistry for p75	79226
@NP	immunohistochemistry	79226
@NP	p75	79251
@NP	implanted SCs or OEG	79275
@NP	the injured spinal cord	79303
@NP	our group and others	79362
@NP	Bunge and Pearse , 2003 ; Pearse et al. , 2004a , b	79384
@NP	Bunge and Pearse	79384
@NP	Bunge	79384
@NP	Pearse	79394
@NP	2003 ; Pearse et al.	79402
@NP	2003	79402
@NP	Pearse et al.	79408
@NP	Pearse	79408
@NP	et al.	79415
@NP	2004a , b	79423
@NP	2004a	79423
@NP	b	79429
@NP	The combination of EGFP labeling and p75 immunochemistry in the current study	79433
@NP	The combination	79433
@NP	EGFP labeling and p75 immunochemistry in the current study	79452
@NP	EGFP labeling and p75 immunochemistry	79452
@NP	the current study	79493
@NP	definite counting	79529
@NP	transplanted	79560
@NP	SCs or OEG versus infiltrating endogenous SCs	79573
@NP	SCs or OEG	79573
@NP	endogenous SCs	79604
@NP	Fig. 3	79620
@NP	endogenous SC migration	79647
@NP	a major component and possibly a confounder in cell implantation paradigms	79674
@NP	a major component	79674
@NP	a confounder in cell implantation paradigms	79705
@NP	a confounder	79705
@NP	cell implantation paradigms	79721
@NP	note	79753
@NP	SC infiltration	79768
@NP	SCI-only spinal cords -LRB- data not shown -RRB-	79800
@NP	SCI-only spinal cords	79800
@NP	data not shown	79823
@NP	data	79823
@NP	a significantly greater amount	79840
@NP	a cell transplant	79885
@NP	The higher numbers of p75þ	79917
@NP	The higher numbers	79917
@NP	p75þ	79939
@NP	EGFP2 cells in SC and OEG	79945
@NP	EGFP2 cells	79945
@NP	SC and OEG	79960
@NP	groups	79979
@NP	controls -LRB- more than 10-fold in cases -RRB- ,	80011
@NP	controls	80011
@NP	more than 10-fold in cases	80021
@NP	more than 10-fold	80021
@NP	cases	80042
@NP	the implantation and/or death of these SCs or OEG	80063
@NP	implantation	80067
@NP	death of these SCs or OEG	80087
@NP	death	80087
@NP	these SCs or OEG	80096
@NP	these SCs	80096
@NP	OEG	80109
@NP	the ingress of endogenous SCs	80132
@NP	the ingress	80132
@NP	endogenous SCs	80147
@NP	the injured spinal cord	80167
@NP	The signals	80192
@NP	the ingress of SCs	80230
@NP	the ingress	80230
@NP	SCs	80245
@NP	the injured spinal cord	80254
@NP	a number	80312
@NP	sources	80324
@NP	angiogenic -LRB- Gilmore et al. , 1993 ; Raine et al. , 1978 -RRB-	80342
@NP	angiogenic	80342
@NP	Gilmore	80354
@NP	et al. , 1993 ; Raine et al. , 1978	80362
@NP	et al.	80362
@NP	1993 ; Raine et al.	80370
@NP	1993	80370
@NP	Raine et al.	80376
@NP	Raine	80376
@NP	et al.	80382
@NP	1978	80390
@NP	immune -LRB- Fukaya et al. , 2003 -RRB-	80397
@NP	immune	80397
@NP	Fukaya	80405
@NP	et al. , 2003	80412
@NP	et al.	80412
@NP	2003	80420
@NP	axonal -LRB- Raine et al. , 1978 -RRB-	80427
@NP	axonal	80427
@NP	Raine	80435
@NP	et al. , 1978	80441
@NP	et al.	80441
@NP	1978	80449
@NP	ECM -LRB- King et al. , 2006 -RRB-	80458
@NP	ECM	80458
@NP	King	80463
@NP	et al. , 2006	80468
@NP	et al.	80468
@NP	2006	80476
@NP	SCI	80493
@NP	SCs migrating into the CNS	80498
@NP	SCs	80498
@NP	the CNS	80517
@NP	close association	80550
@NP	newly formed blood vessels	80578
@NP	Gilmore	80606
@NP	et al. , 1993 ; Raine et al. , 1978	80614
@NP	et al.	80614
@NP	1993 ; Raine et al.	80622
@NP	1993	80622
@NP	Raine et al.	80628
@NP	Raine	80628
@NP	et al.	80634
@NP	1978	80642
@NP	sensory axons -LRB- Bunge et al. , 1994 ; Raine et al. , 1978 -RRB-	80662
@NP	sensory axons	80662
@NP	Bunge	80677
@NP	et al. , 1994 ; Raine et al. , 1978	80683
@NP	et al.	80683
@NP	1994 ; Raine et al.	80691
@NP	1994	80691
@NP	Raine et al.	80697
@NP	Raine	80697
@NP	et al.	80703
@NP	1978	80711
@NP	either angiogenic or axonal signals	80731
@NP	the proliferation and ingress of SCs from the dorsal roots	80777
@NP	the proliferation and ingress	80777
@NP	SCs from the dorsal roots	80810
@NP	SCs	80810
@NP	the dorsal roots	80819
@NP	The observation	80837
@NP	cell grafting into the injured spinal cord	80858
@NP	cell grafting	80858
@NP	the injured spinal cord	80877
@NP	endogenous SC ingress	80910
@NP	the current study and others	80941
@NP	the current study	80941
@NP	others	80963
@NP	possibly chemotaxic factors	80984
@NP	galectin-1 -LRB- Fukaya et al. , 2003 ; Rabinovich et al. , 1999 -RRB-	81021
@NP	galectin-1	81021
@NP	Fukaya	81033
@NP	et al. , 2003 ; Rabinovich et al. , 1999	81040
@NP	et al.	81040
@NP	2003 ; Rabinovich et al.	81048
@NP	2003	81048
@NP	Rabinovich et al.	81054
@NP	Rabinovich	81054
@NP	et al.	81065
@NP	1999	81073
@NP	an enhanced immune response	81092
@NP	the death	81133
@NP	clearance of the implanted cells	81150
@NP	clearance	81150
@NP	the implanted cells	81163
@NP	SC migration	81200
@NP	PNS injury	81225
@NP	there	81236
@NP	close coordination between the immune system	81245
@NP	close coordination	81245
@NP	the immune system	81272
@NP	macrophages , and SCs	81299
@NP	macrophages	81299
@NP	SCs	81316
@NP	repair	81336
@NP	Chumasov and Svetikova , 1992	81344
@NP	Chumasov and Svetikova	81344
@NP	1992	81368
@NP	the implantation	81389
@NP	various ECM constructs	81409
@NP	fibronectin mats -LRB- King et al. , 2006 -RRB-	81441
@NP	fibronectin mats	81441
@NP	King	81459
@NP	et al. , 2006	81464
@NP	et al.	81464
@NP	2006	81472
@NP	SC recruitment	81528
@NP	the injured spinal cord	81546
@NP	The observation	81571
@NP	these ECM structures	81592
@NP	large numbers	81640
@NP	immune cells	81657
@NP	macrophages , newly formed blood vessels and axons	81679
@NP	macrophages	81679
@NP	newly formed blood vessels and axons	81692
@NP	newly formed blood vessels	81692
@NP	axons	81723
@NP	King	81730
@NP	et al. , 2006	81735
@NP	et al.	81735
@NP	2006	81743
@NP	the signal for promoting SC ingress	81765
@NP	the signal	81765
@NP	SC ingress	81790
@NP	the ECM	81821
@NP	the various immune	81841
@NP	vasculature	81861
@NP	axonal elements it supports	81876
@NP	axonal elements	81876
@NP	it	81892
@NP	It	81905
@NP	future experiments	81931
@NP	factor -LRB- s -RRB-	81968
@NP	factor	81968
@NP	the injured spinal cord	81981
@NP	cells and/or the immune system in response	82014
@NP	cells	82014
@NP	the immune system in response	82027
@NP	the immune system	82027
@NP	response	82048
@NP	the grafted cells	82060
@NP	the invasion of peripheral nerve elements	82087
@NP	the invasion	82087
@NP	peripheral nerve elements	82103
@NP	the injured CNS	82134
@NP	these factors	82162
@NP	the need	82194
@NP	glia	82216
@NP	Limited migration of GFPþ SCs and OEG	82222
@NP	Limited migration	82222
@NP	GFPþ SCs and OEG	82243
@NP	all time points post-injury	82276
@NP	all time points	82276
@NP	GFPþ SCs or OEG	82305
@NP	regions of normalappearing white or gray matter	82346
@NP	regions	82346
@NP	normalappearing white or gray matter	82357
@NP	OEG	82405
@NP	rostral and caudal	82422
@NP	the injury , where they exhibited higher cell survival	82444
@NP	the injury	82444
@NP	they	82462
@NP	higher cell survival	82477
@NP	they	82499
@NP	the site of deposition	82527
@NP	the site	82527
@NP	deposition	82539
@NP	host tissue	82567
@NP	other studies	82603
@NP	complete transection -LRB- Ramon-Cueto et al. , 1998 , 2000 -RRB-	82627
@NP	complete transection	82627
@NP	Ramon-Cueto	82649
@NP	et al. , 1998 , 2000	82661
@NP	et al.	82661
@NP	1998	82669
@NP	2000	82675
@NP	These discrepancies in the migratory ability of transplanted OEG	82682
@NP	These discrepancies	82682
@NP	the migratory ability of transplanted OEG	82705
@NP	the migratory ability	82705
@NP	transplanted OEG	82730
@NP	the leakage of dyes used for cell labeling	82773
@NP	the leakage	82773
@NP	dyes used for cell labeling	82788
@NP	dyes	82788
@NP	cell labeling	82802
@NP	transfer	82824
@NP	migrating host cells in these former studies	82836
@NP	migrating host cells	82836
@NP	these former studies	82860
@NP	they	82884
@NP	the different injury environments of specific types of SCI	82907
@NP	the different injury environments	82907
@NP	specific types of SCI	82944
@NP	specific types	82944
@NP	SCI	82962
@NP	the absence of GFPþ SCs or OEG in normal host tissue	82975
@NP	the absence	82975
@NP	GFPþ SCs or OEG	82990
@NP	normal host tissue	83009
@NP	OEG	83034
@NP	4 mm rostral and caudal	83059
@NP	4 mm rostral	83059
@NP	caudal	83076
@NP	the injury site	83086
@NP	GFPþ cells	83103
@NP	the injury epicenter	83135
@NP	The OEG	83157
@NP	access	83182
@NP	the injury epicenter	83192
@NP	the central canal , when the midline injection disrupted its structure	83228
@NP	the central canal	83228
@NP	the midline injection	83252
@NP	its structure	83284
@NP	the pia	83308
@NP	the injection entry site	83322
@NP	It	83348
@NP	labeled glia , following transplantation into the spinal cord ,	83385
@NP	labeled glia	83385
@NP	transplantation into the spinal cord	83409
@NP	transplantation	83409
@NP	the spinal cord	83430
@NP	significant distances -LRB- 12 mm -RRB-	83463
@NP	significant distances	83463
@NP	12 mm	83486
@NP	the central canal -LRB- Li et al. , 2003a -RRB-	83500
@NP	the central canal	83500
@NP	Li	83519
@NP	et al. , 2003a	83522
@NP	et al.	83522
@NP	2003a	83530
@NP	the pia -LRB- Langford and Owens , 1990 -RRB-	83546
@NP	the pia	83546
@NP	Langford and Owens	83555
@NP	1990	83575
@NP	our study	83585
@NP	the GFPþ cells within the central canal	83596
@NP	the GFPþ cells	83596
@NP	the central canal	83618
@NP	the surrounding ependymal layer	83659
@NP	they	83697
@NP	the site of the injury epicenter	83714
@NP	the site	83714
@NP	the injury epicenter	83726
@NP	OEG	83748
@NP	the pia	83793
@NP	SCs in a complete injury	83824
@NP	SCs	83824
@NP	a complete injury	83831
@NP	paradigm -LRB- Ramon-Cueto et al. , 1998 , 2000 -RRB-	83862
@NP	paradigm	83862
@NP	Ramon-Cueto	83872
@NP	et al. , 1998 , 2000	83884
@NP	et al.	83884
@NP	1998	83892
@NP	2000	83898
@NP	note	83908
@NP	regenerating 5-HT fibers	83914
@NP	the OEG/fibroblast milieu	83958
@NP	the OEG	83997
@NP	SC bridge	84006
@NP	this model	84019
@NP	the current study	84034
@NP	none of the specific supraspinal axon populations examined	84062
@NP	none	84062
@NP	the specific supraspinal axon populations examined	84070
@NP	the specific supraspinal axon populations	84070
@NP	these migrating OEG	84148
@NP	The timing of implantation	84169
@NP	The timing	84169
@NP	implantation	84183
@NP	a significant role in the ability of grafted EGFP glia	84210
@NP	a significant role	84210
@NP	the ability of grafted EGFP glia	84232
@NP	the ability	84232
@NP	grafted EGFP glia	84247
@NP	their original site of deposition	84281
@NP	their original site	84281
@NP	deposition	84304
@NP	The implantation of cells	84316
@NP	The implantation	84316
@NP	cells	84336
@NP	injury	84360
@NP	the formation	84375
@NP	a glial scar around the lesion site -LRB- Silver and Miller ,	84392
@NP	a glial scar around the lesion site	84392
@NP	a glial scar	84392
@NP	the lesion site	84412
@NP	Silver	84429
@NP	Miller	84440
@NP	2004	84448
@NP	the cells	84466
@NP	the injection site	84496
@NP	Li et al. , 2003a ; Ram on-Cueto et al. , 1998 , 2000 ; Richter et al. , 2005	84516
@NP	Li et al.	84516
@NP	Li	84516
@NP	et al.	84519
@NP	2003a ; Ram on-Cueto et al.	84527
@NP	2003a	84527
@NP	Ram on-Cueto et al.	84534
@NP	Ram on-Cueto	84534
@NP	et al.	84547
@NP	1998	84555
@NP	2000 ; Richter et al. , 2005	84561
@NP	2000	84561
@NP	Richter et al. , 2005	84567
@NP	Richter	84567
@NP	et al. , 2005	84575
@NP	et al.	84575
@NP	2005	84583
@NP	A study by Plant et al. -LRB- 2003 -RRB-	85174
@NP	A study	85174
@NP	Plant et al. -LRB- 2003 -RRB-	85185
@NP	Plant et al.	85185
@NP	Plant	85185
@NP	et al.	85191
@NP	2003	85199
@NP	transplantation	85227
@NP	OEG into a moderate contusion injury at either 0 or 7 days postinjury	85246
@NP	OEG	85246
@NP	a moderate contusion injury at either 0 or 7 days postinjury	85255
@NP	a moderate contusion injury	85255
@NP	either 0 or 7 days postinjury	85286
@NP	0	85293
@NP	7 days postinjury	85298
@NP	grafts	85328
@NP	both time points , that were largely encased by reactive astrocytes	85339
@NP	both time points	85339
@NP	reactive astrocytes	85386
@NP	these implanted OEG	85410
@NP	little migration	85440
@NP	surrounding host cord tissue	85462
@NP	paradigms	85499
@NP	the use	85514
@NP	p75 immunoreactivity to identify the implant	85525
@NP	p75 immunoreactivity	85525
@NP	the	85558
@NP	endogenous SCs	85604
@NP	the ability to characterize the migratory ability of OEG	85644
@NP	the migratory ability of OEG	85672
@NP	the migratory ability	85672
@NP	OEG	85697
@NP	the lesion environment	85716
@NP	a role	85748
@NP	the ability of implanted glia	85767
@NP	the ability	85767
@NP	implanted glia	85782
@NP	the host cord	85822
@NP	All transplants of GFPþ glia that had formed a substantive graft	86394
@NP	All transplants	86394
@NP	GFPþ glia that had formed a substantive graft	86413
@NP	GFPþ glia	86413
@NP	a substantive graft	86439
@NP	axon growth as seen by dense labeling of neurofilament positive axons	86486
@NP	axon growth	86486
@NP	seen by dense labeling of neurofilament positive axons	86501
@NP	dense labeling of neurofilament	86509
@NP	dense labeling	86509
@NP	neurofilament	86527
@NP	them	86563
@NP	Only grafts of OEG when transplanted into the injury epicenter	86569
@NP	Only grafts	86569
@NP	OEG when transplanted into the injury epicenter	86584
@NP	OEG	86584
@NP	the injury epicenter	86611
@NP	significant axon growth	86650
@NP	the poor survival of the grafts and their inability	86692
@NP	the poor survival	86692
@NP	the grafts and their inability	86713
@NP	the grafts	86713
@NP	their inability	86728
@NP	the formation of large central cysts	86755
@NP	the formation	86755
@NP	large central cysts	86772
@NP	SC grafts	86796
@NP	neurofilament positive axons	86807
@NP	the rostral-caudal axis of the spinal cord in parallel	86861
@NP	the rostral-caudal axis	86861
@NP	the spinal cord in parallel	86888
@NP	the spinal cord	86888
@NP	parallel	86907
@NP	SC processes	86921
@NP	axons	86944
@NP	SC grafts -LRB- Bunge and Pearse , 2003 -RRB-	86987
@NP	SC grafts	86987
@NP	Bunge and Pearse	86998
@NP	2003	87016
@NP	a contused spinal cord	87041
@NP	Takami et al. , 2002b ; Pearse et al. , 2004a , b	87065
@NP	Takami et al.	87065
@NP	Takami	87065
@NP	et al.	87072
@NP	2002b ; Pearse et al.	87080
@NP	2002b	87080
@NP	Pearse et al.	87087
@NP	Pearse	87087
@NP	et al.	87094
@NP	2004a , b	87102
@NP	2004a	87102
@NP	b	87108
@NP	this report	87112
@NP	axon growth	87148
@NP	a SC graft	87165
@NP	a contusion injury	87182
@NP	the use	87209
@NP	nonpromiscuous labels	87220
@NP	grafted cell identification -LRB- see also Hill et al. , 2006 -RRB-	87246
@NP	grafted cell identification	87246
@NP	Hill	87284
@NP	et al. , 2006	87289
@NP	et al.	87289
@NP	2006	87297
@NP	contrast	87307
@NP	OEG transplanted rostral and caudal to the injury epicenter	87317
@NP	OEG transplanted rostral	87317
@NP	caudal to the injury epicenter	87346
@NP	caudal	87346
@NP	the injury epicenter	87356
@NP	neurofilament	87387
@NP	positive axon growth	87401
@NP	the rostral-caudal axis of the spinal cord in alignment	87448
@NP	the rostral-caudal axis	87448
@NP	the spinal cord in alignment	87475
@NP	the spinal cord	87475
@NP	alignment	87494
@NP	the cells	87509
@NP	These effects on axon alignment	87520
@NP	These effects	87520
@NP	axon alignment	87537
@NP	the cell type	87596
@NP	the environment into which the cells were deposited	87636
@NP	the environment	87636
@NP	the cells	87663
@NP	Combination SC and OEG grafts	87689
@NP	more cell	87729
@NP	appearance	87748
@NP	patterns of axon growth similar to the SC	87770
@NP	patterns	87770
@NP	axon growth similar to the SC	87782
@NP	axon growth	87782
@NP	the SC	87805
@NP	The implantation of OEG into normal tissue	87825
@NP	The implantation	87825
@NP	OEG into normal tissue	87845
@NP	OEG	87845
@NP	normal tissue	87854
@NP	the forced alignment of the OEG in a pattern parallel	87880
@NP	the forced alignment	87880
@NP	the OEG in a pattern parallel	87904
@NP	the OEG	87904
@NP	a pattern parallel	87915
@NP	the direction of the injection	87937
@NP	the direction	87937
@NP	the injection	87954
@NP	the injection of SCs into the fragmented tissue of the injury epicenter	87974
@NP	the injection	87974
@NP	SCs into the fragmented tissue of the injury epicenter	87991
@NP	SCs	87991
@NP	the fragmented tissue of the injury epicenter	88000
@NP	the fragmented tissue	88000
@NP	the injury epicenter	88025
@NP	the cells	88063
@NP	more	88082
@NP	These results	88095
@NP	important implications	88126
@NP	the design of surgical cell implantation strategies for the spinal cord	88153
@NP	the design	88153
@NP	surgical cell implantation strategies for the spinal cord	88167
@NP	surgical cell implantation strategies	88167
@NP	the spinal cord	88209
@NP	axonal growth	88246
@NP	a rostral-caudal fashion towards appropriate targets	88263
@NP	a rostral-caudal fashion	88263
@NP	appropriate targets	88296
@NP	Examination	88317
@NP	specific	88332
@NP	axon populations using either immunochemistry	88366
@NP	axon populations	88366
@NP	immunochemistry	88396
@NP	glial grafts	88441
@NP	increased numbers	88474
@NP	short - and long-tract sensory axons	88495
@NP	supraspinal axons from either the brainstem or sensorimotor cortex	88540
@NP	supraspinal axons	88540
@NP	either the brainstem or sensorimotor cortex	88563
@NP	the brainstem	88570
@NP	sensorimotor cortex	88587
@NP	Similar axon growth responses	88608
@NP	fibroblast implants	88657
@NP	It	88692
@NP	SC grafts	88729
@NP	local proprioceptive and sensory axons	88772
@NP	nearby spinal cord segments	88828
@NP	Pearse et al. , 2004a ; Takami et al. , 2002b ; Xu et al.	88857
@NP	Pearse	88857
@NP	et al. , 2004a ; Takami et al. , 2002b ; Xu et al.	88864
@NP	et al. , 2004a	88864
@NP	et al.	88864
@NP	2004a	88872
@NP	Takami et al. , 2002b	88879
@NP	Takami	88879
@NP	et al. , 2002b	88886
@NP	et al.	88886
@NP	2002b	88894
@NP	Xu et al.	88901
@NP	Xu	88901
@NP	et al.	88904
@NP	1995 , 1997	88912
@NP	1995	88912
@NP	1997	88918
@NP	The poor growth support	88925
@NP	long-tract axon populations in animals in which OEG graft survival was high	88952
@NP	long-tract axon populations	88952
@NP	animals in which OEG graft survival was high	88983
@NP	animals	88983
@NP	OEG graft survival	89000
@NP	they	89035
@NP	rostral and caudal	89055
@NP	the injury epicenter	89077
@NP	earlier reports of the potent ability of OEG	89114
@NP	earlier reports	89114
@NP	the potent ability of OEG	89133
@NP	the potent ability	89133
@NP	OEG	89155
@NP	long distance ascending	89170
@NP	long distance	89170
@NP	supraspinal axon regeneration	89198
@NP	Li	89229
@NP	et al. , 1997 , 1998 , 2003b ; Ram on-Cueto et al. , 1998 , 2000	89232
@NP	et al. , 1997	89232
@NP	et al.	89232
@NP	1997	89240
@NP	1998 , 2003b ; Ram on-Cueto et al.	89246
@NP	1998 , 2003b	89246
@NP	1998	89246
@NP	2003b	89252
@NP	Ram on-Cueto et al.	89259
@NP	Ram on-Cueto	89259
@NP	et al.	89272
@NP	1998 , 2000	89280
@NP	1998	89280
@NP	2000	89286
@NP	These disparate results	89293
@NP	differences	89331
@NP	the SCI models	89346
@NP	the cell culture procedures	89371
@NP	the passage of cells at time of use	89405
@NP	the passage	89405
@NP	cells at time of use	89420
@NP	cells	89420
@NP	time of use	89429
@NP	time	89429
@NP	use	89437
@NP	their exposure to mitogens	89442
@NP	their exposure	89442
@NP	mitogens	89460
@NP	the application of cell cryoprotection	89473
@NP	the application	89473
@NP	cell cryoprotection	89492
@NP	the location of the	89517
@NP	the location	89517
@NP	the	89533
@NP	site	89545
@NP	the injury	89562
@NP	Closer injections	89574
@NP	the cells to the injury epicenter	89595
@NP	the cells	89595
@NP	the injury epicenter	89608
@NP	transection injuries -LRB- Ram on - Cueto et al. , 1998 -RRB-	89656
@NP	transection injuries	89656
@NP	Ram on - Cueto et al. , 1998	89678
@NP	Ram	89678
@NP	Cueto et al. , 1998	89686
@NP	Cueto et al.	89686
@NP	Cueto	89686
@NP	et al.	89692
@NP	1998	89700
@NP	the OEG to be more conducive for long-tract axon growth	89724
@NP	long-tract axon growth	89757
@NP	The injection of OEG at 4 mm rostral and caudal to the injury epicenter	89781
@NP	The injection	89781
@NP	OEG at 4 mm rostral and caudal to the injury epicenter	89798
@NP	OEG at 4 mm rostral	89798
@NP	OEG	89798
@NP	4 mm rostral	89805
@NP	caudal to the injury epicenter	89822
@NP	caudal	89822
@NP	the injury epicenter	89832
@NP	the cells very close to the ends of the cone shaped extension	89885
@NP	cells very close to the ends of the cone	89889
@NP	cells	89889
@NP	the ends of the cone	89909
@NP	the ends	89909
@NP	the cone	89921
@NP	the contusion injury	89950
@NP	Hill	89995
@NP	et al. , 2001 ; Pearse et al. , 2004a	90000
@NP	et al.	90000
@NP	2001 ; Pearse et al.	90008
@NP	2001	90008
@NP	Pearse et al.	90014
@NP	Pearse	90014
@NP	et al.	90021
@NP	2004a	90029
@NP	closer injections	90041
@NP	the deposition of OEG	90081
@NP	the deposition	90081
@NP	OEG	90099
@NP	the injury milieu	90119
@NP	their survival	90150
@NP	contrast	90169
@NP	the poor ability	90181
@NP	EGFP glial implants	90201
@NP	significant growth of long-tract	90232
@NP	significant growth	90232
@NP	long-tract	90254
@NP	axons	90289
@NP	regions	90296
@NP	the	90328
@NP	within the lesion	90344
@NP	a mixture of largely p75þ endogenous SCs and immune cells , such as macrophages	90374
@NP	a mixture	90374
@NP	largely p75þ endogenous SCs and immune cells , such as macrophages	90387
@NP	largely p75þ endogenous SCs	90387
@NP	immune cells	90419
@NP	macrophages	90441
@NP	substantial growth/sparing of these axons	90464
@NP	substantial growth/sparing	90464
@NP	these axons	90494
@NP	the rostral or caudal EGFP	90509
@NP	the rostral	90509
@NP	caudal EGFP	90524
@NP	interface	90544
@NP	This differential growth response	90569
@NP	particularly in the EGFP-SC animals	90604
@NP	the EGFP-SC	90620
@NP	both the implant and adjacent regions in the lesion	90647
@NP	both the implant	90647
@NP	both the	90647
@NP	adjacent regions in the lesion	90668
@NP	adjacent regions	90668
@NP	the lesion	90688
@NP	SCs	90725
@NP	the presence of cell types	90753
@NP	the presence	90753
@NP	cell types	90769
@NP	the nongrafted lesion milieu	90787
@NP	appreciable numbers within the EGFP	90842
@NP	appreciable numbers	90842
@NP	the EGFP	90869
@NP	macrophages or NG2þ precursor cells	90895
@NP	macrophages	90895
@NP	NG2þ precursor cells	90910
@NP	NG2	90941
@NP	a CSPG	90948
@NP	the injured spinal cord	90987
@NP	an inhibitor of axon growth -LRB- Jones et al. , 2002 -RRB-	91032
@NP	an inhibitor	91032
@NP	axon growth -LRB- Jones et al. , 2002 -RRB-	91048
@NP	axon growth	91048
@NP	Jones	91061
@NP	et al. , 2002	91067
@NP	et al.	91067
@NP	2002	91075
@NP	a recent study	91082
@NP	chronic SCI	91111
@NP	axons	91132
@NP	regions of SCs	91157
@NP	regions	91157
@NP	SCs	91168
@NP	the lesion site	91179
@NP	both inhibitory NG2 and permissive L1 and NCAM substrates	91210
@NP	both inhibitory NG2	91210
@NP	permissive L1 and NCAM substrates	91234
@NP	Lu	91269
@NP	et al. , 2007	91272
@NP	et al.	91272
@NP	2007	91280
@NP	The presence of macrophages or microglia within this region	91287
@NP	The presence	91287
@NP	macrophages or microglia within this region	91303
@NP	macrophages or microglia	91303
@NP	this region	91335
@NP	growth	91377
@NP	their removal	91412
@NP	inhibitory myelin debris -LRB- Vallieres et al. , 2006 -RRB-	91429
@NP	inhibitory myelin debris	91429
@NP	Vallieres	91455
@NP	et al. , 2006	91465
@NP	et al.	91465
@NP	2006	91473
@NP	their secretion of a variety of growth factors	91482
@NP	their secretion	91482
@NP	a variety of growth factors	91501
@NP	a variety	91501
@NP	growth factors	91514
@NP	the survival and axon growth	91569
@NP	a variety of CNS and PNS neuron populations -LRB- Davies , 1994	91601
@NP	a variety	91601
@NP	CNS and PNS neuron populations	91614
@NP	Davies	91646
@NP	1994	91654
@NP	Eide et al.	91660
@NP	Eide	91660
@NP	et al.	91665
@NP	1993	91673
@NP	Elkabes et al.	91679
@NP	Elkabes	91679
@NP	et al.	91687
@NP	1996	91695
@NP	Nakajima	91701
@NP	et al. , 1998 ; Suzuki et al. , 2001 -RRB-	91710
@NP	et al.	91710
@NP	1998 ; Suzuki et al. , 2001 -RRB-	91718
@NP	1998	91718
@NP	Suzuki et al. , 2001 -RRB-	91724
@NP	Suzuki	91724
@NP	et al.	91731
@NP	2001	91739
@NP	Further investigation	91746
@NP	the mechanism	91773
@NP	the different growth responses within these regions	91803
@NP	the different growth responses	91803
@NP	these regions	91841
@NP	future methods	91869
@NP	cell implants	91897
@NP	their efficacy	91922
@NP	the endogenous cellular response	91949
@NP	the injured host cord milieu	91989
@NP	improved self-repair	92038
@NP	Numerous myelinated axons	92060
@NP	EGFPSC grafts	92102
@NP	no myelination	92127
@NP	areas containing EGFP-OEG	92154
@NP	areas	92154
@NP	EGFP-OEG	92171
@NP	The axons that were myelinated	92181
@NP	The axons	92181
@NP	sensory or spinal cord	92234
@NP	proprioceptive axons as very few supraspinal axons	92257
@NP	proprioceptive axons	92257
@NP	very few supraspinal axons	92281
@NP	the grafts	92319
@NP	The observed reduction	92331
@NP	p75 immunoreactivity	92357
@NP	EGFP-SCs	92381
@NP	implantation	92407
@NP	a phenomenon	92421
@NP	their conversion	92458
@NP	a myelinating phenotype -LRB- Morgan et al. , 1994 -RRB-	92478
@NP	a myelinating phenotype	92478
@NP	Morgan	92503
@NP	et al. , 1994	92510
@NP	et al.	92510
@NP	1994	92518
@NP	further	92525
@NP	the suggestion	92542
@NP	the implanted EGFP-SCs	92562
@NP	myelinate ingrowing axons	92598
@NP	The inability of SCs to migrate from their original site of deposition	92625
@NP	The inability	92625
@NP	SCs to migrate from their original site of deposition	92642
@NP	their original site of deposition	92662
@NP	their original site	92662
@NP	deposition	92685
@NP	their potential	92716
@NP	remyelination strategies	92736
@NP	demyelinated axons	92771
@NP	SCI -LRB- Guest et al. , 2005 ; Totoiu and Kierstead , 2005 -RRB-	92796
@NP	SCI	92796
@NP	Guest	92801
@NP	et al. , 2005 ; Totoiu and Kierstead , 2005	92807
@NP	et al.	92807
@NP	2005 ; Totoiu and Kierstead	92815
@NP	2005	92815
@NP	Totoiu and Kierstead	92821
@NP	2005	92843
@NP	The lack of substantial myelination in OEG	92850
@NP	The lack	92850
@NP	substantial myelination in OEG	92862
@NP	substantial myelination	92862
@NP	OEG	92889
@NP	animals	92901
@NP	SCI	92915
@NP	demyelination lesions	92992
@NP	the spinal cord -LRB- Imaizumi et al. , 1998 ; Kato et al. , 2000 -RRB-	93017
@NP	the spinal cord	93017
@NP	Imaizumi	93034
@NP	et al. , 1998 ; Kato et al. , 2000	93043
@NP	et al.	93043
@NP	1998 ; Kato et al.	93051
@NP	1998	93051
@NP	Kato et al.	93057
@NP	Kato	93057
@NP	et al.	93062
@NP	2000	93070
@NP	previous findings	93095
@NP	Boyd	93116
@NP	et al. -LRB- 2004 -RRB-	93121
@NP	et al.	93121
@NP	2004	93129
@NP	Embryonic OEG	93136
@NP	b-galactosidase	93164
@NP	7 days	93200
@NP	a clip compression injury	93213
@NP	myelinate axons	93250
@NP	immuno-electron microscopy	93285
@NP	3 weeks	93315
@NP	The myelin found near grafted , labeled OEG	93345
@NP	The myelin	93345
@NP	OEG	93384
@NP	endogenous SCs	93422
@NP	Differences in OEG myelination among these studies	93438
@NP	Differences	93438
@NP	OEG myelination among these studies	93453
@NP	OEG myelination	93453
@NP	these studies	93475
@NP	the disparate spinal cord environments	93501
@NP	the OEG	93551
@NP	incongruities in the types and amount of specific ECM proteins	93579
@NP	incongruities	93579
@NP	the types and amount of specific ECM proteins	93596
@NP	the types and amount	93596
@NP	specific ECM proteins	93620
@NP	numbers of specific cell populations	93649
@NP	numbers	93649
@NP	specific cell populations	93660
@NP	neurons , precursor cells , and immune cells	93687
@NP	neurons	93687
@NP	precursor cells	93696
@NP	immune cells	93717
@NP	OEG myelination	93744
@NP	Differences	93761
@NP	the distinct methods	93795
@NP	the OEG cultures -LRB- as described above -RRB-	93836
@NP	the OEG cultures	93836
@NP	The grafting of either SCs or OEG	93875
@NP	The grafting	93875
@NP	either SCs or OEG	93891
@NP	SCs	93898
@NP	OEG	93905
@NP	substantial improvements	93925
@NP	hind limb function	93953
@NP	a modest , though significant , improvement in open-field locomotion	93976
@NP	a modest , though significant , improvement	93976
@NP	open-field locomotion	94021
@NP	the combination grafting of both cell types	94061
@NP	the combination grafting	94061
@NP	both cell types	94089
@NP	the injury site	94110
@NP	An absence of major improvements in behavioral outcomes	94127
@NP	An absence	94127
@NP	major improvements in behavioral outcomes	94141
@NP	major improvements	94141
@NP	behavioral outcomes	94163
@NP	likely results	94183
@NP	an inability of both cell types	94203
@NP	an inability	94203
@NP	both cell types	94219
@NP	supraspinal axon growth in the current study and points	94246
@NP	supraspinal axon growth	94246
@NP	the current study and points	94273
@NP	the current study	94273
@NP	points	94295
@NP	the need for additional pharmacological or molecular strategies	94305
@NP	the need	94305
@NP	additional pharmacological or molecular strategies	94318
@NP	the efficacy of glial grafts	94380
@NP	the efficacy	94380
@NP	glial grafts	94396
@NP	axon growth and functional restitution	94413
@NP	axon growth	94413
@NP	functional restitution	94429
@NP	Bamber	94453
@NP	et al. , 2001	94460
@NP	et al.	94460
@NP	2001	94468
@NP	Fouad et al. , 2005	94474
@NP	Fouad	94474
@NP	et al. , 2005	94480
@NP	et al.	94480
@NP	2005	94488
@NP	Pearse et al. , 2004b	94494
@NP	Pearse	94494
@NP	et al. , 2004b	94501
@NP	et al.	94501
@NP	2004b	94509
@NP	Ruitenberg et al. , 2002	94516
@NP	Ruitenberg	94516
@NP	et al. , 2002	94527
@NP	et al.	94527
@NP	2002	94535
@NP	Tuszynski et al. , 1998	94541
@NP	Tuszynski	94541
@NP	et al. , 1998	94551
@NP	et al.	94551
@NP	1998	94559
@NP	The improved behavior in the combination group	94566
@NP	The improved behavior	94566
@NP	the combination group	94591
@NP	the significant increase in OEG survival	94633
@NP	the significant increase	94633
@NP	OEG survival	94661
@NP	co-implantation of SCs	94686
@NP	co-implantation	94686
@NP	SCs	94705
@NP	the subsequent growth	94713
@NP	axonal tracts not examined in the current study	94738
@NP	axonal tracts	94738
@NP	the current study	94768
@NP	the vestibulospinal or reticulospinal systems	94795
@NP	An absence of behavioral improvements in the other combination group	94842
@NP	An absence	94842
@NP	behavioral improvements in the other combination group	94856
@NP	behavioral improvements	94856
@NP	the other combination group	94883
@NP	the damage	94925
@NP	injections of OEG	94948
@NP	injections	94948
@NP	OEG	94962
@NP	either side of the injury site and possible extension of the lesion	94969
@NP	either side of the injury site	94969
@NP	either side	94969
@NP	the injury site	94984
@NP	possible extension of the lesion	95004
@NP	possible extension	95004
@NP	the lesion	95026
@NP	The microimplantation	95038
@NP	OEG to enhance their survival and thus efficacy in a contusive injury model	95063
@NP	OEG to enhance their survival and thus efficacy	95063
@NP	their survival	95078
@NP	a contusive injury model	95114
@NP	less invasive surgical techniques	95164
@NP	those previously adapted for stem cell delivery -LRB- Bakshi et al. , 2006 -RRB-	95207
@NP	those	95207
@NP	stem cell delivery -LRB- Bakshi et al. , 2006 -RRB-	95236
@NP	stem cell delivery	95236
@NP	Bakshi	95256
@NP	et al. , 2006	95263
@NP	et al.	95263
@NP	2006	95271
@NP	Further investigation	96095
@NP	glial transplantation using specific and reliable cell markers	96120
@NP	glial transplantation	96120
@NP	specific and reliable cell markers	96148
@NP	these questions	96197
@NP	the future	96232
@VP	* ANDRE R.	181
@VP	have shown promise for spinal cord injury repair	794
@VP	shown promise for spinal cord injury repair	799
@VP	were quantified from 3 days to 9 weeks post-transplantation	1192
@VP	quantified from 3 days to 9 weeks post-transplantation	1197
@VP	was observed	1334
@VP	observed	1338
@VP	survived very poorly within the lesion -LRB- < 5 % -RRB-	1364
@VP	was hostile to transplanted cells and or prevented their proliferation	1499
@VP	was hostile to transplanted cells	1499
@VP	or prevented their proliferation	1537
@VP	injected into the injury failed to migrate from the lesion	1733
@VP	failed to migrate from the lesion	1758
@VP	to migrate from the lesion	1765
@VP	migrate from the lesion	1768
@VP	resulted in their migration into the SC-injected injury site , not via normal	1832
@VP	appearing host tissue but along the pia or via the central canal	1910
@VP	were seen in association with or ensheathed by transplanted glia	2005
@VP	seen in association with or ensheathed by transplanted glia	2010
@VP	seen in association with	2010
@VP	ensheathed by transplanted glia	2038
@VP	were found within regions of grafted SCs but not OEG	2097
@VP	found within regions of grafted SCs but not OEG	2102
@VP	grafted SCs but not OEG	2126
@VP	grafting into the contused spinal cord , research previously complicated	2274
@VP	contused spinal cord , research previously complicated	2292
@VP	to overcome many obstacles encountered after SCI	3930
@VP	overcome many obstacles encountered after SCI	3933
@VP	encountered after SCI	3957
@VP	makes them ideal therapeutic candidates for repair	3979
@VP	encourage axonal regeneration after peripheral injury	4112
@VP	reviewed by Grumet , 1997	4507
@VP	guiding their growth from the olfactory epithelium to the olfactory bulb	5221
@VP	demyelinated spinal cord axons -LRB- Imaizumi et al. , 1998 -RRB-	5823
@VP	is promising	5952
@VP	employed labels	6239
@VP	resulting in loss of the label within days or weeks	6509
@VP	to examine various cell implants , including SCs and OEG	7128
@VP	examine various cell implants , including SCs and OEG	7131
@VP	to associate with	7578
@VP	associate with	7581
@VP	directly compare these properties of the two cell types in a single study	7682
@VP	described previously	7952
@VP	as later detailed in Meijs et al.	8028
@VP	were grown to confluency and passaged to new dishes three times	8077
@VP	grown to confluency and passaged to new dishes three times	8082
@VP	grown to confluency	8082
@VP	passaged to new dishes three times	8106
@VP	described earlier -LRB- Takami et al. , 2002b -RRB-	8181
@VP	was found to be 95 -- 98 %	8223
@VP	found to be 95 -- 98 %	8227
@VP	to be 95 -- 98 %	8233
@VP	be 95 -- 98 %	8236
@VP	Highly purified cultures of OEG	8251
@VP	using a procedure modified from one described previously	8446
@VP	modified from one described previously	8464
@VP	described previously	8482
@VP	was taken to minimize the inclusion of nonnerve fiber layer bulb tissue	8537
@VP	taken to minimize the inclusion of nonnerve fiber layer bulb tissue	8541
@VP	to minimize the inclusion of nonnerve fiber layer bulb tissue	8547
@VP	minimize the inclusion of nonnerve fiber layer bulb tissue	8550
@VP	was removed	8622
@VP	removed	8626
@VP	dissociated	8644
@VP	described by Takami	8867
@VP	Checking the purity was similar to SCs except that p75 rather than S100	8903
@VP	was similar to SCs except that p75 rather than S100	8923
@VP	was used with Hoechst nuclear staining	8975
@VP	used with Hoechst nuclear staining	8979
@VP	was found to be 94 -- 98 %	9022
@VP	found to be 94 -- 98 %	9026
@VP	to be 94 -- 98 %	9032
@VP	be 94 -- 98 %	9035
@VP	was performed as previously described by Follenzi et al. -LRB- 2000 -RRB-	9114
@VP	performed as previously described by Follenzi et al. -LRB- 2000 -RRB-	9118
@VP	described by Follenzi et al. -LRB- 2000 -RRB-	9142
@VP	was subcloned into a lentiviral vector plasmid	9248
@VP	subcloned into a lentiviral vector plasmid	9252
@VP	to enhance mRNA transport	9448
@VP	enhance mRNA transport	9451
@VP	was conducted in cultured 293T cells	9521
@VP	conducted in cultured 293T cells	9525
@VP	cultured 293T cells	9538
@VP	concentrated by ultracentrifugation at 20,000 g	9569
@VP	resuspended in phosphate buffered saline -LRB- PBS -RRB-	9620
@VP	buffered saline -LRB- PBS -RRB-	9645
@VP	transducing units either on 293T cells	9715
@VP	quantifying p24 core protein concentrations	9844
@VP	Purified viral vector stocks	9931
@VP	were stored at 280 C until SC or OEG infection	9960
@VP	stored at 280 C until SC or OEG infection	9965
@VP	to express GFP Virus concentrated in PBS	10047
@VP	express GFP Virus concentrated in PBS	10050
@VP	concentrated in PBS	10068
@VP	was used to infect SCs and OEG	10088
@VP	used to infect SCs and OEG	10092
@VP	to infect SCs and OEG	10097
@VP	infect SCs and OEG	10100
@VP	were housed according to NIH and The Guide for the Care and Use of Animals	10451
@VP	housed according to NIH and The Guide for the Care and Use of Animals	10456
@VP	approved all animal procedures	10602
@VP	was induced by the MASCIS weight drop device	10795
@VP	induced by the MASCIS weight drop device	10799
@VP	developed at New York University -LRB- Gruner , 1992 -RRB-	10840
@VP	performed at thoracic vertebra T8	10903
@VP	disrupting the dura mater	11007
@VP	was moderately injured by dropping a 10.0 g rod from a height of 12.5 mm	11058
@VP	dropping a 10.0 g rod from a height of 12.5 mm	11084
@VP	were monitored	11186
@VP	monitored	11191
@VP	exceeded 6 %	11276
@VP	was not within the range of 1.35 -- 1.75 mm	11319
@VP	were sutured in layers	11387
@VP	sutured in layers	11392
@VP	closed with metal wound clips	11423
@VP	were allowed to recover in a warmed cage with water and food easily accessible	11463
@VP	allowed to recover in a warmed cage with water and food easily accessible	11468
@VP	to recover in a warmed cage with water and food easily accessible	11476
@VP	recover in a warmed cage with water and food easily accessible	11479
@VP	was administered immediately postsurgery and then daily for seven days	11619
@VP	administered immediately postsurgery and then daily for seven days	11623
@VP	was delivered postsurgery and daily for 2 days	11788
@VP	delivered postsurgery and daily for 2 days	11792
@VP	received fluid grafts of SCs , OEG or both cell types	11863
@VP	served as controls	12527
@VP	randomized block design due to the large number of animals used for the study	12883
@VP	used for the study	12942
@VP	Prior to implantation , EGFP transduced SCs and OEG	12978
@VP	were harvested from culture via trypsinization	13029
@VP	harvested from culture via trypsinization	13034
@VP	centrifuged , resuspended , and counted	13082
@VP	centrifuged	13082
@VP	resuspended	13095
@VP	counted	13112
@VP	counting	13127
@VP	were resuspended as aliquots in DMEMF12 medium	13149
@VP	resuspended as aliquots in DMEMF12 medium	13154
@VP	were kept on ice prior to surgery	13200
@VP	kept on ice prior to surgery	13205
@VP	were reanesthetized with 2 % halothane	13263
@VP	reanesthetized with 2 % halothane	13268
@VP	was exposed	13321
@VP	exposed	13325
@VP	were injected into the epicenter of the contused area	13485
@VP	injected into the epicenter of the contused area	13490
@VP	were performed using either a 10 or 1 µL	13839
@VP	performed using either a 10 or 1 µL	13844
@VP	using either a 10 or 1 µL	13854
@VP	siliconized Hamilton syringe with a pulled , beveled glass	13880
@VP	was kept in place for an additional 3 min to minimize leakage upon withdrawal	14107
@VP	kept in place for an additional 3 min to minimize leakage upon withdrawal	14111
@VP	to minimize leakage upon withdrawal	14149
@VP	minimize leakage upon withdrawal	14152
@VP	were closed separately	14239
@VP	closed separately	14244
@VP	received postoperative care as described above	14274
@VP	described above	14305
@VP	received no spinal cord injections	14343
@VP	were deeply anesthetized -LRB- 70 mg/kg ketamine , 10 mg/kg xylazine -RRB-	15096
@VP	perfused with 4 % paraformaldehyde -LRB- PFA , 0.1 M , pH 7.4 -RRB-	15179
@VP	removed and postfixed overnight in 4 % PFA at 4 °C	15266
@VP	postfixed for 5 days in 4 % PFA -LRB- refreshed daily -RRB-	15440
@VP	contained the complete lesion and graft site	15549
@VP	dissected	15600
@VP	embedded for injury only and FB transplant	15669
@VP	sectioned at 10 µm on a microtome	15883
@VP	collected during sectioning	16103
@VP	stored at 27 °C until required for hybridization	16220
@VP	required for hybridization	16241
@VP	sectioned at 30 µm on a freezing microtome	16315
@VP	analyzed for EGFP cell migration	16362
@VP	axon growth support in combination with specific immunochemical stains	16399
@VP	tracing	16512
@VP	collected into six series in PBS -LRB- 0.1 M , pH 7.4 -RRB-	16535
@VP	stored at 4 °C until further processing	16588
@VP	was taken and immediately frozen at 280 C in liquid nitrogen	16797
@VP	taken and immediately frozen at 280 C in liquid nitrogen	16801
@VP	taken	16801
@VP	immediately frozen at 280 C in liquid nitrogen	16811
@VP	grafts only	16890
@VP	served as a 0 day baseline control	16948
@VP	described previously -LRB- Pearse et al. , 2001 -RRB-	17025
@VP	to prepare samples with concentrations of 10 mg/mL	17165
@VP	prepare samples with concentrations of 10 mg/mL	17168
@VP	were loaded for one-dimensional 10 % SDSpolyacrylamide gel electrophoresis	17257
@VP	were then transferred to PVDF membranes	17341
@VP	transferred to PVDF membranes	17351
@VP	followed by HRP-conjugated goat	17510
@VP	exposed to Kodak X-OMAT films -LRB- Eastman Kodak , Rochester , NY -RRB-	17718
@VP	was performed in a Fluor-S Multi Imager -LRB- Bio-Rad -RRB-	17809
@VP	performed in a Fluor-S Multi Imager -LRB- Bio-Rad -RRB-	17813
@VP	were made using Quantity One software version 4.2.0 -LRB- Bio-Rad -RRB-	17891
@VP	made using Quantity One software version 4.2.0 -LRB- Bio-Rad -RRB-	17896
@VP	using Quantity One software version 4.2.0 -LRB- Bio-Rad -RRB-	17901
@VP	To ensure consistent loading of equal protein amounts	17954
@VP	ensure consistent loading of equal protein amounts	17957
@VP	stripped	18020
@VP	incubated with b-actin mouse monoclonal antibody -LRB- 1:1,000 , AbCam -RRB-	18038
@VP	was quantified as described above	18120
@VP	quantified as described above	18124
@VP	described above	18138
@VP	was a gift from Dr.	18240
@VP	producing a probe size of 0.1 -- 0.5 kbp	18409
@VP	Diluted probe	18668
@VP	was denatured at 95 C shortly before use	18682
@VP	denatured at 95 C shortly before use	18686
@VP	were first deparaffinized by xylene	18808
@VP	first deparaffinized by xylene	18813
@VP	then hydrated through graded ethanol washes	18848
@VP	graded ethanol washes	18870
@VP	To prepare the tissue for hybridization	18893
@VP	prepare the tissue for hybridization	18896
@VP	was performed overnight at 48 C.	19225
@VP	performed overnight at 48 C.	19229
@VP	followed by alkaline phosphatase detection buffer	19464
@VP	included in each ISH reaction as positive and negative controls , respectively	19845
@VP	described	20045
@VP	mounted onto Snowcoat X-tra slides -LRB- Surgipath -RRB-	21201
@VP	coverslipped with Vectashield mounting	21252
@VP	containing the nuclear dye Hoechst and kept at 4 C.	21322
@VP	dye Hoechst and kept at 4 C.	21345
@VP	dye Hoechst	21345
@VP	kept at 4 C.	21361
@VP	conjugated to rhodamine -LRB- Vector Laboratories -RRB-	21536
@VP	mounted onto Snowcoat X-tra slides -LRB- Surgipath -RRB-	21597
@VP	containing the nuclear dye Hoechst	21716
@VP	dye Hoechst	21739
@VP	kept at 4 °C	21755
@VP	identified through DNA ISH or EGFPþ and p75þ cells	21888
@VP	visualized by fluorescent signal	21940
@VP	was first traced with a 203 objective	22389
@VP	first traced with a 203 objective	22393
@VP	using optical fractionator , the traced contour of each section	22669
@VP	was divided into 50 3 50 µm2 counting frames	22732
@VP	divided into 50 3 50 µm2 counting frames	22736
@VP	encompassed two to four cells	22801
@VP	permit counting of 35 sampling sites within each traced contour of each section	22900
@VP	stained nuclei were then marked with a dissector probe under a 633 objective	23086
@VP	were then marked with a dissector probe under a 633 objective	23101
@VP	marked with a dissector probe under a 633 objective	23111
@VP	were performed according to StereoInvestigator 3.0 -LRB- MicroBrightField -RRB-	23276
@VP	performed according to StereoInvestigator 3.0 -LRB- MicroBrightField -RRB-	23281
@VP	was less than 10 %	23414
@VP	contained Y-probe labeled cells	23582
@VP	labeled cells	23600
@VP	were immunostained for GFAP to define the borders of the injury site	23614
@VP	immunostained for GFAP to define the borders of the injury site	23619
@VP	to define the borders of the injury site	23642
@VP	define the borders of the injury site	23645
@VP	to perform cell counts	23926
@VP	perform cell counts	23929
@VP	described above	23953
@VP	obtained within each grid -LRB- 20 3 5 arrays -RRB-	23997
@VP	was then expressed as a percentage of the total counts for the whole spinal cord	24039
@VP	expressed as a percentage of the total counts for the whole spinal cord	24048
@VP	Using this method	24305
@VP	changed over time within a specific	24521
@VP	implant group	24557
@VP	are obtained using the method	24589
@VP	obtained using the method	24593
@VP	using the method	24602
@VP	could not be made	24653
@VP	be made	24663
@VP	made	24666
@VP	traced fibers BDA - or CTB-labeled axons	24699
@VP	spanning the width of the spinal cord at 12 weeks post-transplantation	24831
@VP	Labeled	24903
@VP	were visualized using fluorescence microscopy	24917
@VP	visualized using fluorescence microscopy	24922
@VP	using fluorescence microscopy	24933
@VP	identified by the GFAP-EGFP or GFAPþ-GFAP2 border	25194
@VP	was then summed for each rat	25583
@VP	summed for each rat	25592
@VP	To estimate the number of fibers per section	25613
@VP	estimate the number of fibers per section	25616
@VP	were then divided by the number of sections examined	25670
@VP	divided by the number of sections examined	25680
@VP	examined	25714
@VP	tracing , respectively , from each animal	25906
@VP	automatically measured , and gave in arbitrary units	26126
@VP	automatically measured	26126
@VP	gave in arbitrary units	26154
@VP	dye staining in each image	26212
@VP	tracing efficiency	26363
@VP	identified by the GFAPEGFP or GFAPþ-GFAP2 border	26672
@VP	summed for each rat -LRB- n = 6 per group at 12 weeks post-transplantation -RRB-	27067
@VP	To estimate the number of fibers per section	27139
@VP	estimate the number of fibers per section	27142
@VP	were then divided by the number of sections examined	27196
@VP	divided by the number of sections examined	27206
@VP	examined	27240
@VP	in vivo using high power	27339
@VP	labeled cells , within three regions of the transplants	27488
@VP	containing the central canal and two at 180 µm on either side , 200 µm2 areas	27567
@VP	obtained of the grafts	27800
@VP	using Neuroleucida meander scan software -LRB- Micro - BrightField -RRB-	27866
@VP	meander scan software -LRB- Micro - BrightField -RRB-	27885
@VP	scan software -LRB- Micro - BrightField -RRB-	27893
@VP	were counted , ratios of myelinated axons to grafted cells obtained	28001
@VP	counted , ratios of myelinated axons to grafted cells obtained	28006
@VP	obtained	28059
@VP	averaged across the three sections	28090
@VP	developed by Basso et al. -LRB- 1995 -RRB- -LRB- n = 12 per group -RRB-	28465
@VP	did not follow the progression of the BBB score	28575
@VP	follow the progression of the BBB score	28583
@VP	were summed to yield a single score -LRB- maximum of 13 per rat -RRB-	29062
@VP	summed to yield a single score -LRB- maximum of 13 per rat -RRB-	29067
@VP	to yield a single score -LRB- maximum of 13 per rat -RRB-	29074
@VP	yield a single score -LRB- maximum of 13 per rat -RRB-	29077
@VP	described previously	29279
@VP	described	29469
@VP	followed by the Bonferroni post-hoc test	29538
@VP	repeated measures	29729
@VP	followed by the Tukey-Kramer test	29754
@VP	was used for comparison of weekly functional recovery patterns after injury	29788
@VP	used for comparison of weekly functional recovery patterns after injury	29792
@VP	0.05 * , < 0.01 **	29930
@VP	are given as standard deviations	30007
@VP	given as standard deviations	30011
@VP	TABLE 1	30050
@VP	injured female rats	30422
@VP	allowing differential identification of grafted versus host cells	30678
@VP	grafted versus host cells	30718
@VP	bar = 20 µm	30751
@VP	= 20 µm	30755
@VP	expressed as a percentage of the original number of cells transplanted	30829
@VP	transplanted	30887
@VP	transplanted into the injury epicenter	31065
@VP	indicated by each horizontal line	31329
@VP	are positive for this marker	31685
@VP	carrying the EGFP gene	31779
@VP	= 20 µm	31895
@VP	labeled Schwann cells and olfactory ensheathing glia in vivo	31940
@VP	shown	32195
@VP	implanted SCs and EGFP2/p75þ endogenous SCs	32233
@VP	dotted line	32284
@VP	dotted line	32378
@VP	containing transplanted EGFPþ SCs and in areas devoid of EGFPþ SCs	32457
@VP	are seen within the injured spinal cord	32987
@VP	seen within the injured spinal cord	32991
@VP	appears to be found on both EGFPþ and EGFP2 cells	33079
@VP	to be found on both EGFPþ and EGFP2 cells	33087
@VP	be found on both EGFPþ and EGFP2 cells	33090
@VP	found on both EGFPþ and EGFP2 cells	33093
@VP	appear to account for almost all of the p75 reactivity	33253
@VP	to account for almost all of the p75 reactivity	33260
@VP	account for almost all of the p75 reactivity	33263
@VP	was used to identify host astrocytes	33355
@VP	used to identify host astrocytes	33359
@VP	to identify host astrocytes	33364
@VP	identify host astrocytes	33367
@VP	are 10 µm-thick confocal projection images	33412
@VP	depict regions that are shown as accompanying higher magnification images	33468
@VP	are shown as accompanying higher magnification images	33488
@VP	shown as accompanying higher magnification images	33492
@VP	accompanying higher magnification images	33501
@VP	= 20 µm , yellow scale bars = 200 µm	33560
@VP	were similar to counts of cells immunoreactive for p75 at 3 days after grafting	33735
@VP	grafting	33806
@VP	remained unchanged	34056
@VP	grafts	34097
@VP	developed at the injury/transplant site	34191
@VP	was significantly higher than counts of EGFPþ cells at these time points	34267
@VP	grafted on either side	34436
@VP	expected	34577
@VP	were co-localized with p75 immunoreactivity from stereological cell counts	34657
@VP	co-localized with p75 immunoreactivity from stereological cell counts	34662
@VP	observed in vitro	34847
@VP	implying that some of the cells may have switched to a myelinating phenotype	34927
@VP	may have switched to a myelinating phenotype	34959
@VP	have switched to a myelinating phenotype	34963
@VP	switched to a myelinating phenotype	34968
@VP	dashed	35025
@VP	labeled Schwann cells after transplantation	35198
@VP	encompassing the injury epicenter/graft site at 3	35392
@VP	stripping	35520
@VP	was used to ensure equal protein loading	35530
@VP	used to ensure equal protein loading	35534
@VP	to ensure equal protein loading	35539
@VP	ensure equal protein loading	35542
@VP	was seen at 21 and 63	35665
@VP	seen at 21 and 63	35669
@VP	were not significantly different between 21 and 63 days	35781
@VP	grafting into the injury site	35877
@VP	transplanted into the injury site at A	36283
@VP	Grafted	36373
@VP	remained concentrated at the initial site of deposition -LRB- red arrow -RRB-	36385
@VP	Transplanted male OEG	36459
@VP	led to a spinal cord distribution of OEG at G	36727
@VP	was similar to their grafting alone	36814
@VP	were grafted into the injury epicenter	36952
@VP	grafted into the injury epicenter	36957
@VP	resulted in a temporal change in EGFPþ OEG distribution from J	36992
@VP	migrated towards the injury site	37104
@VP	represent distances of 500 µm	37256
@VP	counted within the injured spinal cord	37538
@VP	averaged from n	37581
@VP	Underlined cell type	37638
@VP	indicates labeled cell	37659
@VP	labeled cell	37669
@VP	labeled olfactory ensheathing glia and Schwann cells	37710
@VP	to migrate from the original site of deposition within the injury epicenter	38082
@VP	migrate from the original site of deposition within the injury epicenter	38085
@VP	identified host astrocytes	38196
@VP	are 20 µm-thick confocal projection images	38234
@VP	bar 0 20 µm , yellow scale bar 0 1 µm	38290
@VP	to show location of areas in panels D	38407
@VP	show location of areas in panels D	38410
@VP	grafting into the lesion with EGFP-OEG	38515
@VP	injected rostral and caudal to -LRB- B -RRB- or within -LRB- C -RRB- the lesion	38554
@VP	were supportive	38687
@VP	were oriented	38947
@VP	to enter grafts of EGFPþ	39121
@VP	enter grafts of EGFPþ	39124
@VP	grafted rostral to the injury epicenter	39171
@VP	grafted into the injury epicenter	39225
@VP	grafted with unlabeled SCs into the injury epicenter	39273
@VP	found EGFPþ SC or EGFPþ OEG grafts relatively non-permissive for growth	39404
@VP	grafts relatively non-permissive for growth	39432
@VP	was significantly higher than injury-only controls	39554
@VP	was used to identify host astrocytes	39618
@VP	used to identify host astrocytes	39622
@VP	to identify host astrocytes	39627
@VP	identify host astrocytes	39630
@VP	are 20 µm-thick confocal projection images	39667
@VP	depict regions that are shown as accompanying higher magnification images	39723
@VP	are shown as accompanying higher magnification images	39743
@VP	shown as accompanying higher magnification images	39747
@VP	accompanying higher magnification images	39756
@VP	= 50 µm , yellow scale bars = 200 µm	39815
@VP	ascending and descending axon growth into grafts	39879
@VP	CTB-labeled ascending axons from the sciatic nerve	39950
@VP	traced fibers caudal to , or into , the injury-graft site	40120
@VP	traced fibers caudal to	40120
@VP	caudal to	40134
@VP	into , the injury-graft site	40148
@VP	was attained compared to OEG only	40218
@VP	attained compared to OEG only	40222
@VP	observed within	40618
@VP	indicated by the horizontal lines	41038
@VP	were	41265
@VP	examined for the determination of ratios of myelinated axons to EGFPþ cells	41270
@VP	are observed within this region	41491
@VP	observed within this region	41495
@VP	is identified by the white arrow	41542
@VP	identified by the white arrow	41545
@VP	transplanted with unlabeled SCs	41682
@VP	bar 5 20 µm	41777
@VP	receiving combination SC and OEG grafts into the injury epicenter	42124
@VP	had significantly higher scores	42190
@VP	0.05 as compared to injury-only controls , n = 12/group	42485
@VP	walk performance after glial cell transplantation	42605
@VP	observed in animals receiving either SC only grafts	42892
@VP	receiving either SC only grafts	42912
@VP	grafts	42937
@VP	combination SC and OEG grafts into the injury epicenter	42947
@VP	OEG within the injured spinal cord following implantation	43481
@VP	stereologically quantified using the male chromosome as a definitive marker	43550
@VP	using the male chromosome as a definitive marker	43577
@VP	were transplanted into the injury epicenter of female rats at 1 week post-injury	43662
@VP	transplanted into the injury epicenter of female rats at 1 week post-injury	43667
@VP	prepared for transplantation -LRB- 2 million -RRB- , respectively	43844
@VP	was not significantly different from one another	43961
@VP	grafted 1:1 with SCs into the injury site	44049
@VP	grafted 4-mm rostral and caudal to the injury/SC graft site	44094
@VP	were introduced	44336
@VP	introduced	44341
@VP	harvesting procedures from original counting to syringe loading	44448
@VP	observed reduction in cell number in all cell groups	44555
@VP	transplanted into the injury site	45118
@VP	Labeling After Transplantation Into or Near the Injury Site Numbers of SCs	45686
@VP	OEG within the injured spinal cord following implantation	45768
@VP	is present at high levels on both cell types	46067
@VP	received a single exposure to EGFP-encoding lentiviral vectors	46125
@VP	was observed -LRB- Andrade et al. , 2007 -RRB-	46557
@VP	observed -LRB- Andrade et al. , 2007 -RRB-	46561
@VP	receiving the EGFP transgene	46600
@VP	not shown	46747
@VP	were used at passage 4 -LRB- OEG -RRB- or 5 -LRB- SCs -RRB-	46785
@VP	used at passage 4 -LRB- OEG -RRB- or 5 -LRB- SCs -RRB-	46790
@VP	produced substantive grafts that were able to significantly retard cavitation	47034
@VP	were able to significantly retard cavitation	47067
@VP	to significantly retard cavitation	47077
@VP	significantly retard cavitation	47080
@VP	was similar to injury-only controls	47222
@VP	did not produce cell loss	47419
@VP	produce cell loss	47427
@VP	lost from the cells but rather the conditions to which the cells were exposed	47456
@VP	were exposed	47521
@VP	exposed	47526
@VP	resulted in their disappearance -LRB- Fig. 4A -- D , solid lines -RRB-	47534
@VP	stereologically quantified using either EGFP or the male chromosome marker	47773
@VP	using either EGFP or the male chromosome marker	47800
@VP	were injected outside of the injury epicenter -LRB- Fig. 4B , D -RRB-	48055
@VP	injected outside of the injury epicenter -LRB- Fig. 4B , D -RRB-	48060
@VP	employed western blot analysis of GFP signal using only the EGFPþ SC group	48184
@VP	using only the EGFPþ SC group	48229
@VP	Using densitometry measurements of the resulting bands	48500
@VP	described above by stereological quantification	48955
@VP	were restricted to the site of deposition -LRB- Fig. 6A , D , G -RRB-	49097
@VP	exhibiting a rounded shape and few processes	49202
@VP	surrounded by GFAPþ astrocytes from the host spinal cord	49315
@VP	using EGFP	49420
@VP	separated from the main body of the graft by small cavities	49651
@VP	interspersed with areas of immune cells and debris	49714
@VP	were still within the confines of the lesion	49785
@VP	receiving OEG alone into the injury site	49846
@VP	dispersed within the rim of injured tissue surrounding the cavity	50045
@VP	surrounding the cavity	50088
@VP	to both purify and identify SCs and OEG in vitro and in vivo	50319
@VP	both purify and identify SCs and OEG in vitro and in vivo	50322
@VP	purify	50327
@VP	identify SCs and OEG in vitro and in vivo	50338
@VP	injured	50531
@VP	were observed within the injury site	50587
@VP	observed within the injury site	50592
@VP	in trails along the dorsal columns as early as 3 days after contusion	50628
@VP	was also observed on axons within these areas	50719
@VP	observed on axons within these areas	50728
@VP	had increased , though these cells neither significantly filled the injury site	50837
@VP	increased , though these cells neither significantly filled the injury site	50841
@VP	neither significantly filled the injury site	50871
@VP	significantly filled the injury site	50879
@VP	examined -LRB- results not shown -RRB-	50981
@VP	results not shown	50991
@VP	shown	51003
@VP	was seen confined primarily to the injury site -LRB- Fig. 3A -- C -RRB-	51116
@VP	seen confined primarily to the injury site -LRB- Fig. 3A -- C -RRB-	51120
@VP	confined primarily to the injury site -LRB- Fig. 3A -- C -RRB-	51125
@VP	observed in injured only	51345
@VP	injured only	51357
@VP	was a significant loss of EGFPþ cells	51670
@VP	was significantly less than observed with EGFP cell counts	51804
@VP	less than observed with EGFP cell counts	51822
@VP	receiving mixed grafts of nonlabeled SCs and EGFPþ OEG	52160
@VP	expected	52315
@VP	declined -LRB- Figs. 3D -- I and 4C -- D -RRB-	52499
@VP	found in a number of different environments both within and near the injury site	52553
@VP	grafted cells within the injury site	52702
@VP	bridged the injury site and nearby dorsal root entry sites	52859
@VP	grafting -LRB- > 90 % at all time points -RRB-	53069
@VP	had grown into the grafts -LRB- see Myelination section below -RRB-	53657
@VP	grown into the grafts -LRB- see Myelination section below -RRB-	53661
@VP	see Myelination section below	53684
@VP	matter	54072
@VP	receiving grafts of labeled SCs or OEG into the injury site	54517
@VP	did exhibit different distributions within the area of original deposition	54607
@VP	exhibit different distributions within the area of original deposition	54611
@VP	were found more dispersed within the lesion -LRB- Fig. 6D -- I -RRB-	54832
@VP	found more dispersed within the lesion -LRB- Fig. 6D -- I -RRB-	54837
@VP	migrating along the pia from the injection entry site -LRB- Fig. 7A -RRB-	55259
@VP	was often disrupted by the OEG injections into the dorsal columns	55365
@VP	disrupted by the OEG injections into the dorsal columns	55375
@VP	implant that was largely a heterogeneous mix of EGFPþ OEG and p75þ/EGFP2	55547
@VP	was largely a heterogeneous mix of EGFPþ OEG and p75þ/EGFP2	55560
@VP	were located	55686
@VP	Transplanted Glia	55752
@VP	containing EGFPþ SCs	56106
@VP	not quantified , Fig. 8D -- E	56181
@VP	not quantified	56181
@VP	occupied a significant portion of the extracellular space	56257
@VP	to penetrate EGFPþ cell grafts from all directions	56335
@VP	penetrate EGFPþ cell grafts from all directions	56338
@VP	see below	56477
@VP	descending or ascending fiber systems	56588
@VP	using either anterograde tract tracing or immunochemistry	56627
@VP	tracing	56658
@VP	recognized	56722
@VP	to grow for an appreciable distance into any of the graft types employed , i.e.	56745
@VP	grow for an appreciable distance into any of the graft types employed , i.e.	56748
@VP	employed , i.e.	56809
@VP	To characterize ascending sensory axons from the hind limbs	56875
@VP	characterize ascending sensory axons from the hind limbs	56878
@VP	ascending sensory axons from the hind limbs	56891
@VP	employed anterograde tracing with CTB	56938
@VP	tracing with CTB	56959
@VP	-RSB- at 2,000 µm and 13 ± 3 f/s at 500 µm	57131
@VP	was quantified within and caudal to the grafts	57504
@VP	quantified within and caudal to the grafts	57508
@VP	quantified within	57508
@VP	caudal to the grafts	57530
@VP	To identify descending fiber systems	58249
@VP	identify descending fiber systems	58252
@VP	tracing with BDA from the sensorimotor cortex to label corticospinal tract axons	58310
@VP	to label corticospinal tract axons	58356
@VP	label corticospinal tract axons	58359
@VP	are primarily constituents of the raphespinal system	58481
@VP	indicating that neither SC nor OEG grafts alone	59300
@VP	employed , were supportive substrates for significant cortico	59379
@VP	employed	59379
@VP	were supportive	59389
@VP	ascending and descending systems	59505
@VP	were observed when fibroblast implants were employed -LRB- data not shown -RRB-	59538
@VP	observed when fibroblast implants were employed -LRB- data not shown -RRB-	59543
@VP	were employed -LRB- data not shown -RRB-	59577
@VP	employed -LRB- data not shown -RRB-	59582
@VP	not shown	59597
@VP	contained a mixture of largely p75þ endogenous SCs	59896
@VP	implant milieu and the surrounding host	60196
@VP	composed of SCs	60267
@VP	produced by intermingling cell types	60299
@VP	produced seemed to provide a more permissive environment for axon growth	60439
@VP	seemed to provide a more permissive environment for axon growth	60448
@VP	to provide a more permissive environment for axon growth	60455
@VP	provide a more permissive environment for axon growth	60458
@VP	labeled cells in the rostral , central , and caudal regions of EGFPþ SC only	60700
@VP	Myelinated	60819
@VP	were observed in both SC and OEG grafts	60836
@VP	observed in both SC and OEG grafts	60841
@VP	were not intermingled with many EGFP2 exogenous or endogenous SCs	61470
@VP	intermingled with many EGFP2 exogenous or endogenous SCs	61479
@VP	used to analyze myelination	61575
@VP	to analyze myelination	61580
@VP	analyze myelination	61583
@VP	did not encompass EGFP2-p75þ areas of the injury	61603
@VP	encompass EGFP2-p75þ areas of the injury	61611
@VP	would be in abundance	61674
@VP	be in abundance	61680
@VP	were intermingled with EGFPþ OEG	62176
@VP	intermingled with EGFPþ OEG	62181
@VP	Injured Spinal Cord Animals from both the injury only and most transplant groups	62277
@VP	reached a plateau by ≈ 6 weeks	62427
@VP	stepping with no fore limb-hind limb coordination	62631
@VP	received fibroblast grafts	62713
@VP	achieving an endpoint BBB score of 9.8 ± 1.4	62810
@VP	receiving both SCs and OEG into the injury site	62914
@VP	stepping with occasional fore limb-hind limb coordination in the open field	63419
@VP	Injured only	63637
@VP	controls exhibited a BBB subscore of 6.1 ± 3.1 at endpoint	63650
@VP	exhibited a BBB subscore of 6.1 ± 3.1 at endpoint	63659
@VP	reaching 2.6 ± 3.2 at endpoint -LRB- P < 0.05 -RRB-	63834
@VP	showed significantly higher BBB subscores at 8 and 9 weeks compared with injury	63950
@VP	controls	64035
@VP	was 9.2 ± 1.2 -LRB- P < 0.05 -RRB-	64079
@VP	were observed with the other three transplant groups	64153
@VP	observed with the other three transplant groups	64158
@VP	performed conditioned locomotion -LRB- Fig. 12A -- C -RRB-	64304
@VP	revealed a mean angle of rotation of the hind limbs of 13.0 ± 1.0 °	64381
@VP	increased to a mean of 32.2 ± 2.0 °	64477
@VP	did not alter significantly the rotation of the hind limbs , 32.1 ± 3.1 °	64540
@VP	alter significantly the rotation of the hind limbs , 32.1 ± 3.1 °	64548
@VP	improve foot rotation , reducing the degree of deficit to 26.0 ±	64694
@VP	reducing the degree of deficit to 26.0 ±	64717
@VP	were observed in the other transplant groups -LRB- Fig. 12A -RRB-	64831
@VP	observed in the other transplant groups -LRB- Fig. 12A -RRB-	64836
@VP	measured	64909
@VP	showed significant deficits after injury	64954
@VP	were not altered by any of the transplants -LRB- Fig. 12B , C -RRB-	64999
@VP	altered by any of the transplants -LRB- Fig. 12B , C -RRB-	65008
@VP	missed bars	65227
@VP	made by each hind limb	65240
@VP	was recorded	65263
@VP	recorded	65267
@VP	was observed following injury compared with uninjured controls	65310
@VP	observed following injury compared with uninjured controls	65314
@VP	controls -LRB- Fig. 12D -RRB-	65475
@VP	to bridge the injured spinal cord	65541
@VP	bridge the injured spinal cord	65544
@VP	to permit long-term tracking	66409
@VP	permit long-term tracking	66412
@VP	grafted	67163
@VP	had managed to gain access to the central canal	67258
@VP	managed to gain access to the central canal	67262
@VP	to gain access to the central canal	67270
@VP	gain access to the central canal	67273
@VP	had migrated along the pia from the injection entry site	67309
@VP	migrated along the pia from the injection entry site	67313
@VP	were highly supportive substrates for NFþ axons	67393
@VP	descending or ascending axons and only SC grafts	67519
@VP	contained large numbers of myelinated axons	67568
@VP	could lead to partial recovery of function	67889
@VP	lead to partial recovery of function	67895
@VP	are transferred to the cells in culture prior to their transplantation	68144
@VP	transferred to the cells in culture prior to their transplantation	68148
@VP	are stable over a few passages	68261
@VP	making specific identification of the grafted cells very difficult	68570
@VP	is highly expressed in the grafted glia	68718
@VP	expressed in the grafted glia	68728
@VP	can not be made -LRB- Pearse et al. , 2002 , 2004c -RRB-	69117
@VP	be made -LRB- Pearse et al. , 2002 , 2004c -RRB-	69124
@VP	made -LRB- Pearse et al. , 2002 , 2004c -RRB-	69127
@VP	preventing the long-term tracking	69775
@VP	contused spinal cord	70593
@VP	grafting into the hostile milieu of the injury epicenter	70728
@VP	retarded the formation of a central cavity	70893
@VP	occurred between 3 days and 3 weeks post-transplantation	71096
@VP	quantified by the number of male cells	71188
@VP	appeared to result primarily from cell death	71426
@VP	to result primarily from cell death	71435
@VP	result primarily from cell death	71438
@VP	was observed between the cell counts obtained with both markers within	71610
@VP	observed between the cell counts obtained with both markers within	71614
@VP	obtained with both markers within	71647
@VP	implant cohorts across time	71681
@VP	could have been exposed upon the surface of producing cells and thus could	71810
@VP	could have been exposed upon the surface of producing cells	71810
@VP	have been exposed upon the surface of producing cells	71816
@VP	been exposed upon the surface of producing cells	71821
@VP	exposed upon the surface of producing cells	71826
@VP	could	71879
@VP	prime them for rejection by the immune system	71885
@VP	may have played a role in the observed loss of cells	71932
@VP	have played a role in the observed loss of cells	71936
@VP	played a role in the observed loss of cells	71941
@VP	was not the major factor responsible for triggering cell death	72093
@VP	triggering cell death	72134
@VP	occurs	72313
@VP	is largely initiated very soon after implantation -LRB- hours -RRB-	72320
@VP	initiated very soon after implantation -LRB- hours -RRB-	72331
@VP	observed at time points beyond 3 days	72462
@VP	to play a much smaller role in rodents -LRB- Hodgetts and Grounds , 2001 -RRB-	72653
@VP	play a much smaller role in rodents -LRB- Hodgetts and Grounds , 2001 -RRB-	72656
@VP	expressing human placental alkaline phosphatase	72759
@VP	survived better after cyclosporin treatment	72807
@VP	report here	72862
@VP	was due to cell death , not loss of the label -LRB- Hill et al. , 2006 -RRB-	72910
@VP	required for survival	74090
@VP	were used	74256
@VP	used	74261
@VP	employing OEG for SCI repair	74704
@VP	were deposited	74775
@VP	deposited	74780
@VP	preparing the cells in culture prior to their implantation	74954
@VP	to survive within the hostile environment of the injured spinal cord	75052
@VP	survive within the hostile environment of the injured spinal cord	75055
@VP	were implanted within the matrix they had produced during culture	75161
@VP	implanted within the matrix they had produced during culture	75166
@VP	had produced during culture	75199
@VP	produced during culture	75203
@VP	scraped off the culture dishes	75247
@VP	implanted as pieces into the hemisected spinal cord	75282
@VP	used as a fluid implant as	75346
@VP	implant as	75362
@VP	prelabeled OEG and led to improvements in functional outcome	75458
@VP	prelabeled OEG	75458
@VP	led to improvements in functional outcome	75477
@VP	is induced by removal of cells from their matrix	75658
@VP	induced by removal of cells from their matrix	75661
@VP	derived from embryonic tissue or the lamina propria	77016
@VP	used at early passage	77071
@VP	limit glia survival after grafting	77159
@VP	grafting	77185
@VP	poorly vascularized	77252
@VP	injured spinal cord can -LRB- Balentine , 1978 -RRB-	77273
@VP	can	77293
@VP	implanted cells to survive better within hypoxic tissues	77325
@VP	to survive better within hypoxic tissues	77341
@VP	survive better within hypoxic tissues	77344
@VP	makes them less susceptible to hypoxic stress -LRB- Tang et al. , 2005 -RRB-	77608
@VP	observed within the same strains of mice -LRB- Colson et al. , 1995 -RRB-	78009
@VP	employing antiapoptotic	78105
@VP	to enhance graft efficacy	78232
@VP	enhance graft efficacy	78235
@VP	grafted male or GFPþ cells	78293
@VP	were lost	78320
@VP	lost	78325
@VP	to gain access to the injured CNS	78436
@VP	gain access to the injured CNS	78439
@VP	assessed purely histologically or by p75 immunostaining alone	79101
@VP	assessed purely histologically	79101
@VP	by p75 immunostaining alone	79135
@VP	has been employed previously by our group and others	79330
@VP	been employed previously by our group and others	79334
@VP	employed previously by our group and others	79339
@VP	SCs or OEG versus infiltrating endogenous SCs -LRB- Fig. 3 -RRB-	79573
@VP	infiltrating endogenous SCs	79591
@VP	is a major component and possibly a confounder in cell implantation paradigms	79671
@VP	was observed in SCI-only spinal cords -LRB- data not shown -RRB-	79784
@VP	observed in SCI-only spinal cords -LRB- data not shown -RRB-	79788
@VP	not shown	79828
@VP	occurred when a cell transplant was employed	79871
@VP	was employed	79903
@VP	employed	79907
@VP	stimulated the ingress of endogenous SCs into the injured spinal cord	80121
@VP	promoting the ingress of SCs into the injured spinal cord	80220
@VP	are unknown	80278
@VP	migrating into the CNS	80502
@VP	stimulate the proliferation and ingress of SCs from the dorsal roots	80767
@VP	enhances endogenous SC ingress , both in the current study and others	80901
@VP	enhances endogenous SC ingress	80901
@VP	in the current study and others	80938
@VP	targets the death	81125
@VP	clearance of the implanted cells , could stimulate SC migration	81150
@VP	stimulate SC migration	81190
@VP	is close coordination between the immune system	81242
@VP	facilitating repair	81323
@VP	to be highly supportive of SC recruitment to the injured spinal cord	81501
@VP	be highly supportive of SC recruitment to the injured spinal cord	81504
@VP	promoting SC ingress	81780
@VP	supports	81895
@VP	grafted cells and/or the immune system in response to the grafted cells	82006
@VP	enhance the invasion of peripheral nerve elements into the injured CNS	82079
@VP	can obviate the need for grafting glia	82182
@VP	obviate the need for grafting glia	82186
@VP	grafting glia	82207
@VP	was observed at all time points post-injury	82260
@VP	observed at all time points post-injury	82264
@VP	were not observed within regions of normalappearing white or gray matter	82321
@VP	observed within regions of normalappearing white or gray matter	82330
@VP	exhibited higher cell survival	82467
@VP	employing complete transection -LRB- Ramon-Cueto et al. , 1998 , 2000 -RRB-	82617
@VP	be ascribed to either the leakage of dyes used for cell labeling	82751
@VP	ascribed to either the leakage of dyes used for cell labeling	82754
@VP	used for cell labeling	82793
@VP	dye transfer to migrating host cells in these former studies	82820
@VP	could result from the different injury environments of specific types of SCI	82889
@VP	result from the different injury environments of specific types of SCI	82895
@VP	were transplanted at 4 mm rostral and caudal to the injury site	83038
@VP	transplanted at 4 mm rostral and caudal to the injury site	83043
@VP	were observed within the injury epicenter	83114
@VP	observed within the injury epicenter	83119
@VP	disrupted its structure	83274
@VP	had reached the site of the injury epicenter	83702
@VP	reached the site of the injury epicenter	83706
@VP	transplanted with SCs in a complete injury	83806
@VP	bridging paradigm -LRB- Ramon-Cueto et al. , 1998 , 2000 -RRB-	83853
@VP	prefer the OEG/fibroblast milieu , rather than the OEG / SC bridge in this model	83951
@VP	examined	84112
@VP	was found associating with these migrating OEG	84121
@VP	found associating with these migrating OEG	84125
@VP	associating with these migrating OEG	84131
@VP	to migrate from their original site of deposition	84265
@VP	migrate from their original site of deposition	84268
@VP	were largely encased by reactive astrocytes	85362
@VP	encased by reactive astrocytes	85375
@VP	exhibited little migration into surrounding host cord tissue in both paradigms	85430
@VP	to identify the implant	85546
@VP	identify the implant	85549
@VP	implant	85562
@VP	would have identified endogenous SCs	85582
@VP	have identified endogenous SCs	85588
@VP	identified endogenous SCs	85593
@VP	compromised the ability to characterize the migratory ability of OEG	85632
@VP	to characterize the migratory ability of OEG	85656
@VP	characterize the migratory ability of OEG	85659
@VP	altering the ability of implanted glia to migrate outwards into the host cord	85758
@VP	to migrate outwards into the host cord	85797
@VP	migrate outwards into the host cord	85800
@VP	had formed a substantive graft	86428
@VP	formed a substantive graft	86432
@VP	transplanted into the injury epicenter	86593
@VP	to prevent the formation of large central cysts	86744
@VP	prevent the formation of large central cysts	86747
@VP	see also Hill et al. , 2006	87275
@VP	do not appear to be reflective of the cell type	87562
@VP	appear to be reflective of the cell type	87569
@VP	to be reflective of the cell type	87576
@VP	be reflective of the cell type	87579
@VP	may be dependent upon the environment into which the cells were deposited	87614
@VP	be dependent upon the environment into which the cells were deposited	87618
@VP	were deposited	87673
@VP	deposited	87678
@VP	dense in appearance	87739
@VP	exhibited patterns of axon growth similar to the SC only grafts	87760
@VP	grafts	87817
@VP	may have allowed the cells to align more freely	88046
@VP	have allowed the cells to align more freely	88050
@VP	allowed the cells to align more freely	88055
@VP	to align more freely	88073
@VP	align more freely	88076
@VP	facilitate axonal growth in a rostral-caudal fashion towards appropriate targets	88235
@VP	ascending	88341
@VP	descending axon populations using either immunochemistry	88355
@VP	using either immunochemistry	88383
@VP	tracing	88415
@VP	were observed when fibroblast implants were employed	88638
@VP	observed when fibroblast implants were employed	88643
@VP	were employed	88677
@VP	employed	88682
@VP	was high	89019
@VP	were implanted rostral and caudal to the injury epicenter	89040
@VP	implanted rostral and caudal to the injury epicenter	89045
@VP	ascending	89184
@VP	implant site relative to the injury	89537
@VP	may have allowed the OEG to be more conducive for long-tract axon growth	89707
@VP	have allowed the OEG to be more conducive for long-tract axon growth	89711
@VP	allowed the OEG to be more conducive for long-tract axon growth	89716
@VP	to be more conducive for long-tract axon growth	89732
@VP	be more conducive for long-tract axon growth	89735
@VP	described elsewhere	89974
@VP	resulting in the deposition of OEG directly within the injury milieu	90068
@VP	limiting their survival	90141
@VP	to support significant growth of long-tract ascending or descending axons	90221
@VP	support significant growth of long-tract ascending or descending axons	90224
@VP	ascending or descending axons	90265
@VP	implant interface , respectively	90536
@VP	implant	90656
@VP	were largely comprised of SCs	90699
@VP	comprised of SCs	90712
@VP	were not observed in appreciable numbers within the EGFP implant	90821
@VP	observed in appreciable numbers within the EGFP implant	90830
@VP	implant	90878
@VP	is highly expressed within the injured spinal cord	90960
@VP	expressed within the injured spinal cord	90970
@VP	is thought to be an inhibitor of axon growth -LRB- Jones et al. , 2002 -RRB-	91015
@VP	thought to be an inhibitor of axon growth -LRB- Jones et al. , 2002 -RRB-	91018
@VP	to be an inhibitor of axon growth -LRB- Jones et al. , 2002 -RRB-	91026
@VP	be an inhibitor of axon growth -LRB- Jones et al. , 2002 -RRB-	91029
@VP	growing axons	91124
@VP	contained both inhibitory NG2 and permissive L1 and NCAM substrates	91200
@VP	may be conducive to axon growth	91352
@VP	be conducive to axon growth	91356
@VP	to axon growth	91369
@VP	axon growth	91372
@VP	to enhance their efficacy	91911
@VP	enhance their efficacy	91914
@VP	to facilitate improved self-repair	92024
@VP	facilitate improved self-repair	92027
@VP	were present in EGFPSC grafts	92086
@VP	almost no myelination was seen in areas containing EGFP-OEG	92120
@VP	seen in areas containing EGFP-OEG	92146
@VP	containing EGFP-OEG	92160
@VP	were myelinated	92196
@VP	myelinated	92201
@VP	penetrated the grafts	92308
@VP	were able to myelinate ingrowing axons	92585
@VP	to migrate from their original site of deposition	92646
@VP	migrate from their original site of deposition	92649
@VP	substantiates previous findings by Boyd	93081
@VP	labeled with b-galactosidase	93151
@VP	transplanted at 7 days after a clip compression injury	93184
@VP	demonstrated by immuno-electron microscopy at 3 weeks post-transplantation	93269
@VP	found near grafted	93356
@VP	grafted	93367
@VP	labeled OEG	93376
@VP	was shown to be formed instead by endogenous SCs	93388
@VP	shown to be formed instead by endogenous SCs	93392
@VP	to be formed instead by endogenous SCs	93398
@VP	be formed instead by endogenous SCs	93401
@VP	formed instead by endogenous SCs	93404
@VP	could affect OEG myelination	93731
@VP	affect OEG myelination	93737
@VP	employed to prepare the OEG cultures -LRB- as described above -RRB-	93816
@VP	to prepare the OEG cultures -LRB- as described above -RRB-	93825
@VP	prepare the OEG cultures -LRB- as described above -RRB-	93828
@VP	described above	93857
@VP	did not produce substantial improvements in hind limb function	93909
@VP	produce substantial improvements in hind limb function	93917
@VP	observed with the combination grafting of both cell types into the injury site	94047
@VP	enhance the efficacy of glial grafts for axon growth and functional restitution	94372
@VP	not examined in the current study	94752
@VP	to enhance their survival	95067
@VP	enhance their survival	95070
@VP	previously adapted for stem cell delivery -LRB- Bakshi et al. , 2006 -RRB-	95213
@VP	using specific and reliable cell markers	96142
@VP	should enable these questions to be addressed in the future	96183
@VP	enable these questions to be addressed in the future	96190
@VP	to be addressed in the future	96213
@VP	be addressed in the future	96216
@VP	addressed in the future	96219
